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“Do not go where the path may lead, go instead where there is no path and leave a trail.” 
 
Ralph Waldo Emerson 
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1.1 FELINE CORONAVIRUSES 
In the sixties, a new emerging and fatal disease entity was described in cats, classically 
characterized by a diffuse, fibrinous and granulomatous peritonitis in the presence of ascites 
(Holzworth, 1963; Wolfe & Griesemer, 1966). In 1970, the aetiological agent causing this 
devastating feline infectious peritonitis (FIP) was discovered to be a coronavirus, designated 
feline infectious peritonitis virus (FIPV) (Ward, 1970). Only in 1981, it was found that many 
healthy cats shed a harmless coronavirus in their faeces (Pedersen et al., 1981). This feline 
enteric coronavirus (FECV) was morphologically and antigenically indistinguishable from 
FIPV and explained the inconsistency seen between the high feline coronavirus (FCoV) 
seroprevalence and the infrequent occurrence of FIP. Moreover, with the discovery that FIPV 
was a virulent mutant of FECV (Vennema et al., 1998), it became rapidly clear that this 
‘harmless’ virus was the root of all problems. Despite many attempts to combat FIP in the last 
5 decades, preventive and curative tools are still lacking, and FECV is still residing in 
virtually all multi-cat environments, where FIP has remained one of the most feared 
infectious causes of death in cats due to its enormous financial and emotional impact.  
1.1.1 Classification and nomenclature 
Feline coronaviruses belong to the family of the Coronaviridae, which together with the 
family of the Arteriviridae, Roniviridae, and Mesoniviridae are grouped within the order of 
the Nidovirales. Within the Coronaviridae family, feline coronaviruses are classified together 
with canine coronaviruses (CCoV), transmissible gastroenteritis virus (TGEV), and porcine 
respiratory coronavirus (PRCV) in the Alphacoronavirus 1 species of the Alphacoronavirus 
genus (Table 1.1) (ICTV; King et al., 2012). The close antigenic relationship between FCoVs, 
CCoVs, TGEV and PRCV, and their potential to cross species barriers, have led to the 
classification of those viruses as one species, and all these viruses can induce infections in 
cats, though most of them are asymptomatic (Barlough et al., 1984; Reynolds & Garwes, 
1979; Stoddart et al., 1988a; Woods & Pedersen, 1979). However, at least one CCoV isolate 
has been shown to induce FIP upon systemic inoculation of cats (McArdle et al., 1992). 
FCoVs are associated with both harmless enteric and fatal systemic diseases in cats. Based on 
this difference in pathogenicity, they are classified as either the enteritis-inducing FECV or 
the FIP-inducing FIPV. Based on antigenic and genetic differences in their spike proteins, 
each pathotype is further divided into two serotypes (Table 1.2) (Fiscus & Teramoto, 1987a, 
b; Hohdatsu et al., 1991a). Worldwide, the majority of all strains (both FECVs and FIPVs) 
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are serotype I viruses (Addie et al., 2003; Benetka et al., 2004; Hohdatsu et al., 1992; 
Kummrow et al., 2005; Lin et al., 2009; Vennema, 1999). Serotype II viruses arise by double 
recombination events between serotype I FCoVs and CCoVs and bear spike and parts of the 
adjacent genes that are of canine origin (Herrewegh et al., 1998; Lin et al., 2013). Despite 
their low prevalence, most in vitro studies have been performed with serotype II strains, as 
these viruses are more easily cultivable compared to the serotype I strains (Dewerchin et al., 
2005; McKeirnan et al., 1987; Rottier et al., 2005; Stoddart & Scott, 1989).  
Table 1.1. Overview of the Coronaviridae family. 
Subfamily Genus Species Subspecies 
Coronavirinae Alpha-
coronavirus 
Alphacoronavirus 1 Canine coronavirus type I 
Canine coronavirus type II 
Feline coronavirus type I 
Feline coronavirus type II 
Porcine respiratory coronavirus 
Transmissible gastroenteritis virus 
Alphacoronavirus 2a Ferret enteric coronavirus 
 Ferret systemic coronavirus 
 Mink coronavirus 
Human coronavirus 229E  
Human coronavirus NL63  
Porcine epidemic diarrhoea virus  
Miniopterus bat coronavirus 1 Miniopterus bat coronavirus 1A 
Miniopterus bat coronavirus 1B 
Miniopterus bat coronavirus HKU8  
Rhinolophus bat coronavirus HKU2  
Scotophilus bat coronavirus 512  
Beta-
coronavirus 
Betacoronavirus 1 Bovine coronavirus 
Human coronavirus OC43 
Equine coronavirus 
Human enteric coronavirus 
Porcine haemagglutinating 
encephalomyelitis virus 
Canine respiratory coronavirus 
Human coronavirus HKU1  
Murine coronavirus Murine hepatitis virus 
Puffinosis coronavirus 
Rat coronavirus 
Pipistrellus bat coronavirus HKU5  
Rousettus bat coronavirus HKU9  
Severe acute respiratory syndrome-
related coronavirus 
Human SARS coronavirus 
Rhinolophus bat coronaviruses 
Palm civet coronaviruses 
Chinese ferret badger coronavirus 
Tylonycteris bat coronavirus HKU4  
 Middle East respiratory syndrome virus  
Gamma-
coronavirus 
 
 
 
Avian coronavirus Infectious bronchitis virus 
Pheasant coronavirus 
Duck coronavirus 
Pigeon coronavirus 
Goose coronavirus 
Turkey coronavirus 
Cetacean coronavirusb Beluga whale coronavirus SW1 
Bottlenose dolphin CoV HKU22 
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a This species has been proposed by (Vlasova et al., 2011) 
b This species has been proposed by (Woo et al., 2014) 
c  (Woo et al., 2012) 
Table 1.2. Characteristics of the FCoV serotypes. 
Pathotype Serotype Characteristics Frequently used strains 
FECV 
I 
§ High prevalencea 
§ Poor in vitro growth: no in vitro cultivable 
strains available; currently propagated by 
cat-to-cat passage 
UCD 
RM 
II § Low prevalence 
§ In vitro cultivable (?) 
WSU 79-1683b 
FIPV 
I 
§ High prevalencec 
§ Poor growth in cell culture: few in vitro 
passaged strains available, but most show 
signs of attenuation 
Black (TN406)d 
UCD-1 
II 
§ Low prevalencee 
§ In vitro cultivable 
WSU 79-1146 
DF2 
Nor15 
a Serotype I FECVs account for 79-98% of all FCoV infections in healthy cats (Addie et al., 2003; Duarte et al., 
2009; Hohdatsu et al., 1992; Kummrow et al., 2005). 
b FCoV strain WSU 79-1683 is an enteritis-inducing strain, but is believed to rather be an avirulent FIPV than a 
real FECV, as this strain has genetic hallmarks of FIPVs. So far, no other serotype II enteric strain has been 
cultivated. 
c  Serotype I FIPVs account for 69-89% of all FIP cases (Benetka et al., 2004; Duarte et al., 2009; Hohdatsu et 
al., 1992). 
d The abundantly used high passage Black strain has been shown to be completely attenuated by cell culture 
propagation, as it does no longer induce FIP upon inoculation (Tekes et al., 2012). 
e Recently described in an epizootic outbreak of FIP (Wang et al., 2013). 
1.1.2  Virus characteristics 
Coronaviruses are roughly spherical particles measuring 80-160 nm in diameter. The helical 
nucleocapsid, comprising the positive single stranded RNA associated with the nucleocapsid 
(N) proteins, is surrounded by a lipid membrane, the viral envelope. In the viral envelope, 3 
structural proteins are embedded, the spike (S), membrane (M) and envelope (E) proteins 
(Figure 1.1).  
 
Delta-
coronavirus 
Bulbul coronavirus HKU11  
Thrush coronavirus HKU12  
Munia coronavirus HKU13 
Porcine coronavirus HKU15c 
White-eye coronavirus HKU16c 
Sparrow coronavirus HKU17c 
Magpie robin coronavirus HKU18c 
Night heron coronavirus HKU19c 
Wigeon coronavirus HKU20c 
Common moorhen coronavirus HKU21c 
 
Torovirinae 
 
 
 
 
Bafinivirus White bream virus  
Torovirus Bovine torovirus  
Equine torovirus  
Human torovirus  
Porcine torovirus  
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Figure 1.1.  FCoV virion. Coronaviruses contain a positive, single stranded RNA (+ ssRNA), complexed with 
nucleocapsid (N) proteins. This helical nucleocapsid is surrounded by an envelope in which 3 structural proteins 
are embedded, the spike (S), the membrane (M), and the envelope (E) protein.  
1.1.2.1 Genome organization 
FCoVs have a single-stranded, positive-sense polyadenylated RNA genome of around 29 
kilobases (Figure 1.2). This positive single stranded RNA directly serves as mRNA for the 
generation of the viral replicative proteins via translation of open reading frame (ORF)1a and 
ORF1b, which make up two-thirds of the viral genome. To allow translation of ORF1b, a 
ribosomal frameshifting mediated by pseudoknot structural element occurs (Bredenbeek et 
al., 1990). Translation of ORF1a and 1b yields two polyproteins, pp1a and pp1ab, which 
further guide the viral replication and transcription (see below), regulate cellular processes 
and potentially also fulfil other yet unknown functions (Neuman et al., 2014). The remaining 
3’ proximal third of the genome contains 6 additional ORFs, encoding the structural proteins 
S, E, M, and N (ORF2, ORF4, ORF5, and ORF6, respectively), and the non-structural, 
accessory proteins 3a, 3b, 3c (ORF3), and 7a, 7b (ORF7). As for eukaryotic mRNA, the viral 
RNA genome also contains non-translated regions such as the 5’ cap, the 5’ untranslated 
region (UTR), the 3’ UTR and the 3’ poly-A tail. The 5’ UTR contains the leader sequence 
and the ORF1 transcription regulatory sequence (TRS), the latter which is also found in front 
of each ORF (Sawicki et al., 2007). 
 
 
 
Figure 1.2. FCoV genome organization. The 5’ end of the genome contains the leader sequence (black box), 
followed by the transcription regulatory sequence (TRS, white box) of the polymerase gene, which is comprised 
of the overlapping open reading frame (ORF)1a and ORF1b. The other ORFs, each of them preceded by a TRS, 
encode for the structural (S, E, M, N) and accessory proteins (3abc and 7ab).  
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1.1.2.2 Structural proteins 
The trimeric, club-like spike (S) proteins project from the surface of the virions, giving the 
particle its corona-like appearance (Figure 1.1 and 1.3). S proteins are involved in entry by 
mediating attachment and virus-cell fusion processes and are essential determinants of host-
range and pathogenicity of coronaviruses (Cowley & Weiss, 2010; Krempl et al., 1997; 
Sanchez et al., 1999).  They are class I fusion proteins of about 170-222 kilodalton (kDa) in 
size, and are highly N-glycosylated with complex and mannose-rich oligosaccharides (Bosch 
et al., 2003; Siddell et al., 1983). S proteins are integral transmembrane proteins consisting of 
an N-terminal ectodomain, a transmembrane helix and a short C-terminal cytoplasmic tail. 
They have common structural features with the fusion proteins of other enveloped viruses 
such as orthomyxo-, paramyxo-, retro-, filo-, and arenaviruses (Bosch et al., 2003; White et 
al., 2008). Typically, these fusion proteins contain a region rich in hydrophobic residues, 
called the fusion peptide. In addition, they are characterized by 2 heptad repeat (HR) regions, 
consisting of a series heptapeptides in which the first and the fourth amino acids are typically 
hydrophobic. These give the HR regions their homotrimeric coiled-coil structure. Viral fusion 
proteins are synthesized as precursor proteins that undergo endoproteolytical cleavage by host 
proteases, generating a metastable complex of the receptor binding and the fusion subunit, 
which remain covalently or non-covalently linked, dependent on the virus (Eckert & Kim, 
2001). This brings the protein in a fusion competent state, allowing the rapid dissociation 
when encountering the fusion trigger (see paragraph 1.2). In contrast to other viruses, 
coronaviruses differ with regard to the cleavage of their S proteins in between the receptor 
binding subunit (S1) and the fusion subunit (S2). It seems that cleavage does not occur for 
most alphacoronaviruses, whereas cleavage of beta-and gammacoronavirus’ spikes depends 
on the virus strain and cell type. This implies that many coronavirus exit infected cells with 
uncleaved spikes. However, these viruses seem to use cellular proteases encountered during 
viral entry for activation of their fusion proteins (see paragraph 1.2). As exception in the 
genus Alphacoronavirus, serotype I FCoVs can carry a furin cleavage site, and potentially 
carry pre-cleaved spikes (de Haan et al., 2008). Mutations in this furin cleavage site have 
recently been linked to the pathotype switch (Licitra et al., 2013).  
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Figure 1.3. The coronavirus spike protein. S proteins are composed of a globular receptor binding subunit 
(S1) and a stalk-like transmembrane fusion (S2) subunit. S proteins protrude from the viral envelope as 
homotrimer complexes. The globular head represents the S1 subunit and mediates the attachment, which can be 
performed by the N-terminal and/or C-terminal receptor binding domain (RBD). The stalk-like S2 subunit 
contains a fusion peptide (FP) and 2 heptad repeat regions (HR 1 and 2) and is responsible for the membrane 
fusion after proteolytical dissociation from the S1 subunit. 
 
The 25-35 kDa triple spanning membrane (M) protein is the most abundant envelope 
protein. It is a type III integral membrane protein with a short N-terminal glycosylated 
ectodomain, 3 transmembrane domains and a long C-terminal endodomain (Rottier, 1995). 
During virus assembly, M proteins interact with each other and with N and S proteins (de 
Haan et al., 2000; Narayanan et al., 2000; Opstelten et al., 1995). These M-S interactions are 
needed to retain the spike proteins at the budding site, allowing their integration in the virion 
(Opstelten et al., 1995). M proteins have key roles in virus assembly/budding, and mediate 
induction of neutralizing antibodies and immune-evasion processes (Dewerchin et al., 2006; 
Rottier, 1995). 
The envelope (E) protein is a small, non-glycosylated, hydrophobic protein of 9-12 kDa in 
size. It is only in restricted numbers present in the virus envelope and is an integral membrane 
protein spanning the envelope twice with both ends oriented to, and the C-terminal end even 
extending in, the viral lumen (Maeda et al., 2001). Together with the M protein, the E protein 
plays crucial roles in virus assembly and budding (Lim & Liu, 2001). This multifunctional 
protein also displays ion channel activity, contributing to virus virulence and pathogenesis of 
at least severe acute respiratory syndrome coronavirus (SARS-CoV) (Nieto-Torres et al., 
2014). 
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Nucleocapsid (N) proteins are highly phosphorylated structural proteins (50-60 kDa) 
involved in packaging the viral genomic RNA to form the helical nucleocapsid (Spaan et al., 
1988). Incorporation of the nucleocapsid into the virion is mediated by N-M interactions. In 
addition to the RNA packaging and protecting role, N proteins fulfil many other functions, 
such as facilitating viral RNA synthesis (Baric et al., 1988; Sawicki et al., 2007) and 
perturbation of several cellular processes such as IFN-induced responses (Kopecky-Bromberg 
et al., 2007; Ye et al., 2007). In addition to S proteins, N proteins are important inducers of 
cell-mediated immunity (Takano et al., 2014a; Zhao et al., 2005). 
1.1.2.3 Accessory proteins 
Apart from the structural genes, the 3’ one-third of the genome also contains several non-
structural genes. Homologous genes are found in viruses from the same genus (formerly 
called group, and hence often referred to as group-specific genes), but have no or very few 
similarity with genes of coronaviruses from different genera. Although their evident role in 
virulence in vivo, they are often described as ‘accessory’ genes, since it has been shown that 
the proteins encoded by these genes are largely dispensable for in vitro growth (de Haan et 
al., 2002; Haijema et al., 2004; Ortego et al., 2003). Two gene clusters, ORF3abc and 
ORF7ab, code for the 5 non-structural proteins of FCoVs. Although shown to be of key 
importance for efficient viral-host interactions in vivo (Haijema et al., 2004), the exact 
function of most of these proteins is still largely unknown and a matter of speculation (Table 
1.3).  
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Table 1.3. Properties and potential function of the FCoV accessory proteins. 
Protein Properties Role during FCoV infections 
3abc Combines the effect of 3a, 3b and 3c proteins • Determinant of virulence in vivo (Haijema et 
al., 2004) 
• Deletion enhances (FIPV DF-2) (Balint et al., 
2012) or impairs (FIPV 79-1146) 
(Dedeurwaerder et al., 2013) replication in 
monocytes, but has no effect in bone 
marrow-derived macrophages (BMDM) in 
vitro (Rottier et al., 2005) 
• Restoration of deletion converts FIPV DF-2 
into an enteric biotype in vivo (Balint et al., 
2014a)  
• Necessary for ORF7-dependent protection 
against interferon (IFN)-α in vitro 
(Dedeurwaerder et al., 2014) 
• Not involved in antibody-mediated 
internalisation of viral glycoproteins or in 
escape from antibody-dependent complement 
mediated lysis (Cornelissen et al., 2009) 
 
3a 
 
• Soluble protein (70-71 amino acids) 
• Well conserved among FCoVs of the same 
serotype 
• Not necessary for replication in BMDM in 
vitro (Rottier et al., 2005) 
3b 
 
• Soluble protein (72-73 amino acids) 
• Well conserved among FCoVs of same 
serotype 
 
3c • Class III triple spanning membrane protein, 
similar to SARS 3a protein 
• Intact and well conserved in all faecal 
strains, deleteriously mutated in 60-71.4 % 
of FIPV strains (Chang et al., 2010; 
Pedersen et al., 2012) 
 
• Potential determinant of intestinal replication, 
and hence efficient oro-faecal transmission in 
between cats (Chang et al., 2010; Pedersen et 
al., 2009; Pedersen et al., 2012) 
7ab Combines the effect of 7a and 7b proteins • Determinant of virulence in vivo (Haijema et 
al., 2004)  
• Deletion negatively affects sustainability of 
FIPV replication in monocytes 
(Dedeurwaerder et al., 2013), but has no 
effect in BMDM in vitro (Rottier et al., 2005) 
• Not involved in antibody-mediated 
internalisation of viral glycoproteins or in 
escape from antibody-dependent complement 
mediated lysis (Cornelissen et al., 2009) 
 
7a • 10 kDa membrane protein 
• 72% homologous to TGEV protein 7 
• Relatively well conserved among FCoVs 
• IFN-α antagonist (Dedeurwaerder et al., 
2014) 
7b • 24 kDa soluble glycoprotein, secreted from 
infected cells 
• Least well conserved among FCoVs 
• Specific for FCoVs, CCoVs, and ferret 
CoVs 
• Deleted/truncated in cell culture adapted 
strains 
• Potential competitive inhibitor of host 
cytokines and/or inducer of T-cell apoptosis 
(Haagmans et al., 1996; Herrewegh et al., 
1995; Rottier, 1999) 
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1.1.3 Replication cycle 
As obligate intracellular parasites, coronaviruses depend on host cell machinery for their 
replication, a highly organised multistep process that takes about 9-12 hours to complete 
(Figure 1.4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. FCoV replication cycle. The positive sense genomic RNA, released into the cytosol upon receptor 
binding and subsequent fusion processes, directly serves as mRNA for the translation of ORF1a and ORF1b, 
yielding 2 polyproteins, pp1a and pp1ab. Autoproteolytical cleavage of pp1a and pp1ab yields at least 16 
proteins, many of them forming the replication transcription complex (RTC) at ER-derived double membrane 
vesicles (DMV). The RNA-dependent RNA polymerase makes a negative stranded copy of the genome, which 
subsequently serves as a template for the generation of new genomic RNA, as well as the formation of minus-
strand, subgenomic mRNAs via discontinuous transcription. These minus-strand intermediates then serve as 
template for the generation of the actual subgenomic mRNAs, from which all non-polymerase viral proteins are 
translated. Structural proteins accumulate at the ER-to-Golgi intermediate compartment (ERGIC), from where 
budding of new virions occurs. These new particles are subsequently transported through the secretory pathway 
and are released in the extracellular environment by exocytosis. 
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1.1.3.1 Entry 
In order to gain access to the host cell transcription and translation tools, coronaviruses have 
to release their genome in the cytosol of the target cell. This entry process requires cell 
attachment and subsequent fusion between the viral envelope and the host plasma- or 
endosomal membrane. Both steps of the entry process are carried out by the viral S protein 
and are discussed in detail in paragraph 1.2. 
1.1.3.2 Replication and transcription 
Once the nucleocapsid is released into the cellular cytoplasm, the ribonucleoprotein complex 
disassembles and the 2 precursor proteins pp1a and pp1ab are directly synthesized from the 
genomic RNA. Subsequent autoproteolytical cleavage of these polyproteins yield 16 mature 
non-structural proteins (nsp). Together with the N proteins and some cellular proteins, these 
nsp assemble in the replication-transcription complex (RTC) where both genome replication 
and production of subgenome-sized mRNA occur. These RTCs are associated with double 
membrane vesicles at the perinuclear region of infected cells. Since only ORFs at the 
beginning of a mRNA can be read by eukaryotic ribosomes, coronaviruses, as for all 
nidoviruses, typically generate a nested-set of subgenomic mRNAs during their replication 
(Siddell et al., 1983). These subgenomic mRNAs are generated by a process of discontinuous 
transcription, which via minus-strand intermediates result in 6 subgenomic RNAs with a 
common 5’ leader and the ORF-specific TRS, followed by a variable length sequence 
containing 1 or more ORFs and a 3’ poly(A) stretch (Figure 1.4) (Sawicki et al., 2007). 
Although most of the subgenomic mRNAs are structurally polycistronic, only the first ORF 
of each mRNA is generally translated. However, translation of coronavirus accessory proteins 
results from functional polycistronic subgenomic mRNAs, generating 3 (ORF3) or 2 (ORF7) 
proteins from 1 ORF through a leaky scanning mechanism (Schaecher et al., 2007). 
1.1.3.3 Assembly and release 
To produce progeny viruses, new nucleocapsids have to be assembled and subsequently need 
to be enveloped by a lipid membrane in which all structural proteins are embedded. Assembly 
of ribonucleoproteins occurs in the cytoplasm, after which they bud through the endoplasmic 
reticulum-to-Golgi intermediate compartment (ERGIC) within which the S, M, and E proteins 
are membrane-embedded. M and E proteins play a central role in this assembly/budding 
process (Vennema et al., 1996). M proteins interact with both genomic RNA and N proteins 
to exclude the incorporation of non-genomic RNA (as N proteins can bind non-selectively to 
all RNA present in the cell), they associate with S proteins to ensure their incorporation, and 
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they form homotypic interactions necessary for the morphology of the envelop (de Haan et 
al., 2000; Narayanan et al., 2000; Opstelten et al., 1995). E proteins contribute to the 
envelope formation and determine the site of budding (Fischer et al., 1998; Lim & Liu, 2001). 
Assembled virions are transported out of the infected cell by the secretory pathway, during 
which glycosylation of S and M proteins occurs, and S proteins may become proteolytically 
cleaved, the latter depending on the virus and the strain (see paragraph 1.2.2). To allow S-M 
interactions and hence incorporation of S proteins in virions, posttranslational palmitoylation 
of cysteine residues in the cytoplasmic tail of S proteins is required (Thorp et al., 2006). This 
palmitoylation contributes to the sorting process of S proteins, as only abundantly 
palmitoylated spike are incoported in the virions, whereas other S proteins are sorted to the 
cell surface where they can mediate cell-cell fusion and enhance the viral cell-to-cell spread 
(Shulla & Gallagher, 2009). 
1.1.4  Epizootiology and pathogenesis 
The exact viral and host key players in the onset of FIP are still largely unknown, and after 
many years of research it has become increasingly clear that the pathogenesis of FCoVs is 
much more complex than initially thought. Although described as an enteric virus, FECV is 
not confined to the intestinal tract. Eighty to ninety percent of all healthy coronavirus-infected 
cats show a monocyte-associated viraemia which can last for at least 12 months (Gunn-Moore 
et al., 1998). In addition, FCoV RNA can be detected in all parenchymal organs of healthy 
cats, showing that systemic dissemination and widespread tissue distribution is not a hallmark 
of FIPVs (Meli et al., 2004). However, the viral load detected in parenchymal tissues of FIP 
cats is substantially higher than in healthy coronavirus-infected animals. Hence, not the 
ability to spread systemically, but the rate of viral replication in monocytic cells and/or the 
ability to clear these infected cells have been linked to the development of FIP (see below) 
(Kipar et al., 2006a). The pathogenesis of FCoVs is depicted in Figure 1.5 and will be further 
divided into 3 phases for discussion. 
1.1.4.1 Intestinal replication and faecal-oral transmission of FCoVs 
It is widely accepted that the majority of all FIP cases are the consequence of mutations 
arising in the viral genome during a common FECV infection (Chang et al., 2010; Pedersen et 
al., 2009; Pedersen et al., 2012; Poland et al., 1996). Although this internal mutation theory 
can be questioned during infrequently observed epizootics of FIP, i.e. when FIP deaths 
greatly exceed the normally encountered 5-12% of all seropositive cats (Addie & Jarrett, 
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1992; Kipar & Meli, 2014; Pedersen, 2009; Wang et al., 2013), there is so far no firm proof 
for horizontal transmission of FIPVs (Barker et al., 2013). 
FECVs are found in virtually all multi-cat environments worldwide (Addie & Jarrett, 1992; 
Pedersen et al., 1981), except for the Falkland Islands, which have remained FCoV 
seronegative so far by extensive testing of incoming cats (Addie et al., 2012). Faeces from 
shedders are highly contagious, resulting in a very fast and efficient faecal-oral transmission 
of the virus to non-infected susceptible cats, which in turn start to shed a high amount of 
FECV in their faeces within one week after uptake (Pedersen et al., 2008; Pedersen et al., 
2004; Pedersen et al., 1981; Vogel et al., 2010). Kittens in endemic environments are usually 
protected by maternal immunity and often do not shed virus before the age of 5-10 weeks 
(Addie et al., 2009; Foley et al., 1997; Harpold et al., 1999; Pedersen et al., 2008). However, 
shedding by kittens from 2 weeks of age has been described, explaining why the success of 
early weaning in preventing FIP is variable (see below) (Lutz et al., 2002).  
After ingestion, FECV proceeds to the intestinal tract where it finds its target cell, the 
enterocyte, notably lining the jejunum, ileum, caecum and colon, from which subsequent 
shedding of progeny virus occurs (Herrewegh et al., 1997; Kipar et al., 2010; Meli et al., 
2004; Pedersen et al., 1981). This replication causes a transient enteritis, occasionally 
accompanied by loss of appetite and/or diarrhoea, but which is most often too mild to be 
noticed (Hickman et al., 1995; Pedersen et al., 1981; Vogel et al., 2010). Faecal shedding is 
much higher in young (<2 years), immunocompromised, and, to a lesser extent, old (> 8 
years) cats compared to adult cats. This increased rate of replication potentially favours the 
onset of pathotype switching mutations, which can, apart from the impaired capacity of these 
animals to clear mutated viruses, additionally explains the higher incidence of FIP in these 
groups of animals (Pedersen et al., 2008; Poland et al., 1996). However, it remains elusive so 
far whether these mutations indeed arise during intestinal replication or whether their 
introduction results from selective pressure when taken up by monocytes/macrophages, 
allowing this mutated virus to eventually adapt to and efficiently replicate in these new target 
cells, with all known consequences (Pedersen et al., 2012).  
In contrast to many other enteric viruses, FECVs, and notably serotype I strains, are known to 
establish long-lasting infections, as duration of shedding usually takes 2-18 months to 
eventually wane (Addie & Jarrett, 2001; Addie et al., 2003; Pedersen, 2009; Pedersen et al., 
2008). In addition, around 13% of all FECV infected cats will become life-long shedders, 
comprising a continuous threat for susceptible animals (Addie & Jarrett, 2001). Endemic 
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coronavirus infections are the result of the readily declining local immunity. This lack of 
memory immune response allows continuous reinfections of cats, resulting from the high 
population number (and hence great chance that one cat is still shedding why the other one 
has become negative), but notably resulting from the persistently shedding cats in multi-cat 
households (Addie & Jarrett, 2001; Foley et al., 1997; Pedersen, 2009). Although cats can 
become reinfected several times with the same or a different strain, reinfections do not 
increase the onset of FIP (Addie et al., 2003). The long-lasting presence of FECV in the cat’s 
body implies that, as known for FIPV (see below), FECV potentially uses some immune 
evasion strategies, but these have yet to be characterized. 
1.1.4.2 Systemic dissemination of FCoVs by monocyte-associated viraemia 
As mentioned before, viruses are not confined to the intestinal tract in the majority of all 
FECV infections, but additionally undergo a notably cell-associated viraemia with viral 
distribution throughout the cat‘s body (Gunn-Moore et al., 1998; Meli et al., 2004). It remains 
unclear whether this cell-associated viraemia results from uptake of FCoVs by monocytic 
cells underneath the epithelium in the intestine, or even tonsils as previously proposed for 
FIPV (Stoddart et al., 1988b), or whether cell-free virus enters the draining lymph vessels and 
subsequently finds monocytic cells in or on its way to the blood. Nevertheless, systemic 
spread occurs in virtually every healthy cat and this has not only complicated the diagnosis of 
FIP, but also the search for FIP-inducing mutations, as viral RNA found in cats’ tissues does 
not always reflect a real FIP-inducing strain. Indeed, whereas one report found a typical 
‘FIPV mutation’ (M1058L or S1060A) in the spike protein by comparing faecal strains of 
healthy cats with tissue strains found in FIP cats (Chang et al., 2012), a subsequent study 
revealed these mutations to be a hallmark of all systemic FCoVs found in tissues of both non-
FIP and FIP cats (Porter et al., 2014). 
A peculiar observation is that intraperitoneal inoculation of FECV can occasionally result in 
faecal shedding which is very similar in onset and shedding levels to the shedding seen in 
orally inoculated cats (Foley et al., 1997; Pedersen et al., 2012). This implies that most 
probably FECV can also be carried back by monocytic cells from the periphery to the 
intestine. Whether this way of enterocyte infection is also the source of the persistent 
shedding remains to be investigated. 
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1.1.4.3 Virus distribution and replication in parenchymal organs 
Although systemic spread occurs in both healthy and FIP cats, FCoV RNA is found in a far 
greater proportion of tissue samples and in much higher copy numbers in FIP cats compared 
to healthy cats (Kipar et al., 2006a; Porter et al., 2014). Moreover, except for some antigen 
positive sinus macrophages in mesenteric lymph nodes and pulmonary intravascular 
macrophages in persistently infected healthy cats, viral antigen detection has only been 
successful in tissues of FIP cats so far (Kipar et al., 2010; Porter et al., 2014).  These findings 
strongly indicate that the pathotype difference is related to the level of viral replication in 
parenchymal organs. Indeed, in vitro experiments have shown that key determinants of the 
FIPV pathotype are the ability of the virus to induce efficient and sustainable replication in 
and subsequent activation of monocytes (Dewerchin et al., 2005; Regan et al., 2009; Rottier 
et al., 2005; Stoddart & Scott, 1989). This activation contributes to the typical 
(pyo)granulomatous vasculitis, as it does not only cause enhanced extravasation, but 
potentially also renders these cells more susceptible to FIPV infection (Kipar & Meli, 2014; 
Kipar et al., 2005). Infected cells release several inflammatory mediators that further 
contribute to the typical progressive granuloma formation by 1) continuous chemotactic 
attraction of neutrophils and new infectable monocytes, the latter which can be continuously 
supplied by indirect virus-induced monocyte/macrophage proliferation in haemolyphatic 
tissues, and by 2) mediating tissue damage (Goitsuka et al., 1990; Hasegawa & Hasegawa, 
1991; Kipar et al., 2001; Kipar et al., 2005; Weiss et al., 1988). In addition, at least one of 
those substances released from infected cells, vascular endothelial growth factor (VEGF), 
additionally increases the vascular permeability and is a determining factor in effusion 
formation (Takano et al., 2011). The exaggerated extravasation of leukocytes at the site of 
granulomatous vascular lesions has been shown to be the consequence of a general systemic 
upregulation of leukocyte-associated adhesion molecules combined with the restricted 
upregulation of endothelial counter ligands (P-selectin, E-selectin, intercellular adhesion 
molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1)) at the site of 
infection. The latter is the result of specific mediators released by infected monocytes and 
explains why, despite the systemic activation of leukocytes, extravasation is confined to these 
specific sites (Olyslaegers, 2014; Olyslaegers et al., 2013).   
Although the consequences of the pathotype switch are clear, the exact mutations causing the 
virus to change its cell tropism remain elusive. Mutations in several viral proteins (notably S 
and 3c) have been proposed to be involved (Chang et al., 2010; Chang et al., 2012; Licitra et 
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al., 2013; Pedersen et al., 2009; Pedersen et al., 2012; Rottier et al., 2005), but the lack of a 
clinically relevant serotype I FECV/FIPV infectious clone and notably a susceptible cell line 
to grow and study these viruses have seriously hampered this search so far. 
Regardless of the viral genetics, the onset of FIP is additionally determined by the cat’s 
genetics. Indeed, cats in the same environment are exposed to the same strains, but only a 
restricted number of them will eventually develop FIP, and some breeds or notably lines 
within breeds have a higher incidence of FIP (Pedersen, 2009). It is now well established that 
not the humoral but only a strong cellular immunity is of key importance in the survival from 
FIPV infection. Cats experimentally infected with highly virulent FIPV typically show waves 
of viral replication and viraemia, provoked by acute indirect virus-induced T-cell 
lymphopenia, which coincide with fever and weight loss. These waves of disease are 
interspersed with a period of apparent recovery, during which (partial) reconstitution of 
antiviral T-cell immunity seems to temporally confine the infection in all cats. Subsequent 
disease progression and final outcome of this infection is cat-dependent: whereas some cats 
develop a fulminant T cell lymphopenia in blood and lymphoid tissues, consequently 
resulting in rapid disease progression and death, others gain control over the infection, 
resulting in complete recovery and long-term survival (de Groot-Mijnes et al., 2005). This 
prolonged survival of FIPV infection does not necessarily mean that the virus is cleared from 
the body, as inducing immune suppression in surviving cats still evoked the onset of FIP 
(Pedersen, 1987, 2009). This and the fact that in normal conditions FIPV arises during FECV 
infections, make it hard to determine the incubation period and the source of infection in 
naturally occurring FIP cases.  
The substantial loss of immunological control during FIP development is not confined to the 
cellular immunity. FIPV-infected cats typically mount an excessive antibody response, but 
antibodies are not protective and can even enhance the course of the infection in FCoV 
seropositive cats, the latter at least upon experimental inoculation with certain FIPV strains 
(Pedersen, 2009; Pedersen & Boyle, 1980; Vennema et al., 1990; Weiss & Scott, 1981) . This 
antibody-dependent enhancement of infectivity (ADEI) has been attributed to the promotion 
of Fc-receptor mediated uptake of FIPV by macrophages (Hohdatsu et al., 1991b). However, 
as in natural conditions development of FIP often occurs on first exposure to FCoVs, and cats 
are not exposed to FIPV but to FECV, the role of ADEI in naturally occurring FIP is 
questioned and is believed to be a non-natural phenomenon occurring during experimental 
infections (Addie et al., 1995; Pedersen, 2009). In addition, ADEI cannot explain why the 
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cat’s immune system is not able to clear the infected monocytes/macrophages. An explanation 
for the latter was found in vitro, showing that half of the FIPV-infected monocytes do not 
express viral proteins on the cell surface (= retention), whereas the others rapidly internalize 
the membrane-expressed viral proteins upon anti-FCoV antibody addition. These 2 
phenomena, retention and antibody-mediated internalization of viral proteins, protect infected 
cells from antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent 
complement-mediated lysis (ADCML) and hence explains why FIPV cannot be cleared from 
the body despite the enormous amount of antibodies present in those cats (Cornelissen et al., 
2007; Dewerchin et al., 2005, 2006).  
Cytokine expression in healthy and FIP cats (including tumor necrosis factor alpha, 
interleukin (IL) 1, 2, 4, 6, 10, and 12, and IFN-γ) have been extensively studied in order to 
find out how the immune system is involved in the onset of FIP (Berg et al., 2005; Dean et 
al., 2003; Goitsuka et al., 1987; Goitsuka et al., 1990; Hasegawa & Hasegawa, 1991; Kipar et 
al., 2006b; Kiss et al., 2004; Takano et al., 2007). However, great variability is observed 
between individual animals, and even between different tissues within 1 animal, often 
resulting in contradictory conclusions on the expression level of a specific cytokine in FIP 
cats. But although the triggers for the onset of FIP remain largely elusive, the consequences 
are unambiguously clear: FIP is associated with a proliferation and activation of the FIPV 
target cells (monocytes/and macrophages) and with an evident suppression of protective 
innate (NK-cells) and adaptive (CD4+ and CD8+ T cells, and regulatory T cells) immunity to 
attack the virus and to deal with excessive damaging inflammatory processes (de Groot-
Mijnes et al., 2005; Kipar & Meli, 2014; Kipar et al., 2005; Vermeulen et al., 2013). 
1.1.5 Lesions and symptoms 
1.1.5.1 FECV infections 
Although affecting nearly all cats in multi-cat environments, FECV infections pass unnoticed 
in most of these cases, as they are generally associated with no or rather mild and non-specific 
(transient anorexia and/or diarrhoea) symptoms. Consequently, most cattery owners are not 
aware of the presence of FECV until one or more of their cats suddenly succumb(s) to FIP. 
1.1.5.2 FIP 
FIP was first described as a disease typically characterised by a diffuse granulomatous 
peritonitis in presence of ascites (Holzworth, 1963). However, it became rapidly clear that 
peritonitis is only one amongst several other pathological changes seen in FIP, affecting many 
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organs and tissues besides the peritoneum. FIP manifests in different clinical forms, 
depending on the presence (effusive or wet FIP) or absence (non-effusive or dry FIP) of 
effusions, and depending on the affected organ(s). Effusions (abdominal, thoracic and/or 
pericardial) are seen in 60-80% of all cases, but care should be taken when using this as the 
only factor to consider FIP as diagnosis, as only 51% of all cats with effusion do actually 
have FIP (Hartmann et al., 2003). Moreover, the highly variable and non-specific clinical 
signs do not further help clinicians in finding the right aetiology for the cats’ disease (see 
below). Mostly, FIP cats are presented with lethargy, anorexia, and weight loss, but it is not 
uncommon that seemingly normally conditioned cats, initially presented with other symptoms 
as dyspnoea, polyuria/polydipsia (due to kidney disease or pancreas damage-induced 
diabetes), neurological signs and/or ocular lesions, are finally diagnosed with FIP. Upon 
physical examination, many FIP cats show jaundice (which can have a hepatic and pre-
hepatic origin) and/or mild fever, which upon treatment, shows to be unresponsive to 
antibiotics. Palpation/medical imaging will confirm the presence of abdominal fluid (which is 
present in 65% of all effusive forms), and can reveal enlargement or deformation of kidneys, 
liver, intestines and/or mesenteric lymph nodes in the dry form of the disease (Addie et al., 
2009).  
Distinction between the effusive and non-effusive form was initially thought to be a reflection 
of the lesions, serosal and parenchymatous granulomatous lesions, respectively. However, 
profound pathological examinations have shown that this is merely a clinical distinction, as a 
mixture of both serosal and parenchymatous (pyo)granulomas are found in nearly all cats 
(Kipar & Meli, 2014).  
 
 
Figure 1.6. FIP pathology. (A) Typically big-bellied FIP cat due to abdominal effusion. (B) Macroscopic 
lesions consisting of diffuse granulomatous serositis affecting the omentum, spleen, liver, intestines, and 
peritoneum. (C) Diffuse, small granulomas on mesentery with enlargement of mesenteric lymph node. (D) 
Vasculitis and large granulomas on the kidney. 
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1.1.6  Diagnosis 
Ante-mortem diagnosis of FIP is often non-conclusive for the following reasons: 1) the 
symptoms are too vague to discriminate from other diseases and vary in between FIP cats 
depending on the affected organs, 2) serology is hampered by the detection of anti-FECV 
antibodies, and 3) changes in haematological parameters and protein electrophoresis can be 
suggestive but are certainly not pathognomonic. FIP can hitherto only undoubtedly be 
demonstrated by detection of FCoV antigens in macrophages in effusions (by means of 
immunofluorescence) or affected tissue samples (by means of immunohistochemistry). 
Detection of positive macrophages in effusion is 100% predictive of FIP (Hartmann et al., 
2003), but is currently only done in a few laboratories. Tissue samples for the more widely 
available immunohistochemical detection of antigens can be obtained by laparotomy or 
percutaneously, but both methods have their advantages and disadvantages. Whereas 
percutaneous biopsy is less risky and hence preferred to perform on these seriously ill cats, 
laparotomy allows a better-controlled sample taking of affected sites and hence creates less 
false negative results (Giordano et al., 2005). In many cases, FIP cannot be confirmed and the 
diagnosis remains a probability diagnosis, whereby history, clinical signs, and analysis of 
effusion, blood and in some cases cerebrospinal fluid should be combined to obtain a high 
FIP probability (Figure 1.7) (Addie et al., 2009; Kipar & Meli, 2014; Pedersen, 2009, 2014). 
Diagnosing FIP with the highest probability is important, as misdiagnosis will often 
unnecessarily lead to the cat’s death, since the main ‘treatment’ for FIP remains euthanasia. In 
addition, as in some cases prednisolone is used to try to prolong the cat’s survival, other 
infectious FIP differential diagnoses (Table 1.4) should be excluded, as for most of them 
prednisolone is highly contra-indicated and can also result in unnecessary cat’s death. 
Recently, a new FECV-FIPV discriminatory test (IDEXX FIP Virus RealPCR™ Test) was 
launched based on 2 mutations (M1058L or S1060A) in the S2 domain of the spike protein, 
which are found in 96 % of all FIP tissues, but not in faeces of healthy cats (Chang et al., 
2012). It has been recommended to use this test on effusions or biopsies taken from FIP 
suspected cats to make a definite FIP diagnosis. However, another study reports that the 
mutations can be found in tissues from both non-FIP and FIP cats (Porter et al., 2014), and 
more details on the sensitivity and notably specificity of the test on biopsies/effusions of both 
non-FIP and FIP cats should therefore reveal the value of this test. If a specificity of nearly 
100% can be shown, this test will add an alternative/additional test method (apart from 
antigen detection in macrophages) to ascertain that a cat has FIP.  
 
Introduction 21 
 
 
 
Fi
gu
re
 1
.7
. A
nt
e-
m
or
te
m
 F
IP
 d
ia
gn
os
is.
 
22 
 
Table 1.4. Important FIP differential diagnoses to take into consideration if testing is not conclusive or 
unlikely for FIP (Davies & Forrester, 1996; Jones, 1975; Pedersen, 2009, 2014; Poindessault Santa-Croce, 
2006). 
 
                 Effusive FIP                Non-effusive FIP 
1. Abdominal effusion 
• Hypoproteinemia  
(liver or kidney disease, protein 
losing enteropathy) 
• Congestive heart failure 
• Infections 
(bacterial, parasitic) 
• Traumatic hemo- or uro- 
peritoneum 
• Cholangitis 
• Pancreatitis 
• Tumours 
2. Thoracic effusion/dyspnoea 
• Heart failure 
• Infections 
(bacterial, parasitic) 
• Chylothorax 
• Hemothorax 
• Tumour 
• Intoxication 
• Hernia diaphragmatica 
1. Systemic infections 
• Toxoplasmosis 
• Mycosis 
• Feline leukemia virus (FeLV) 
• Feline immunodeficiency virus (FIV) 
• Tuberculosis 
• Actinomycosis 
2. Tumours 
3. Other disorders 
• Degenerative disease of CNS 
• Meningitis 
• Trauma 
• Storage diseases 
• Idiopathic uveitis 
• Hepatic/renal amyloidosis 
1.1.7 Prevention 
1.1.7.1 Vaccination 
Vaccination is a very effective approach for the eradication of viral infections, but despite 
numerous attempts, development of a safe and effective vaccine against FIPV has been 
largely unsuccessful so far. Since cell-mediated immune responses are needed for protection 
against FIP, many studies focused on the use of live or modified live viruses.  Vaccination 
with avirulent FIPV strains (Pedersen & Black, 1983), recombinant viruses carrying the FIPV 
S, N, or M proteins (Glansbeek et al., 2002; Hebben et al., 2004; Klepfer et al., 1995; 
Vennema et al., 1990; Wasmoen et al., 1995), and closely related coronaviruses (CCoV, 
TGEV and human coronavirus (HCoV) 229E) did not protect cats against challenge with 
FIPV (Barlough et al., 1984; Barlough et al., 1985; Stoddart et al., 1988a; Woods & 
Pedersen, 1979). Moreover, antibodies induced by vaccination, enhanced development of FIP 
Introduction 23 
 
 
after challenge in most of those studies. The use of a sublethal dose of a virulent FIPV 
showed to be effective, but this virus was not safe enough to be considered as a vaccine 
candidate (Pedersen & Black, 1983). In the late eighties, a modified-live temperature sensitive 
FIPV was derived from the virulent DF2 FIPV strain and used as an intranasal vaccine 
(Christianson et al., 1989; Gerber et al., 1990a; Gerber et al., 1990b). This vaccine was the 
first and to date only commercially marketed vaccine (Primucell® FIP) and has been found to 
be safe for vaccination of healthy cats, immunosuppressed cats (dexamethasone treated or 
FeLV viraemic) and cats with pre-existing coronavirus antibodies. However, Primucell® FIP 
has not been approved for pregnant queens and kittens before the age of 16 weeks. Moreover, 
the efficacy of the Primucell® vaccine is highly dependent on the successful prevention of 
exposure to FCoVs prior to vaccination (Fehr et al., 1997). Since most kittens are infected at 
5-10 weeks of age and vaccination is only safe and efficacious in seronegative animals from 
the age of 16 weeks, vaccination will never be successful if the infection pressure is not 
correctly managed (see below). In addition, it remains questionable if this serotype II-based 
vaccine is efficacious against the predominant serotype I strains (Olsen, 1993; Pedersen, 
2009). Promising results were obtained using FIPV 79-1146 deletion mutants, truncated in 
their ORF3 or ORF7 genes, as vaccine candidates. These ORF3 and ORF7 deleted viruses 
conferred 100% and 80% protection to homologous challenge with the highly virulent FIPV 
79-1146, respectively (Haijema et al., 2004). However, reports on follow-up research are still 
lacking. A similar approach was recently described by Balint et al. (2014). Two infectious 
FIPV DF2 clones were generated, one with a truncated ORF3 and the other with an intact 
ORF3, displaying a low virulent and completely avirulent phenotype, respectively. Both 
vaccine candidates conferred 100% protection against homologous challenge with virulent 
FIPV DF2 in specific pathogen free (SPF) cats. However, application of the same vaccination 
strategy in purebred British Shorthair cats resulted in 100% deaths after challenge, again 
highlighting the role of the cat’s genetics and immunological responses in the determination 
of outcome of a FIPV infection (Balint et al., 2014b).  
Recently, a new vaccination approach has been considered. As Th1-responses, and 
consequently IFN-γ production, can confer protection against FIP, this strategy is based on 
the induction of Th1-responses by using Th1-stimulating peptides derived from viral 
structural proteins. These peptide-based vaccines were administered with feline CpG-
oligodeoxynucleotides as vaccine adjuvant, and peptide-vaccines with Th1-epitopes from the 
N protein of serotype I FIPV KU-2 conferred slightly better protection against FIPV 79-1146. 
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However, immune tolerance was also reported and hence more studies are required to 
optimize the concentration of peptides and fCpG-ODNs, along with dose, frequency and route 
of administration (Takano et al., 2014a). In another report, these researchers showed that 
peripheral blood mononuclear cells (PBMCs) of cats vaccinated with an M- or S-derived 
peptide had significantly higher IFN-γ production compared to controls (Takano et al., 
2014b). Whether these peptide-vaccines will also be able to protect cats from FIP 
development should be further investigated by challenge studies. 
1.1.7.2 Management 
As FIP is the consequence of a common FECV infection, prevention of FIP can be directed at 
controlling transmission of this parent virus (Addie et al., 2004). FECV is shed via the faeces 
and can survive for 7 weeks in a dry environment. Consequently, measures should be taken to 
prevent faecal contamination of the environment (floors, water, food) by regular (and 
preferably daily) cleaning en disinfection of floors, litter trays, water- and food bowls (Addie 
et al., 2009). Infected cats shed the virus for many weeks, months, or in case of persistent 
shedders, years and these cats are a continuous source of (re)infection for negative cats 
(Addie & Jarrett, 2001; Addie et al., 2003; Pedersen, 2009; Pedersen et al., 2008). Therefore, 
if one wants to prevent FECV infection, the most important measure to be taken is to prevent 
any contact between shedders and naive animals. In the past, this separation policy has been 
successfully applied to either completely eradicate FCoVs (Hickman et al., 1995), or to 
control transmission to the most susceptible population in breeding catteries, namely the 
several weeks old kittens (Addie & Jarrett, 1992). Hickman et al. reported the introduction of 
FECV in a closed SPF facility of the University of California, Davis, which had been 
unnoticed until several cats started to die from FIP. As these cats were of high value, the 
researchers decided to completely eradicate FCoVs from the colony by serological testing and 
grouping based on antibody titres, since no diagnostic PCR tests were available at that time. 
Only seronegative animals were kept to create offspring, and cats that remained seropositive 
were removed from the colony. By regular testing and strict quarantine measurements, these 
researchers were able to recreate a FCoV-negative SPF population (Hickman et al., 1995). In 
practice, however, this method has many drawbacks and is hardly feasible. Indeed, by using 
PCR to measure faecal shedding, many researchers reported inconsistent conclusions on the 
correlation between antibody titre and shedding, indicating that it is very difficult to reliably 
isolate shedders from non-shedders based on their serum antibody titre (Addie et al., 2003; 
Foley et al., 1997; Harpold et al., 1999; Pedersen et al., 2008). In addition, even if this would 
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be successful, it is quite challenging in practice to remain FCoV-negative, as FCoV infections 
are present in virtually all multi-cat environments from where new cats are frequently 
imported. FIP is typically seen in kittens in the post-weaning period and most kittens are 
protected by maternally derived antibodies until 5-10 weeks of age. Therefore, it has been 
recommended to direct the control of FIP towards the control of FECV transmission from 
shedders to the kittens, more specifically by isolating the queens 2-3 weeks prior to partus, 
taking the kittens away from their mother at 4-6 weeks of age (= early weaning) and raise 
them in complete isolation (Addie et al., 2004). Although clearly demonstrated that early 
weaning can strongly decrease the incidence of FIP (Addie & Jarrett, 1992), the success rate 
is variable and depends on the isolation procedure and the shedding state of the queen (Addie 
et al., 2004). When kittens are faced with a high infection pressure, viruses break through the 
maternal immunity and kittens can become infected as soon as 2 weeks of age (Lutz et al., 
2002). In addition, early weaning has been questioned by its negative impact on the 
socialisation of kittens, and is therefore not regularly applied in practice. 
FECV remains enzootic by continuous faecal-oral transmission of the virus from shedders to 
non-shedders (Addie et al., 2003; Foley et al., 1997). Consequently, grouping of cats based 
on their shedding state has been opposed to avoid (re)infections, but no reports on successful 
isolation of shedders from non-shedders have yet been published. However, this strategy 
would allow protection of FECV exposure to kittens without the need for early weaning and 
complete isolation, as this would allow selection of negative animals for breeding and 
socialisation of kittens. Although cattery owners are aware of the fact that adapting 
management is currently the only way to deal with FIP, the time- and money-consuming 
measures to be taken (due to the long-lasting and highly contagious character of FECV) 
remain a drawback for many of them. 
1.1.8  Treatment 
To date, there is no treatment with proven efficacy available to cure cats from FIP. Some FIP-
affected cats will undergo a spontaneous remission without ever showing clear symptoms, but 
once the clinical signs become apparent, mortality is nearly 100%. Several attempts have been 
made to treat FIP, including the use of immune-suppressive drugs, viral replication inhibitors, 
and non-specific immunostimulant drugs (reviewed by (Pedersen, 2014)), but, despite some 
claims, properly controlled clinical trials to evaluate the real efficacy is still lacking for many 
of those products. Although the lack of evidence on efficacy for any of those products, some 
of them including prednisolone, interferon omega, polyprenyl immunostimulant, and 
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pentoxyfillin, have been frequently used in practice. Although it will not cure the cat, 
prednisolone is probably the most rational one to use, as it makes the cat feel better and 
stimulates appetite, which will certainly enhance the quality of the cat’s life. In addition, 
prednisolone is the treatment of choice to cure lymphocytic cholangitis, one of the most 
difficult differential diagnoses to make with FIP. Hence, if one would have misdiagnosed a 
cat with FIP, prednisolone can make this cat survive. Recently, promising results were 
obtained in vitro with synthetic peptides targeting either the viral spike (Liu et al., 2013) or 
the viral 3C-like protease (Kim et al., 2013), but results of in vivo safety and efficacy testing 
are still to be reported.  
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1.2 ENTRY OF CORONAVIRUSES 
Coronaviruses infect a wide range of mammalian species and birds, causing medically and 
economically important diseases in humans, birds, lifestock and pets. The host and the 
tissue(s) infected by a certain strain are largely determined by the expression of the viral 
receptor(s) and fusion triggers, which vary greatly amongst the different members of the 
Coronaviridae family. Both coronavirus’ receptors and fusion processes are reviewed below. 
1.2.1 Receptors and attachment factors involved in coronavirus infections 
Every virus infection is initiated by attachment of the virus particle to one or more cell surface 
molecules. Whereas some of these ‘receptors’ only mediate absorption of the virus to the host 
cells and hence should merely be considered as ‘attachment factors’, others are absolutely 
necessary to guide the infectious entry of the virus in its target cell by generating fusion-
competent spikes or allowing the endocytosis of the virus. A wide variety of cell surface 
receptors/attachment factors have been described for coronaviruses, including both proteins 
and sugars, but for some coronaviruses, including serotype I FCoVs, receptors remain elusive 
to date (Table 1.5). In general, coronavirus attachment occurs by spike-carbohydrate, spike-
protein, and/or viral mannose carbohydrate-host lectin interactions. All three classes of 
receptors are discussed below with respect to their role in coronavirus infections. 
1.2.1.1 Carbohydrates: sialic acids and heparan sulfate 
Two types of carbohydrate receptors have been described for coronaviruses: sialic acids and 
heparan sulfate. However, whereas sialic acids are clearly involved during in vivo infections, 
heparan sulphate is thought to be less, if not at all, relevant, as it is only reported as receptor 
for some cell-culture propagated strains (de Haan et al., 2005; de Haan et al., 2008; Madu et 
al., 2007). 
Sialic acids are acidic monosaccharides, typically found at the outermost end of N-glycans, 
O-glycans, and glycosphingolipids. They occur in many diverse forms (all of them derivatives 
of neuraminic acid), depending on the substitutions at the 4-, 5-, 7-, 8-, and 9-carbon group 
(Figure 1.8) (Schauer, 2004; Varki & Schauer, 2009). N-acetylneuraminic acid (Neu5Ac), N-
glycolylneuraminic acid (Neu5Gc) and N-acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2) are 
the most predominant forms in mammalian cells (Schauer, 2004). From the 2-carbon, sialic 
acids are α-glycosidically linked to the underlying sugar chain. This can occur to the 3- or 6-
carbon position of galactose, N-acetyl-D-glucosamine, or N-acetyl-D-galactosamine residues. 
Some sialic acids can even occupy internal positions, most commonly attached to another 
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sialic acid at the 8-carbon position. These 2,3-, 2,6-, and 2,8-α-linkages highly impact the 
glycan structure and further contribute the diversity within the sialic acids family (Varki & 
Schauer, 2009).   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Overview of naturally occurring sialic acids. Adapted from (Schauer, 2004) 
Many viruses, including influenzavirus, feline calicivirus, some rotaviruses, adenoviruses, 
and coronaviruses, have evolved to use a specific type of sialic acids for their entry 
(Haselhorst et al., 2009; Kaludov et al., 2001; Schwegmann-Wessels & Herrler, 2006; Skehel 
& Wiley, 2000; Stuart & Brown, 2007). Given the species-, tissue-, or even molecule-specific 
expression of sialic acid linkages and modifications (Varki & Schauer, 2009), sialic acids are 
often major determinants of virus tropism.  
Within the coronaviruses, TGEV and the related PRCV are probably the most well known 
examples of how sialic acid binding activity can determine virus tropism. TGEV is an enteric 
pathogen, causing fatal diarrhoea in newborn piglets. PRCV emerged in 1984 from TGEV by 
mutations and shares an overall homology of 96% (Pensaert et al., 1986; Rasschaert et al., 
1990). Although both viruses use the same receptor, porcine aminopeptidase N, PRCV has 
lost its enterotropism and replicates very efficiently in the respiratory tract (Cox et al., 1990; 
Delmas et al., 1993; Delmas et al., 1992). A major difference between both viruses lies in the 
spike gene, as PRCV spike lacks 224 to 227 amino acids in its S1 subunit (Rasschaert et al., 
1990; Wesley et al., 1991), thereby missing 2 antigenic sites (Sanchez et al., 1990) and the 
sialic acid (preferentially N-glycolylneuraminic acid) binding capacity found in TGEV 
(Schultze et al., 1996). Although dispensable for in vitro infections, the TGEV sialic acid 
binding activity is undoubtedly involved in the virus’ enterotropism in vivo, as not only 
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PRCV, but also mutants lacking the sialic acid binding site were no longer capable of 
inducing enteropathy (Bernard & Laude, 1995; Krempl et al., 1997). Indeed, TGEV binds to a 
second receptor in the intestinal brush border, a 200 kDa mucin-type glycoprotein, which 
seems indispensable to allow intestinal infections, most probably by attaching to and passing 
through the mucus layer covering the intestinal epithelial cells (Schwegmann-Wessels et al., 
2003).   
In addition to TGEV, many other coronaviruses possess sialic acid binding potential, 
including porcine epidemic diarrhoea virus (PEDV), bovine coronavirus (BCoV), human 
coronavirus OC43, porcine haemagglutinating encephalomyelitis virus (HEV), and avian 
infectious bronchitis virus (IBV) (Table 1.5) (Kunkel & Herrler, 1993; Schultze & Herrler, 
1992; Schultze et al., 1990; Vlasak et al., 1988; Winter et al., 2006). The betacoronaviruses 
BCoV, HCoV-OC43, and HEV recognize 9-O-acetyl-5-N-acetylneuramininc acid (Neu 5,9 
Ac2), which at least for BCoV is a receptor determinant, as treatment of cells with 
neuraminidase or acetylesterase renders cells resistant to infection (Schultze & Herrler, 1992). 
Those viruses share the characteristic feature to express an additional structural protein in 
their envelope, the haemagglutinin esterase (HE) glycoprotein. This HE protein serves as a 
receptor destroying enzyme and potentially has similar functions to the receptor-destroying 
enzyme of orthomyxoviruses, such as facilitating viral spread by enhancing virus release from 
infected cells and by preventing the formation of virus aggregates (Schwegmann-Wessels & 
Herrler, 2006). Some strains of murine hepatitis virus (MHV) also contain such HE protein, 
but they rather hydrolyse 4-O-acetyl-5-N-acetylneuraminic acid (Smits et al., 2005). For 
MHV, the expression of HE and the ability to attach to O-acetylated sialic acids have been 
linked to neurovirulence (Kazi et al., 2005; Yokomori et al., 1995). 
For FCoVs, no information is available on the role of sialic acids in virus infection. However, 
it has been shown that healthy FCoV-positive cats typically mounted an acute phase reaction 
consisting of hypersialylated serum alpha1-acid glycoprotein (AGP), whereas cats that went 
on to develop FIP had hyposialylated serum AGP (Ceciliani et al., 2004). If and how this 
feature contributes to FIP pathogenesis remains elusive.  
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1.2.1.2 Protein receptors 
For most coronaviruses, attachment to specific transmembrane proteins, notably peptidases, is 
the key determinant for the initiation of infection. Although coronaviruses need enzymatic 
cleavage of their spikes to allow efficient fusion processes, the enzymatic activity of these 
receptor peptidase is not involved in this process for most, if not all, of them (Delmas et al., 
1994; Li et al., 2003; Raj et al., 2013). 
Aminopeptidase N (APN) or CD13 is a type II transmembrane Zn2+-dependent protease 
(metalloprotease) with a wide tissue/cell type distribution (epithelial cells, endothelial cells, 
fibroblasts, and leukocytes). It is an ectoenzyme cleaving N-terminal neutral amino acids 
from peptides and proteins, thereby fulfilling many different functions such as regulation of 
peptides, tumour-cell invasion, differentiation, migration, proliferation, apoptosis, 
chemotaxis, and antigen presentation. In addition, APN is known to execute many other 
enzymatic-activity-independent processes by mediating endocytosis or initiating cell-
signalling cascades upon ligand binding (for a comprehensive review see (Mina-Osorio, 
2008)). One of the protease-independent processes includes its receptor function for many 
alphacoronaviruses, including serotype II FCoVs, PRCV, TGEV, CCoV, PEDV, and HCoV 
229E (Benbacer et al., 1997; Delmas et al., 1993; Delmas et al., 1992; Hohdatsu et al., 1998; 
Oh et al., 2003; Van Hamme et al., 2011; Yeager et al., 1992). Apart from their species 
specific APN, TGEV, CCoV, and HCoV 229E also bind to feline (f)APN, and it has 
consequently been proposed that cats can be potential mixing vessels for new emerging 
viruses (Tresnan et al., 1996). fAPN is the sole receptor for serotype II FCoV in continuous 
cell cultures (Hohdatsu et al., 1998; Tresnan et al., 1996; Van Hamme et al., 2011). In 
monocytes, however, at least serotype II FIPV is able to use an alternative yet unidentified 
receptor to induce infection (Van Hamme et al., 2011). In contrast to the serotype II viruses, 
the entry factors involved in serotype I infections are still mainly unknown. There have been 
some conflicting evidences regarding the use of fAPN for the functional entry of serotype I 
FCoVs. Tresnan et al. reported replication of the serotype I FIPV UCD-1 after transfection of 
fAPN cDNA in otherwise unsusceptible hamster and mouse cells (Tresnan et al., 1996). 
However, further reports evidenced against the role of fAPN in the serotype I infection (Dye 
et al., 2007; Hohdatsu et al., 1998; Van Hamme et al., 2011), which can explain the 
difficulties to propagate serotype I FCoVs on all (fAPN-expressing) feline cell lines.  
Angiotensin-converting enzyme (ACE2) is a type I integral membrane carboxy-
metallopeptidase expressed by alveolar and intestinal epithelial cells, and arterial and venous 
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endothelial cells (Hamming et al., 2004). ACE2 functions as a receptor for SARS-CoV, 
HCoV NL63, and bat SARS-like CoV WIV1 (Ge et al., 2013; Hofmann et al., 2005; Li et al., 
2003).  
Dipeptidyl peptidase 4 (DPP4) was recognized in 2013 as an additional coronavirus receptor 
used by the recently emerged Middle East respiratory syndrome coronavirus (MERS-CoV) 
(Raj et al., 2013) and the related bat CoV HKU4 (Yang et al., 2014). It is a cell surface serine 
protease expressed on epithelial cells, endothelial cells, and leukocytes in various tissues, but 
it also occurs in a soluble form in plasma or other body fluids (Boonacker & Van Noorden, 
2003; Lambeir et al., 2003). DPP4 typically releases proline-containing dipeptides from 
polypeptide chains, thereby regulating bioactivity of many molecules, but this enzymatic 
activity is not involved in MERS-CoV entry (Raj et al., 2013). 
Carcinoembryonic antigen-cell adhesion molecule 1 (CEACAM1), a type I 
transmembrane protein belonging to the immunoglobulin superfamily, has been identified as 
the MHV receptor (Dveksler et al., 1991). Both isoforms of CEACAM1, CEACAM1a and 
1b, can function as MHV receptor, but CEACAM1a has much higher affinity (Ohtsuka et al., 
1996). In contrast to all other coronaviruses, the amino acids responsible for the spike-
CEACAM1 receptor interaction have not been mapped to the C-RBD, but to the N-RBD of 
the spike (Figure 1.3), a region that is typically involved in sialic acid binding in other 
coronaviruses. Interestingly, the crystal structure of the MHV receptor-binding domain 
revealed a similar galectin-like structure of the N-RBD as found in sialic acid binding viruses 
as BCoV and HCoV OC43, but the lack of a peptide loop makes the MHV spike not operative 
as a lectin, but as a ligand for CEACAM1 receptor engagement (Peng et al., 2011). One 
MHV strain, MHV/BHK, has lost its CEACAM1 tropism by acquiring 2 heparan sulfate 
binding sites (de Haan et al., 2005).     
1.2.1.3 C-type lectins 
Many coronaviruses use dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN or 
CD209), or DC-SIGN related (DC-SIGNR), also called L-SIGN (liver/lymph node specific) 
or CD209L as entry factor. DC-SIGN and L-SIGN are transmembrane Ca2+-dependent 
carbohydrate binding proteins (C-type lectins). DC-SIGN is expressed on subsets of dendritic 
cells/macrophages, whereas L-SIGN is found in liver, lung, lymph node, and intestine, 
expressed on endothelial cells or alveolar cells (Khoo et al., 2008). They specifically 
recognize high-mannose carbohydrates and serve as adhesion molecules and pattern 
recognition receptors, as these mannoses are expressed by many microbial proteins, including 
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the highly glycosylated spike protein of coronaviruses (Siddell et al., 1983). The (mis)use of 
C-type lectins as receptor determinants for coronaviruses was first noticed for human 
coronaviruses. For SARS-CoV, DC-SIGN and L-SIGN can function either as alternative 
receptors (Han et al., 2007; Jeffers et al., 2004) or as enhancing factors during ACE2-
mediated entry (Marzi et al., 2004). L-SIGN can also act as an additional receptor for HCoV 
229E (Jeffers et al., 2006), whereas DC-SIGN is an enhancing factor in the ACE2-medated 
entry for HCoV NL63 (Hofmann et al., 2006). For animal coronaviruses, the role of C-type 
lectins as entry factors has only been reported for FCoVs. Serotype II FCoV, including strains 
79-1146, DF2 and 79-1683, use DC-SIGN as a co-entry factor in APN-expressing susceptible 
cells (Regan & Whittaker, 2008; Van Hamme et al., 2011). In addition, DC-SIGN also acts as 
a co-receptor in serotype I FIPV infections of feline monocytes and DCs (Regan et al., 2010; 
Van Hamme et al., 2011), and both serotype I and serotype II FIPV infections can be reduced 
in cell cultures by addition of mannose-binding lectins (Keyaerts et al., 2007; van der Meer et 
al., 2007). However, the primary receptor for serotype I FCoV infections remains unidentified 
so far. 
1.2.2 Fusion processes in coronavirus biology 
Coronavirus spike proteins are class I fusion proteins, mediating fusion processes during two 
events in the replication cycle, namely very early to deliver the nucleocapsid from virions into 
the host cell (virus-cell fusion), and late in the infection cycle to spread the infection from the 
infected cell to the neighbouring uninfected cell without the need for cell-free viruses to be 
formed (cell-cell fusion). Viral class I fusion proteins are typically synthesized as inactive 
precursor proteins and require proteolytical cleavage to acquire their fusion competent state. 
This fusion competent protein, comprised of a metastable complex of receptor binding 
subunit and fusion subunit, undergoes subsequent conformational changes upon receptor 
binding, acidification, and/or additional proteolysis (= fusion triggers), resulting in the 
dissociation of both subunits, which finally allows the insertion of the hydrophobic fusion 
peptide into the host membrane (Figure 1.9, I-II). By refolding to its most stable 
conformation, i.e. the formation of a 6 helical bundle (6HB) by the association of the 
trihelical HR1 and HR2 domains, the fusion protein mediates close apposition and subsequent 
fusion of the viral envelope with the host membrane (Figure 1.9, III-V) (Bosch et al., 2003; 
Eckert & Kim, 2001; White et al., 2008). 
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Figure 1.9. Schematic representation of membrane fusion processes mediated by coronavirus S proteins. 
Dissociation of the S1 receptor binding subunit and the S2 fusion subunit upon proteolysis, receptor binding, 
and/or pH reduction liberates the viral fusion peptide, which becomes inserted into the host membrane (I-II). 
Subsequent refolding of HR1 and HR2 into a 6 helix bundle (6HB) finally results in fusion of viral and host 
membrane and the release of the viral genome in the cytoplasm (III-V). 
 
As for the receptor usage, coronaviruses also show great distinctions in entry pathways and 
fusion activating triggers. These differences largely influence virus tropism and 
pathogenicity, and can explain why 2 viruses or even strains using the same receptor can 
show such great distinction in cell tropism. In addition, it seems that some coronaviruses have 
evolved to use multiple cell entry routes, depending on the cell type the virus is faced with. 
Figure 1.10 reviews entry pathways and fusion triggers of different coronaviruses.  
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Many viruses carrying class I fusion proteins require an early proteolytical activation of their 
fusion proteins in the virus-producing cells, usually mediated by furin-like cellular proteases 
encountered during exocytosis processes. For most of them, this proteolytical cleavage occurs 
directly N-proximal of the hydrophobic fusion peptide, allowing its immediate insertion into 
the target cell membrane after introducing conformational changes upon receptor binding 
and/or low pH exposure (Dimitrov, 2004). The exact location of the coronavirus fusion 
peptide is not known, but based on the sequence, the structure, the position within the S 
trimer, and the conservation among coronaviruses, the sequence SFIEDLLFNKVTLADAGF 
of SARS-CoV, and the related sequence in other coronaviruses, has been suggested as the 
putative coronavirus fusion peptide (Belouzard et al., 2012; Madu et al., 2009). Remarkably, 
furin cleavage of the coronavirus spike into the receptor binding S1 subunit and the S2 fusion 
subunit occurs not directly adjacent to this fusion peptide (Figure 1.11, CS1) (Bosch et al., 
2008; Bosch et al., 2004). In addition, many coronaviruses do not posses the multibasic furin 
cleavage motif (R-X-R(K)-R) at the S1/S2 boundary, and hence carry uncleaved spikes 
(Belouzard et al., 2012; de Haan et al., 2008; Wesseling et al., 1994; Yao et al., 2004). For 
viruses that carry pre-cleaved spikes, such as IBV, MHV-A59, and MHV-4, receptor 
engagement and/or exposure to acid pH have generally been believed to be sufficient to allow 
genome release in the cell (Figure 1.10 pathway 1 and 2), although it has recently been 
questioned if these are the only triggers. Indeed, furin cleavage occurs not directly adjacent to 
the putative fusion peptide, and both MHV-A59 and IBV spikes seem to become additionally 
cleaved within their S2 subunit during entry (Wicht et al., 2014a; Yamada & Liu, 2009). In 
contrast to IBV, MHV-4 and MHV-A59, most coronaviruses carry uncleaved spikes and 
indisputably rely on proteolytical activation with proteases encountered during virus entry to 
allow infections (Figure 1.10 pathway 3, 4, and 5). It has become clear that the presence or 
absence of furin cleavage has no impact on coronavirus infectivity (Hingley et al., 2002), 
although it can impact the fusion trigger/entry pathway required to initiate infections. Indeed, 
SARS-CoV and MHV-2, which lacks the furin recognition site, normally depend on 
endosomal cathepsins, but this dependence can be counteracted by introducing a consensus 
furin cleavage site (Qiu et al., 2006; Watanabe et al., 2008). In addition, rendering cleaved 
spikes uncleavable by mutations in the multibasic motif or by furin inhibition did not affect 
MHV-A59 infectivity (de Haan et al., 2004; Gombold et al., 1993), but it made the virus 
more susceptible to inhibitors of endocytosis (de Haan et al., 2004). In contrast to the virus-
cell fusion, S1-S2 cleavage during virus infections increases the cell-cell fusion (de Haan et 
al., 2004; Yamada et al., 1997), explaining the advantage for those viruses to produce pre-
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cleaved spikes, and highlighting the fact that virus-cell and cell-cell fusion processes are 
differently regulated. 
Different, alternative entry pathways have been demonstrated for many coronaviruses, and the 
pathway that is used seems to be determined by the target cell/tissue. It is well established that 
infectivity of many coronaviruses, such as MHV, SARS-CoV, and PEDV, can be enhanced 
by exogenous treatment of trypsin, and that this treatment can bypass the endocytosis 
pathway (Matsuyama et al., 2005; Qiu et al., 2006; Sturman et al., 1985; Wicht et al., 2014b). 
In addition to trypsin, SARS-CoV fusion at the plasmamembrane can also be induced by 
treatment with elastase or thermolysin, or by expression of transmembrane serine proteases 
such as TMPRSS2 (Belouzard et al., 2010; Bertram et al., 2011; Glowacka et al., 2011; 
Matsuyama et al., 2005; Shulla et al., 2011). At least for SARS-CoV, this mode of entry is 
much more efficient than the cathepsin-dependent entry (Matsuyama et al., 2005). The 
monobasic cleavage sites recognized by these proteases are not only found at the S1/S2 
boundary, but also directly upstream of the putative fusion peptide (Figure 1.11, CS2) 
(Belouzard et al., 2009; Belouzard et al., 2012; Bosch et al., 2008; Matsuyama et al., 2005; 
Simmons et al., 2004). As cleavage at the S1/S2 boundary seems not to be a determinant of 
infectivity and cannot liberate the internal fusion peptide, cleavage at CS2 is considered as the 
key fusion-determining factor for many coronaviruses (Belouzard et al., 2009). Indeed, for 
IBV Beaudette (and related strains), 2 furin cleavage sites are found, one at amino acid 
position 531-538 (CS1) and the other at amino acid position 684-692 (CS2) (Figure 1.11). 
Whereas the first cleavage site can promote cell-cell fusion, only the latter is the key 
determinant for induction of both virus-cell and cell-cell fusion. At that position, FCoV 79-
1683, TGEV, CCoV, and bat HKU5-1 also have a furin cleavable motif (RKYR), whereas 
other coronaviruses have a highly conserved trypsin cleavable site (Yamada & Liu, 2009).  
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Figure 1.11. Coronavirus spike cleavage sites and sequence of different coronaviruses at these sites. 
Coronavirus S proteins are composed of the S1 receptor binding (S1) and the transmembrane fusion (S2) 
subunit. The S2 subunit contains a fusion peptide (FP) and 2 heptad repeat regions (HR 1 and 2) and mediates 
fusion of the viral envelope with the host membrane after proteolytical activation. Two proteolytic cleavage sites 
(CS) have so far been identified in coronaviruses: CS1 is located at the S1/S2 boundary, whereas CS2 is located 
just upstream of the putative fusion peptide. Furin recognition motifs are indicated in red. 
Viruses carrying uncleaved spike can theoretically be proteolytically activated during either 
extracellular transit (e.g. by trypsin in the gastro-intestinal tract) or during entry of the virus 
by proteases at the plasma membrane or in endosomes. For most coronaviruses, however, 
only receptor-associated S proteins seem to be available for proteolysis, potentially due to 
fusion-promoting conformational changes upon receptor engagement (Kam et al., 2009; 
Matsuyama et al., 2005; Park et al., 2011; Simmons et al., 2005; Wicht et al., 2014b).  
With some exceptions, endocytosis is the main route for entry of most coronaviruses, 
potentially because this route advantages the virus to pass through the cortical actin network 
and allows genome release ‘deep’ into the cytoplasm near the nucleus were replication occurs 
(Heald-Sargent & Gallagher, 2012). Consequently, it is not surprising that most coronaviruses 
rely on endosomal proteases and/or acidification for fusion activation (Figure 1.10). 
Endocytosis has also been described as the main entry route for serotype II FCoVs (Van 
Hamme et al., 2007). After APN engagement, FIPV 79-1146 undergoes clathrin- and 
40 
 
caveolae- independent, but dynamin-dependent endocystosis (Van Hamme et al., 2008). 
Proteolytical cleavage is mediated by cathepsin B, and is only mildly dependent on low pH. 
In contrast, the avirulent 79-1683 strain depends on both cathepsin B and low pH-activated 
cathepsin L activity for infection, at least in cell culture (Regan et al., 2008). If this strain also 
uses the same dynamin-dependent endocytosis pathway as its virulent counterpart is 
unknown. Based on the molecular weight of the cleavage products, it has been suggested that 
cleavage of serotype II spikes by cathepsins occurs at the CS2 site (Belouzard et al., 2012; 
Regan et al., 2008). As for attachment factors and receptors, no information is available on 
fusion triggers for serotype I FCoVs.  
The determinants of the FCoV tropism have fascinated researchers for years, and the spike 
protein is considered of key importance in the FCoV pathotype switch (Chang et al., 2012; 
Licitra et al., 2013; Rottier et al., 2005). So far, 2 regions in the spike protein have been found 
very often affected by mutations when comparing faecal with tissue strains, one which is 
located at the S1/S2 boundary comprising the furin cleavage site (Licitra et al., 2013), and the 
other which is located in the S2 subunit (Chang et al., 2012). As described above, it has 
recently been shown that the second mutation typically occurs in viruses (both FIP-inducing 
as avirulent ones) that can undergo systemic dissemination, but it remains elusive if and how 
these mutations contribute to the FIP pathogenesis (Porter et al., 2014). In addition, the onset 
of FIP is most probably the result of various mutations in the genome. Indeed, although 
highly important, the spike is not the sole determinant of coronavirus tissue tropism and 
pathogenicity. This has already been shown for other coronaviruses, as introduction of MHV-
A59 spike in MHV-JHM background did not confer hepatotropism to the virus (Navas & 
Weiss, 2003), and chimeric viruses carrying IBV M41 spikes in a Beaudette background was 
still attenuated in vivo (Hodgson et al., 2004). For FIPV, the 3c protein has been proposed as 
one of the proteins for which mutation can contribute to the pathotype switch, but if and how 
this protein is involved remains enigmatic (Chang et al., 2010; Pedersen et al., 2009; 
Pedersen et al., 2012). Establishing a reverse genetic system and notably cell lines to grow 
and study both serotype I FECVs and FIPVs, would certainly be an enormous leap forward to 
unravel this intriguing mystery. 
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Coronaviruses are associated with either harmless or highly fatal intestinal, respiratory, and 
systemic infections in many animal species and humans. These RNA viruses are prone to 
genetic changes and recombination events, which not only allow them to cross species barriers 
and cause new (zoonotic) emerging diseases, but also enable them to switch virulence within 
their host. Feline infectious peritonitis virus (FIPV) is probably the most well known 
coronavirus emerging from mutational changes occurring in the viral genome during replication 
of its parent virus, feline enteric coronavirus (FECV). Although FECV often passes unnoticed, it 
affects 90-100% of all cats in virtually all multi-cat environments worldwide, and up to 12% 
will finally develop and succumb to FIP. Despite decades of research and attempts to combat 
this highly feared and dreadful disease, effective vaccines and/or antivirals are still lacking, 
ante-mortem diagnosis of FIP is still challenging, and the complex pathogenesis remains an 
enigma. 
FIP is the consequence of mutations arising in the viral genome during a common FECV 
infection, but almost no information is available on the interaction of this parent virus with its 
host. Therefore, this thesis aimed at contributing to the complex puzzle by focussing on these 
roots of the FIP pathogenesis. At the start of this project, no relevant FECV strains were 
available for in vitro research, as these faecal strains had been uncultivable in the available cell 
lines. In fact, the lack of susceptible cell lines is the most important factor why information on 
these viruses is missing, and why unravelling of the pathotype switching mutations has been 
hampered. To address this lack, the first study (Chapter 3) aimed at establishing intestinal 
epithelial cell lines to enable the propagation and further study of these viruses. These cultures 
and strains were then used to further unravel the early beginning of FECV infections, and hence 
to define some of the entry factors involved in enterocyte infections (Chapter 4.1 and 4.2).  
A second part of the present thesis aimed to add upon the knowledge on in vivo FECV 
infections and to investigate the feasibility to control this virus in the fight against FIP. Indeed, 
since every FECV replication cycle holds the risk for mutated viruses to emerge, prevention of 
FIP can be directed towards controlling faecal-oral transmission of this parent virus. To broaden 
our knowledge on the FECV pathogenesis and to validate detection methods, three feline 
leukaemia virus-, feline immunodeficiency virus-, and feline coronavirus-negative cats were 
inoculated with the serotype I FECV strain UCD and immunological, virological and clinical 
parameters were followed during 3 months after inoculation (Chapter 5.1). As there is a great 
demand for effective measures to control FCoV infections in practice, it was investigated in 2 
catteries whether successful prevention of transmission of FECV from shedders to naive 
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cats/kittens is feasible by adapting the management. Since FECV shedding is known to be long-
lasting and immunity does not protect against reinfections, control of cat-to-cat transmission in 
both catteries was based on regular monitoring of faecal shedding and grouping of cats 
(Chapter 5.2). 
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Summary 
Feline infectious peritonitis (FIP) is the most feared infectious cause of death in cats, induced 
by feline infectious peritonitis virus (FIPV). This coronavirus is a virulent mutant of the 
harmless, ubiquitous feline enteric coronavirus (FECV). To date, feline coronavirus (FCoV) 
research has been hampered by the lack of susceptible cell lines for the propagation of 
serotype I FCoVs. In this study, long-term feline intestinal epithelial cell cultures were 
established from primary ileocytes and colonocytes by simian virus 40 (SV40) T-antigen- and 
human Telomerase Reverse Transcriptase (hTERT)-induced immortalization. Subsequently, 
these cultures were evaluated for their usability in FCoV research. Firstly, the replication 
capacity of the serotype II strains WSU 79-1683 and WSU 79-1146 was studied in the 
continuous cultures as was done for the primary cultures. In accordance with the results 
obtained in primary cultures, FCoV WSU 79-1683 replicated significantly more efficient 
compared to FCoV WSU 79-1146 in both continuous cultures. In addition, the cultures were 
inoculated with faecal suspensions from healthy cats and with faecal or tissue suspensions 
from FIP cats. The cultures were susceptible to infection with different serotype I enteric 
strains and two of these strains were further propagated. No infection was seen in cultures 
inoculated with FIPV tissue homogenates. In conclusion, a new reliable model for FCoV 
investigation and growth of enteric field strains was established. In contrast to FIPV strains, 
FECVs showed a clear tropism for intestinal epithelial cells, giving an explanation for the 
observation that FECV is the main pathotype circulating among cats. 
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3.1 Introduction 
Feline coronaviruses (FCoVs) are associated with both enteric and systemic diseases in 
domestic and wild Felidae. The feline enteric coronavirus (FECV) is an ubiquitous 
enteropathogenic virus, replicating in epithelial cells of both small and large intestine after 
oral uptake (Hayashi et al., 1982; Herrewegh et al., 1997; Kipar et al., 2010; Meli et al., 
2004; Pedersen et al., 1981). The mild enteritis caused by this replication is usually 
unapparent or is manifested by a transient diarrhoea in young kittens (Pedersen et al., 1981). 
Around 13% of all infected cats are not able to clear the virus (Addie & Jarrett, 2001). In 
these cats, the virus persists for several months or even years in the epithelium of the large 
intestine (Hayashi et al., 1982; Herrewegh et al., 1997; Kipar et al., 2010; Pedersen et al., 
1981; Stoddart et al., 1988). Since FECVs are easily transmitted from cat to cat by faecal-oral 
route, they are enzootic among most cat populations (Addie & Jarrett, 1992; Pedersen et al., 
1981). Although FECV infections manifest subclinically, they may be the start of a lethal 
outcome. During replication, mutations can occur in the viral genome, providing the virus 
with tools to productively replicate in monocytes/macrophages (Dewerchin et al., 2005; 
Rottier et al., 2005; Stoddart & Scott, 1989; Vennema et al., 1998). This mutational variant, 
designated feline infectious peritonitis virus (FIPV), causes a chronic and highly fatal 
systemic disease, FIP, characterized by a diffuse pyogranulomatous (peri)phlebitis and 
serositis in presence (wet form) or absence (dry form) of fibrinous exudate in the affected 
body cavities (Horzinek & Osterhaus, 1979; Kipar et al., 1998; Montali & Strandberg, 1972). 
In contrast to FECV, which is highly infectious but seldom causes disease, FIPV shows a low 
infectivity but high mortality (95-100%) (Addie et al., 1995). Losses from FIP are typically 
unpredictable and occur in only a restricted fraction (<12%) of all seropositive cats (Addie & 
Jarrett, 2001; Addie et al., 1995; Pedersen, 2009; Pedersen et al., 2012). However, the lack of 
tools to successfully prevent and control the disease has an enormous financial, emotional and 
ethical impact, and makes FIP the most feared infectious cause of death in cats (Wolf, 1995). 
To date, it remains unknown why FECV and FIPV show such a clinically (mild enteritis 
versus FIP) and epidemiologically (easy versus restricted transmission) different behaviour. 
Besides the two pathotypes, FCoVs also occur as two serotypes (Fiscus & Teramoto, 1987). 
Worldwide, the majority of all strains (both FECVs and FIPVs) are serotype I viruses (Addie 
et al., 2003; Benetka et al., 2004; Hohdatsu et al., 1992; Kummrow et al., 2005; Lin et al., 
2009; Vennema, 1999). In contrast to the type I viruses that are 100% feline, type II viruses 
possess spike and adjacent genes of canine origin, since they have arisen by double 
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recombination events between type I FCoVs and canine coronavirus (CCoV) (Herrewegh et 
al., 1998; Lin et al., 2013). Despite their lower prevalence, most comparative in vitro studies 
have been performed with the easily cell culture growing serotype II strains WSU 79-1683 
and WSU 79-1146 (Dewerchin et al., 2005; McKeirnan et al., 1987; Rottier et al., 2005; 
Stoddart & Scott, 1989). FCoV WSU 79-1146 has been shown to be a highly virulent, readily 
FIP-inducing virus due to its efficient infection of monocytes/macrophages. FCoV WSU 79-
1683, on the other hand, is an avirulent virus, inducing at most a mild enteritis in kittens. The 
poor systemic dissemination of this virus has been attributed to a restricted, inefficient 
infection of monocytes/macrophages (Dewerchin et al., 2005; Pedersen et al., 1984; Rottier et 
al., 2005; Stoddart & Scott, 1989). To date, cell culture propagation of the abundantly present 
serotype I FECVs has never been achieved and only few serotype I FIPV strains have been 
adapted to grow in felis catus whole fetus (fcwf) cells. However, most of these strains have 
lost their pathogenicity through cell culture adaptation (Pedersen, 2009; Tekes et al., 2012). 
Hence, comparative studies between non-culture adapted FECVs and FIPV have only been 
possible by comparing genomes of both naturally occurring strains (Chang et al., 2011; 
Chang et al., 2010; Chang et al., 2012; Pedersen et al., 2009; Pedersen et al., 2012). To date, 
it remains unclear which genetic determinants make up a certain pathotype.   
In the present study, cultures of intestinal epithelial cells from the ileum (ileocytes) and colon 
(colonocytes) were established by inducing a combined expression of SV40 T-antigen and 
hTERT in primary ileocytes and colonocytes. The reliability of these cultures for their use in 
FCoV-research was first investigated by comparing replication capacities of the, at high titre 
available, avirulent FCoV WSU 79-1683 and the highly virulent FCoV WSU 79-1146 with 
results obtained for the primary cultures. Since those serotype II strains have been heavily cell 
culture adapted, the usability of the intestinal epithelial cell cultures in FCoV research was 
further evaluated by investigating their susceptibility for different field strains, present in 
faeces and tissues of coronavirus-infected cats.  
3.2 Materials and methods 
3.2.1 Cats 
Since cats are euthanized every day in practice, tissues of these animals can be used in 
research in order to reduce the number of laboratory cats. Using tissues of euthanized animals 
is in agreement with the statements of the Local Ethical Committee. Therefore, the intestines 
of euthanized conventional cats were used in this study and were a kind contribution to 
research by the owners. Faecal extracts from SPF cats (Harlan laboratories, Indianapolis, IN, 
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USA) experimentally infected with FECV UCD were used as a source of this enteric field 
strain. These infection experiments were approved by the Local Ethical and Welfare 
Committee of the Faculty of Veterinary Medicine of Ghent University (EC2010/043). 
3.2.2 Isolation and cultivation of primary ileocytes and colonocytes 
Cats were sedated by intramuscular injection of a mixture of Ketamin (0.05 ml/kg; 
Anesketin®, Eurovet, Heusden-Zolder, Belgium) and Midazolam (0.05 ml/kg; Dormicum®, 
Roche, Brussels, Belgium). Subsequently, the cats were euthanized by intracardial injection 
of 20% Sodium Pentobarbital (1 ml/1.5 kg; Kela Laboratories, Hoogstraten, Belgium). The 
protocol used for the isolation of primary ileocytes and colonocytes was based on the one 
described by Rusu and co-workers, with minor adaptations (Rusu et al., 2005). Directly after 
euthanasia, the colon was aseptically removed and transported in ice-cold Dulbecco’s 
Modified Eagle Medium (DMEM; Gibco BRL, Merelbeke, Belgium) supplemented with 100 
U/ml penicillin (Continental Pharma Inc., Puurs, Belgium), 0.1 mg/ml streptomycin (Certa, 
Braine l'Alleud, Belgium), 0.1 mg/ml gentamycine (Gibco BRL) and 10% foetal bovine 
serum (FBS; Gibco BRL). Subsequently, the pieces of intestine were inverted, i.e. mucosal 
side facing outwards, and the intestinal content was removed by three vigorous washings in 
ice-cold DMEM supplemented with antibiotics. The intestinal mucosa was digested in 
DMEM containing collagenase I (0.4 mg/ml, Invitrogen, Paisley, UK) and dispase (1.2 
mg/ml, Sigma, St. Louis, MO, USA) for 15 minutes (ileum) or 20 minutes (colon) at 37°C. 
Then, the digestion medium was refreshed and the pieces were incubated for another 45 
minutes (ileum) or 60 minutes (colon) at 37°C. Subsequently, the pieces were longitudinally 
opened and the digested mucosa was scraped with a sterile scalpel blade. The scrapings were 
incubated in warm DMEM supplemented with antibiotics and dispase (1.2 mg/ml) for 10 
minutes whilst pipetting. After centrifugation (140 g, 3 min) the pellet was resuspended in 
DMEM containing 2% D-Sorbitol (Sigma) and 10% FBS, and centrifuged (50 g, 3 min) in 
order to separate as much single cells (most probably contaminating stromal cells) as possible 
from the epithelial cell clusters. This sorbitol centrifugation was repeated 5 times. The 
resulting pellet was subsequently resuspended 1:3 (vol:vol) in culture medium consisting of 
DMEM/F-12 supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin and 0.1 mg/ml 
gentamycin, 10% FBS (Gibco BRL), 10 ng/ml epidermal growth factor (Sigma), 1% insulin-
transferrin-selenuim-X (Invitrogen), 100 nM hydrocortisone (Sigma), 1% non-essential amino 
acids 100x (Gibco BRL), and 1 µg/ml 3,3’,5-Triiodo-L-thyronine sodium salt (Sigma). The 
cells were seeded on glass coverslips coated with collagen type I (Roche Diagnostics, 
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Vilvoorde, Belgium). The cells were cultivated in a 37°C / 5% CO2 atmosphere. After 24 
hours, the culture medium was replaced by medium containing 2% FBS to restrict the 
outgrowth of non-epithelial cells. Medium was changed every other day. Morphological 
features of the primary cultures were evaluated every day by light microscopy (Olympus). 
3.2.3 Characterization of the primary cultures 
To assess the origin of the primary cells, double-immunostainings were performed against 
pancytokeratin and vimentin. Therefore, the cells were fixed with 4% paraformaldehyde in 
PBS for 10 minutes at room temperature (RT) followed by permeabilization with 0.1% Triton 
X-100 for 2 minutes at RT. The cells were incubated with monoclonal anti-cytokeratin 
antibodies (Dako Denmark A/S) containing 10% normal goat serum for 1 h at 37°C, followed 
by goat anti-mouse-Texas Red labelled antibodies for 1 h at 37°C (Molecular Probes, Eugene, 
Oregon, USA). Afterwards, the cells were incubated for 45 minutes at 37°C with monoclonal 
anti-vimentin antibodies (Lab Vision Corporation, Fremont, CA, USA) labelled with Zenon® 
Alexa Fluor 488 (Invitrogen) according to the manufacturer’s protocol. Nuclei were stained 
with Hoechst 33342 (Molecular Probes) for 10 minutes at RT. The slides were mounted using 
glycerine-PBS solution (0.9:0.1, vol:vol) with 2.5% 1,4-diazabicyclo[2.2.2]octane (Janssen 
Chimica, Beerse, Belgium) and analysed by fluorescence microscopy (DM B fluorescence 
microscope, Leica Microsystems GmbH, Heidelberg, Germany). 
3.2.4 Immortalization of primary feline ileocytes and colonocytes 
At 4 days post isolation, primary cultures of ileocytes and colonocytes from the same cat were 
transduced with both recombinant lentiviruses expressing either the SV40 large T antigen or 
the hTERT protein (Applied Biological Materials Inc., Canada) in addition of polybrene (8 
µg/ml, Applied Biological Materials Inc.). After 30 minutes, medium was added and the cells 
were further incubated with the virus (1:1 vol:vol in medium) overnight. The following day, 
the viral supernatant was removed and cells were further incubated in medium. After 5 days, 
the cells were detached by trypsinization with 0.25% trypsin - 0.02% EDTA, subcultured in 
collagen-coated wells (split ratio 1:2) and evaluated daily for clonal expansion by light 
microscopy (Olympus). Clusters of cells with epithelial (cobblestone-like) morphology were 
marked and other cells in the well were removed by scraping. Subsequently, the epithelial 
clusters were detached by trypsinization and further expanded in collagen-coated flasks to 
generate a long-term culture of both small and large intestinal epithelial cells. 
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3.2.5 Characterization of the ileocyte and colonocyte cell lines 
To confirm the epithelial character of both cell lines, double-immunostainings were 
performed against cytokeratin and vimentin as described above. The success of transduction 
was assessed by performing immunocytochemical stainings against the SV 40 large T antigen 
and hTERT. Therefore, cells seeded on collagen-coated glass coverslips were fixed with 4% 
paraformaldehyde, followed by permeabilization with 0.1% Triton X-100. The cells were 
incubated with polyclonal rabbit antibodies against hTERT (Applied Biological Materials 
Inc.) containing 10% normal goat serum for 1 h at 37°C, followed by goat ant-rabbit-FITC 
labelled antibodies (Molecular Probes) for 1 h at 37°C. Subsequently, the cells were incubated 
with monoclonal antibodies against the SV40 large T antigen (Applied Biological Materials 
Inc.) containing 10% normal goat serum, followed by goat anti-mouse-AF594 labelled 
antibodies (Molecular Probes), each for 1 h at 37°C. Nuclei were stained and slides were 
mounted as described above. The cells were analysed by fluorescence microscopy (DM B 
fluorescence microscope, Leica Microsystems GmbH). In addition, immunocytochemical 
stainings against the intestinal brush border hydrolase aminopeptidase N were performed. 
Therefore, cells were fixed with 1% paraformaldehyde and incubated with the monoclonal 
antibody R-G-4 (kindly provided by Dr. Hohdatsu, Department of Veterinary Infectious 
Diseases, Towada, Japan) containing 10% normal goat serum followed by goat anti-mouse-
FITC labelled antibodies (Molecular Probes), each for 1 h at 37°C. Images were obtained 
using a Leica TCS SPE laser scanning spectral confocal system linked to a DM B 
fluorescence microscope (Leica Microsystems). Argon and He/Ne lasers were used for 
exciting FITC and Texas Red fluorochromes, respectively. Leica confocal software was used 
for image acquisition. 
3.2.6 Expression kinetics of viral antigens in FCoV WSU 79-1683 and FCoV 79-1146 
infected cells 
A third passage of the FCoV strains 79-1683 and 79-1146 grown in Crandell feline kidney 
(CrFK) cells were used. FCoV WSU 79-1683 was obtained from the American Type Culture 
Collection (ATCC) and FCoV WSU 79-1146 was kindly provided by Dr. Egberink 
(Department of Infectious Diseases and Immunology, Utrecht University, the Netherlands). 
At 4 days post isolation, primary cells of three cats were inoculated at a multiplicity of 
infection (m.o.i.) of 1. After 1 h incubation (37°C, 5% CO2) the cells were washed 3 times 
with warm DMEM and further incubated in medium. Monolayers of continuous ileocyte and 
colonocyte cultures were inoculated in the same way. At different time points (0, 3, 6, 9, 12 
and 24 h) post inoculation, cells were fixed with 4% paraformaldehyde for 10 minutes and 
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permeabilized with 0.1% Triton X-100 for 2 minutes at RT. For the primary cultures, double-
immunostainings against both FCoV-antigens and cytokeratin were performed to visualize the 
infected epithelial cells. For the continuous cultures, only viral antigens were stained. Viral 
antigens were visualized with polyclonal FITC-labelled anti-FCoV antibodies (VMRD, 
Pullman, USA). Cytokeratin-positive cells were visualized as described above. Nuclei were 
stained with Hoechst, the slides were mounted and analysed by fluorescence microscopy 
(Leica Microsystems GmbH). All experiments were performed 3 times. The area under the 
curve was determined for each experiment. Triplicate assays were compared using a Mann-
Whitney U test. Statistical analysis was performed using GraphPad Prism version 5.0c 
(GraphPad software, San Diego, CA, USA). P values ≤ 0.05 were considered significantly 
different. 
Using primary cells of conventional cats holds the risk that cultured cells are already infected 
with FCoVs. Therefore, mock-infected cells were accurately screened to exclude the presence 
of inherent infected cells. All cells were negative for inherent coronavirus. 
3.2.7 One-step real time RT-PCR for the detection of the viral load in field strain 
suspensions 
RNA was extracted from the faecal suspensions using the QIAamp Viral RNA Mini Kit 
(Qiagen, Benelux BV, Belgium) and from tissue suspensions with the RNeasy Mini Kit 
(Qiagen). To avoid detection of subgenomic mRNA’s, primers were designed using the 
Primer 3 plus software within a conserved region of ORF1b based on FCoV sequences 
available in GenBank. A 20 µl PCR mixture was used per reaction and contained 10 µl 
Precision OneStep™ qRT-PCR Mastermix with SYBR Green and ROX (PrimerDesign, 
Southampton, UK), 0.2 µM forward primer ORF1bFW (5’-TGGACCATGAGCAAGT 
CTGTT-3’), 0.4 µM reverse primer ORF1bRV (5’-CAGATCCATCATTGTGTACTT 
TGTAAGA-3’) and 3 µl RNA or diluted standard RNA (see below). A reverse transcription 
step of 10 min at 55°C and an enzyme activation step at 95°C for 8 min were followed by 40 
cycles, each 10 s at 95°C and 60 s at 58°C. A first-derivative melting curve analysis was 
performed by heating the mixture to 95°C for 15 s, then cooling to 60°C for 1 min, and 
heating back to 95°C at 0.3°C increments. Reverse transcription, amplification, monitoring, 
and melting curve analysis were carried out in a Step One Plus™ real-time PCR system 
(Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA). 
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3.2.8 Synthetic RNA standards for absolute quantitation 
RNA was extracted from faecal suspensions containing FECV UCD using the QIAamp Viral 
RNA Mini Kit (Qiagen). The RNA was reverse-transcribed into cDNA using the 
SuperScript™ III First-Strand Synthesis System for RT-PCR (Invitrogen). Briefly, 250 ng 
RNA was incubated for 5 min at 65°C with 2 µM reverse primer ORF1bRV and 10 mM 
dNTP mix. Afterwards, an equal volume of cDNA synthesis mix, containing 10x RT buffer, 
25 mM MgCl2, 0.1 M DTT, 40 U/µl RNase OUT and 200 U/µl Superscript III RT was added 
and incubated for 50 min at 50°C. The reaction was terminated at 85°C for 5 min. RNA was 
removed by incubation with RNase H for 20 min at 37°C. The 50 µl PCR mixture for the 
amplification of the cDNA contained 10 µl 5x Herculase II reaction buffer, 0.8 µl dNTP mix, 
2 µl DNA template, 0.25 µM forward primer ORF1bFW modified with a T7 promoter 
sequence at its 5’ end (5’-TAATACGACTCACTATAGGGTGGACCATGAGCAAGTCT 
GTT-3’), 0.25 µM reverse primer ORF1bRV, and 1 µl Herculase II fusion DNA polymerase 
(Agilent Technologies Inc., Santa Clara, CA, USA). After a denaturation step for 1 min at 
95°C, 30 cycles of amplification, each 20 s at 95°C, 20 s at 50°C, and 60 s at 68°C, were 
followed by a terminal elongation of 4 min at 68°C. Fragment length was controlled by 
agarose gel electrophoresis and fragments with the correct length were excised and purified 
from the gel using the Nucleospin® Gel and PCR Clean-up kit (Macherey-Nagel, Düren, 
Germany). cRNA standards were transcribed by incubation for 1 h at 37°C with 10x 
transcription buffer, 500 µM rNTPs and 20 U T7 RNA polymerase-Plus Enzyme Mix 
(Applied Biosystems). Transcription reactions were DNase I treated and the amount of RNA 
was determined using the Nanodrop 2000 system. Ten-fold serial dilutions of the RNA were 
made over a range of 6 log units (107-102) for the generation of the standard curve 
(Efficiency: 93.96 ± 0.76%; R2: 0.999). 
3.2.9 Assessment of the infectious coronavirus titre in faecal and tissue suspensions 
Faecal samples were collected from healthy cats housed in 3 different catteries / multi-cat 
environments that have dealt with FIP in the past. Faecal extracts of experimentally infected 
cats containing an unknown titre of FECV strain UCD (originally isolated at UC Davis, 
(Pedersen et al., 1981)) were a kind gift of Dr. Rottier (Department of Infectious Diseases and 
Immunology, Utrecht University, the Netherlands). This suspension was clarified by 
centrifugation at 4000 g for 10 min and SPF cats were infected with the supernatant. Faecal 
extracts from one cat were used as a source of this enteric field strain. From all faecal 
samples, 20% suspensions were made in DMEM supplemented with 2% FBS (Gibco, BRL), 
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100 U/ml penicillin (Continental Pharma Inc.), 0.1 mg/ml streptomycin (Certa), and 0.1 
mg/ml gentamycin (Gibco BRL). From 4 cats with FIP (immunohistochemically confirmed), 
faeces and affected tissues were collected. From tissue homogenates, 20% suspensions were 
made in DMEM supplemented with 100 U/ml penicillin (Continental Pharma Inc.), 0.1 mg/ml 
streptomycin (Certa), and 0.1 mg/ml gentamycin (Gibco BRL). Suspensions were centrifuged 
(1200 g, 4°C, 20 min), and the supernatant was aliquoted and stored at -70°C until use. All 
samples were initially screened by immunofluorescence in both cell lines by inoculating 
monolayers, seeded on collagen coated coverslips, with 250 µl of the suspensions for 1 h at 
37°C. Thereafter, cells were washed and further incubated in medium for 24 h. After fixation 
and permeabilization, infected cells were visualized as described above. In addition, the 
amount of infectious virus was quantified in all samples, including the initially negative ones. 
Therefore, monolayers of colonocytes, seeded in collagen I coated 96-well plates, were 
inoculated with 50 µl of serially diluted (1/10) faecal or tissue suspensions (ranging from 100 
to 10-7). After 1 h (37°C, 5% CO2), medium was added and the cells were further incubated 
for 72 h. To reduce cell loss due to toxicity, undiluted suspensions were removed from the 
wells 1 h p.i. and the cells were washed 2 times before they were further incubated in 
medium. Then, plates were washed with PBS, air-dried (1 h, 37°C) and frozen (-20°C). The 
50% tissue culture infectious dose (TCID50) was determined by means of immunoperoxidase 
monolayer assay (IPMA). Therefore, cells were fixed and permeabilized by incubation with 
PF 4% (10 minutes, RT), followed by incubation with methanol containing 1% H2O2 (5 
minutes, RT). Then, cells were incubated with PBS containing 10% normal goat serum and 
0.1% Tween 80 for 30 minutes at 37°C. Subsequently, cells were incubated with monoclonal 
antibodies against the N-protein (produced and characterized in the laboratory of the authors), 
followed by incubation with goat anti-mouse HRP-labelled antibodies. Infected cells were 
visualized by adding sodium-acetate buffer containing amino-ethylcarbazole (AEC) and H2O2 
for 10 minutes at RT. The fifty percent end-point was calculated according to the method of 
Reed and Muench. The serotype of all samples was determined by means of RT-PCR 
described by Addie et al. (Addie et al., 2003).  
3.2.10  Determination of infectious virus in FIPV-suspensions by inoculation of monocyte-
derived macrophages 
Feline monocytes were isolated and seeded on glass coverslips as previously described 
(Dewerchin et al., 2005). At 7 days post seeding, cells were inoculated with 250 µl of the 
suspensions. After 1 h at 37°C, cells were washed and further incubated in medium for 24 h. 
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After fixation and permeabilization, infected cells were visualized by immunofluorescence 
staining as described above.  
3.2.11  Propagation and titration of FECV UCD and UG-FH8 
Two different faecal strains, UCD and UG-FH8, were passaged 3 times in continuous 
colonocyte cultures, starting from the faecal suspensions. After 3 passages, the TCID50 was 
determined as described above. In addition, sequencing of ORF3 and ORF7 was performed to 
check for their integrity. Therefore, primers were designed using published sequences of 
FCoV ORF3 and ORF7 in GenBank. Viral RNA was extracted from the faecal suspensions 
with the QIAamp Viral RNA Mini Kit (Qiagen) and cDNA was generated using 
SuperScript™ III First-Strand Synthesis System for RT-PCR (Invitrogen). Amplification was 
carried out in a 50 µl reaction using Herculase II fusion DNA polymerase (Agilent 
Technologies Inc., Santa Clara, CA, USA). The Nucleospin® Gel and PCR Clean-up kit 
(Macherey-Nagel) was used for purification of the PCR products. Sequencing was performed 
by the GATC Biotech Company (Konstanz, Germany). Additionally, it was investigated if 
both third passage strains still showed a specific enterotropism by inoculating other feline cell 
lines (CrFK and fcwf cells). Twenty-four hours p.i., infected cells were visualized by 
immunofluorescence staining as described above. 
3.3 Results  
3.3.1 Morphological features and characterization of the primary cultures 
By using a combination of dispase and collagenase, epithelial cells were isolated from the 
underlying basement membrane in clusters (Figure 3.1A). Four hours post seeding, the 
majority of the cells had attached and foci of polygonal cells became visible within 24 h post 
seeding (Figure 3.1B/D). Primary ileum cultures were always ‘contaminated’ with a lot of 
elongated or stellate-like cells, present in between the epithelial foci, while the colon cultures 
were more pure. For the ileum, the epithelial cells did not further grow beyond 24 h post 
seeding, whereas mesenchymal cells started to expand in between the epithelial cell clusters. 
In the colonic cultures, the epithelial cells showed a confined proliferation within 3-4 days 
post isolation, resulting in the formation of (sub)confluent cobblestone-like layers (Figure 
3.1E). Then, these cells had reached a state of replicative senescence, which became typically 
characterized by morphological changes such as increase in cell size and development of 
multiple nuclei at 6-7 days post isolation. The growth arrest seemed not to be the result of the 
confluent state since, despite many attempts, it was not possible to subculture the cells. A part 
of the cells started to degenerate from 7 days post seeding. However, most of the cells could 
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be kept for another week. To prevent cell loss due to inherent degeneration and to prevent 
overgrowth by mesenchymal cells, both ileum and colon cultures were always infected at 4 
days post isolation for studying the viral replication. 
Immunofluorescence stainings against cytokeratin (intermediate filaments typically found in 
the cytoskeleton of epithelial cells) and vimentin (intermediate filaments expressed by 
mesenchymal cells) confirmed the epithelial nature of the polygonal, cobblestone-like cells 
(Figure 3.1C/F). At 4 days post isolation, the majority of the cells (> 90%) in the colon 
cultures was still of epithelial origin. For the ileum cultures, the vimentin positive 
mesenchymal cells had expanded in between the epithelial clusters, occupying around 50% of 
the wells. Remarkably, some of the ileum epithelial cells did also express vimentin, 
resembling dedifferentiated epithelial cells typically found after injury or in tumours (Figure 
3.1C). 
 
 
Figure 3.1. Morphological features and immunocytochemical characterization of the primary ileum (A-C) 
and colon (D-F) cultures. (A) Epithelial cells were isolated in cell clusters. (B, D) Polygonal cells started to 
spread from these clusters giving rise to several foci of cells. (E) (Sub)confluent layers were reached 3-4 days 
after seeding due to a restricted proliferation of the cells. (C, F) Double-immunostainings against cytokeratin 
(red) and vimentin (green) filaments 4 days after isolation, confirming the epithelial nature of the polygonal 
cells. 
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3.3.2 Expression kinetics of viral antigens in FCoV WSU 79-1683 and WSU 79-1146-
infected primary ileocytes and colonocytes 
Primary ileocytes and colonocytes were susceptible to infection with both serotype II FCoV 
strains. However, the antigen expression kinetics differed greatly between the avirulent FCoV 
WSU 79-1683 and the virulent FCoV WSU 79-1146 (Figure 3.2). For both strains, the first 
antigen-positive cells appeared at 6 h p.i. and increased further over time. However, the 
avirulent enterotropic WSU 79-1683 strain infected the cells significantly more efficient (P= 
0.05 for both ileum and colon) compared to WSU 79-1146.  
 
 
Figure 3.2. Kinetics of FCoV replication in primary ileum and colon cultures from 3 conventional cats. 
Cells were inoculated with FCoV WSU 79-1683 or FCoV WSU 79-1146 at a m.o.i. = 1. At different time points 
post inoculation, cytoplasmically expressed viral proteins were visualized and the percentage of infected 
epithelial cells was determined. 
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3.3.3 Morphological features and characterization of the established continuous ileocyte 
and colonocyte cultures 
By introducing a combinational expression of SV40 large T-antigen and hTERT, a 
successfully transformed cell line was generated for both ileocytes and colonocytes (Figure 
3.3 and 3.4). Indeed, a various number of the transduced cells started to proliferate from 1 
week after transduction onwards, forming layers of cobblestone-like cells with a cell diameter 
of 20-25µm and 30-35µm for ileocytes and colonocytes, respectively. Both SV40 large T-
antigen as hTERT expression was detected in these cultures, confirming the success of 
transduction. These cell lines could be further expanded and passaged for over 30 passages 
now, which is in sharp contrast to the primary cultures. Besides its typical cobblestone-like 
appearance, the epithelial character was confirmed by the expression of cytokeratin and dome 
formation in the cultures. The latter is indicative for the polarization of cells in monolayers. 
Remarkably, most of the cells in both cultures co-expressed both cytokeratin and vimentin in 
the freshly formed monolayers, suggesting a more dedifferentiated state of the cells. For 
further characterization, APN expression in the cultures was investigated, since APN is an 
intestinal brush border associated hydrolase, and moreover an important receptor for serotype 
II FCoVs. All cells expressed APN at their surface. However, the expression levels varied 
greatly from cell to cell in both cultures, most probably due to different differentiation levels 
of the cells in culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Morphological and immunocytochemical characterization of the continuous ileocyte cultures. 
(A) Proliferating isles. (B) Cobblestone morphology of the monolayer. (C) Dome formation. (D) Double-
immunostaining against cytokeratin (red) and vimentin  filaments. 
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Figure 3.4. Morphological and immunocytochemical characterization of the continuous colonocyte 
cultures. (A) Proliferating isles. (B) Cobblestone morphology of the monolayer. (C) Dome formation. (D) 
Double-immunostaining against cytokeratin (red) and vimentin  filaments. 
 
3.3.4 Antigen expression kinetics of FCoV WSU 79-1683 and WSU 79-1146 in 
continuous ileocyte and colonocyte cultures 
Since the continuous cultures seemed to be less differentiated compared to the primary 
cultures, the reliability of the established cell lines as model for intestinal epithelial cells was 
further investigated. Therefore, antigen expression kinetics were assessed in both continuous 
ileocyte and colonocyte cultures as was done for the primary cells (Figure 3.5). In accordance 
with the results obtained for the primary cultures, FCoV WSU 79-1683 significantly infected 
both ileocytes as colonocytes more efficiently than WSU 79-1146. At 24 h p.i., FCoV WSU 
79-1683 had infected 19.46 ± 4.37 % and 18.47 ± 4.61% of the colonocytes and ileocytes, 
respectively, whereas only 0.03 ± 0.02% of the colonocytes and 0.22 ± 0.18% of the ileocytes 
were infected by FCoV WSU 79-1146 at that time point. 
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Figure 3.5. Kinetics of FCoV replication in continuous ileocyte and colonocyte cultures. Cells were 
inoculated with FCoV WSU 79-1683 or FCoV WSU 79-1146 at a m.o.i. = 1. At different time points post 
inoculation, the percentage of infected cells was determined. Data are expressed as the means ± standard 
deviation of the results of 3 separate experiments. 
 
3.3.5 Titration of field strains in faecal and tissue suspensions 
A major restriction in FCoV research is the lack of cell lines supporting the growth of 
serotype I enteric strains. Therefore, the newly established cell lines were further validated by 
investigating their susceptibility for different field strains. All those strains were serotype I 
viruses as confirmed by PCR. Table 3.1 gives the results obtained by titration of different 
faecal and tissue suspensions on colonocyte cultures. Comparable results were obtained by 
titration on ileocyte cultures with FECV UCD. Hence, titration of other field strains was not 
repeated on this cell line. All but two of the samples collected from healthy cats were positive 
for coronavirus, with qPCR titres ranging from 104.18 to 109.06 viral copies / g faeces. 
Infectious virus was detected by IPMA in 50% of all positive samples (8/16), with 57% of 
positivity in samples with qPCR titres above 105. This number increased to 64% (7/11) and 
80% (4/5) when the cutoff was made at qPCR titres above 106 and 107 viral copies / g faeces, 
respectively. In the one sample (UG-FH9) with a qPCR above 107 that was negative on 
IPMA, enterotropic virus was detected by immunofluorescence staining. All but one of the 
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samples collected from FIP cats were positive for coronavirus on qPCR, with the number of 
viral copies / g ranging from 103.98 to 109.16. As determined by both IPMA and 
immunofluorescence staining, none of those samples, except for one, contained enterotropic 
virus. However, 3 tissue samples (UG-TF5, UG-TF9 and UG-TF17) did contain infectious 
virus as determined on monocyte-derived macrophages. Despite its high viral load, no 
infectious virus (neither on enterocytes nor on monocytes/macrophages) was found in faecal 
suspensions of FIP cat 1 (UG-FF1). Faeces of FIP cat 2 (UG-FF2) did contain enterotropic 
virus that was not infectious for macrophages. 
3.3.6 Propagation and titration of FECV UCD and UG-FH8 
To date, no serotype I enteric field strains have been propagated in vitro and availability of 
such FECV strains would be valuable in feline coronavirus research. Therefore, two faecal 
strains, FECV UCD and UG-FH8, were further propagated in colonocyte cultures (Table 3.2). 
After 3 passages, both strains were raised in titre with around 3 log10 TCID50 / ml. In addition, 
ORF3 and ORF7 from each of the third passage strains were sequenced to check for signs of 
cell culture adaption. Both strains still carried intact accessory genes that were 100% identical 
to the original strain. Typically, a lot more CPE was noticed in UG-FH8 infected wells 
compared to FECV UCD (Figure 3.6). After 3 passages, both strains still showed a specific 
enterotropism, since no infection was seen after inoculation of other feline cell lines (fcwf and 
CrFK cells). 
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Table 3.1.  QPCR- and infectious titre of different faecal and tissue suspensions from healthy and FIP 
cats. 
 
Sample Source 
QPCR titre  
(Log10 copies / g) 
Infectious titre 
(Log10 TCID50 / g) 
 
UG-FH1 
 
Faeces healthy cats 
 
6.03 
 
- 
UG-FH2 Faeces healthy cats 6.64 2.67 
UG-FH3 Faeces healthy cats 5.51 - 
UG-FH4 Faeces healthy cats 5.41 2.36 
UG-FH5 Faeces healthy cats 7.22 2.50 
UG-FH6 Faeces healthy cat 6.88 - 
UG-FH7 Faeces healthy cat - - 
UG-FH8 Faeces healthy cat 6.30 3.33 
UG-FH9 Faeces healthy cats 7.69 - 
UG-FH10 Faeces healthy cat 7.89 2.50 
UG-FH11 Faeces healthy cats 8.44 2.67 
UG-FH12 Faeces healthy cats 4.66 - 
UG-FH13 Faeces healthy cats - - 
UG-FH14 Faeces healthy cats 6.27 - 
UG-FH15 Faeces healthy cat 6.62 2.50 
UG-FH16 Faeces healthy cats 4.18 - 
FECV UCD Faeces healthy cat 6d p.i. 9.06 5.00 
UG-FF1 Faeces FIP cat 1 7.57 - 
UG-FF2 Faeces FIP cat 2 9.16 3.50 
UG-FF3 Faeces FIP cat 3 - - 
UG-FF4 Faeces FIP cat 4 3.98 - 
UG-TF2 Kidney FIP cat 1 6.79 - 
UG-TF5 Omentum FIP cat 2 6.87 - 
UG-TF9 Spleen FIP cat 3 5.83 - 
UG-TF17 
 
Omentum FIP cat 4 
 
8.00 - 
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Table 3.2. Infectious titre and status of ORF3 and ORF7 in cell culture propagated viruses. 
 
Strain Infectious titre  
(Log10 TCID50 / ml) 
Status ORF3 
at P3 
Status ORF7 
at P3 
 P0 P3   
 
FECV UCD 
 
3.97 
 
6.30 
 
Intact 
 
Intact 
 
UG-FH8 
 
2.63 5.97 Intact Intact 
 
 
 
Figure 3.6. Immunoperoxidase staining of infected colonocytes. Infected colonocytes 3 days p.i. with (A) 
102.99 TCID50 FECV UCD and (B) 102.67 TCID50 UG-FH8. 
3.4 Discussion 
In this study, immortalized cultures of both small (ileum) and large (colon) intestinal 
epithelial cells were established and validated for their use in feline coronavirus research.  
Intestinal epithelial cells are important target cells in FCoV pathogenesis, but to date such cell 
lines are not available. The establishment of primary intestinal epithelial cell cultures has been 
proven to be difficult because of the induction of programmed cell death after disruption from 
the extracellular matrix, the uncontrolled contamination with stromal cells, and the still 
unknown homeostatic components needed for the maintenance of these cultures (Kaeffer, 
2002). To avoid induction of apoptotic signals by disrupting cell-matrix adhesions, a 
combination of collagenase and dispase was used in this study to digest the mucosa, allowing 
the isolation of epithelial cell clusters. These were subsequently separated as much as possible 
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from the contaminating single stromal cells by D-sorbitol density centrifugation. The primary 
colon cultures showed a relative high purity of epithelial cells, whereas primary ileum 
cultures were much more contaminated with stromal cells. The contamination with 
mesenchymal cells is intrinsic to the isolation method used and therefore inevitable. Yet, the 
epithelial cells could be cultured for a week without overgrowth by these cells, making both 
primary cultures ideal models for studying interactions with enterotropic infectious agents. 
Remarkably, some primary cells co-expressed cytokeratin and vimentin filaments, which is 
often found in injured epithelial cells, tumours and in primary cultures due to the detachment 
of the cells from their natural environment during isolation. In these cells, the epithelial 
differentiation is turned back to a more embryonic state, amongst others characterized by de 
novo expression of vimentin filaments (Baer & Bereiter-Hahn, 2012). Only a minority of the 
cells did express vimentin, suggesting that most cells were able to restore their differentiation 
with the used culture conditions. 
Although the doubtful origin and clear signs of cell culture adaptation (Pedersen, 2009; 
Pedersen et al., 2008), FCoV WSU 79-1683 and FCoV WSU 79-1146 were the only available 
strains representing an avirulent and related virulent strain at the time of the study. Hence, 
those strains were initially used for investigating the susceptibility of primary enterocytes to 
both virulent and avirulent FCoVs. Replication of both strains have been studied in CrFK 
cells, fcwf cells, peritoneal macrophages, bone marrow-derived macrophages and peripheral 
blood monocytes (Dewerchin et al., 2005; McKeirnan et al., 1987; Rottier et al., 2005; 
Stoddart & Scott, 1989). In contrast to the available continuous cultures (CrFK and fcwf 
cells), the difference in virulence between both strains was reflected in vitro when using 
primary FIPV target cells (monocytes/macrophages). The highly efficient and mostly 
sustained infection of FIPV in macrophages and monocytes from susceptible cats, in contrast 
to an inefficient and not sustained infection of the avirulent WSU 79-1683 in those cells, may 
explain why FIPV behaves as a harmful invasive virus causing this progressive systemic 
disease (Dewerchin et al., 2005; Rottier et al., 2005; Stoddart & Scott, 1989). As was 
previously shown for monocytes/macrophages, the present study confirms that both strains 
exhibit clear differences in cell tropism. In contrast to FCoV WSU 79-1146, the avirulent 
WSU 79-1683 efficiently infected and replicated in intestinal epithelial cells, resulting in 
exactly opposing kinetics as were found for macrophages (Rottier et al., 2005).  
Primary cultures are ideal tools to reliably investigate virus-host interactions. Nevertheless, 
isolation of primary epithelial cells is labour-intensive, the cultures are often contaminated 
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with a various amount of mesenchymal cells and the yield is variable and rather low. To allow 
research with those cells, long-term cultures were derived from both primary ileocytes and 
colonocytes by SV40 T-antigen- and hTERT-induced immortalization, resulting in the 
generation of two feline intestinal epithelial cell cultures. The epithelial nature of both cell 
lines was confirmed by their cobblestone morphology, dome formation and cytokeratin 
expression. These newly established cell lines could be valuable tools for virus research. 
However, immortalized cell lines are often phenotypically transformed, making reliable 
research with these cells questionable. In the present study it was shown that, in contrast to 
the primary cultures, the majority of the cells co-expressed cytokeratin and vimentin 
filaments, suggesting that the cultures were less differentiated compared to their primary 
counterparts. Therefore, the reliability of the established cell lines for their use in feline 
coronavirus research was further investigated and confirmed. Antigen expression kinetics of 
FCoV WSU 79-1683 and FCoV WSU 79-1146 were comparable with the results obtained 
with the primary cultures, showing a significant difference in cell tropism between both 
strains. As mentioned before, comparative studies in the available continuous feline cell lines 
(CrFK and Fcwf cells) showed no replicative differences between both serotype II strains 
(Dewerchin et al., 2005; McKeirnan et al., 1987; Rottier et al., 2005). However, both cultures 
are hardly sensitive to serotype I FCoVs. To date, cultivation of serotype I FECVs has never 
been achieved and only few serotype I FIPV strains could be adapted to grow in continuous 
cell cultures. In addition, most of these strains seem to have lost their pathogenicity through 
cell culture adaptation (Pedersen, 2009; Tekes et al., 2012). In the present study, the newly 
established intestinal epithelial cell cultures were further evaluated for their susceptibility to 
serotype I field strains.  Infectious, enterotropic virus was found in 57% (8/14) of all FCoV-
positive faecal samples originating from healthy cats in 3 geographically distinct multi-cat 
environments. One of those samples was detected only by immunofluorescence staining. This 
higher sensitivity can be explained by the use of more inoculum in that test. In the majority of 
the positive samples, infectious titres were always between 103.05 to 105.77 times lower 
compared to the total virus titre. This difference can be attributed to the presence of defective 
particles, but infectious titres in such faecal samples can possibly be underestimated due to 
faecal toxicity to the cells and the presence of neutralizing IgA antibodies as well. In infection 
experiments with FECV UCD, the amount of infectious particles was typically 3-4 log10 times 
lower compared to the total amount of particles in the first week p.i., but this further increased 
thereafter most probably due to the generation of neutralizing antibodies (see chapter 5.1). It 
is impossible to estimate when cats in multi-cat environments became infected and the 
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presence of neutralizing antibodies can explain why infectious virus in some of the faecal 
samples with a quite high viral load was not detectable. Coronavirus was detected in 3/4 of 
the tested faecal samples from FIP cats. Previously, it has been shown that faecal viruses from 
FIP cats did not cause enteric infections or FIP upon inoculation of laboratory cats (Pedersen 
et al., 2012). This can explain why, despite its high viral load, no infectious virus (neither in 
enterocytes nor in monocytes/macrophages) was found in the faeces of FIP cat 1 (UG-FF1). 
However, enterotropic virus was found in the faeces from another FIP cat (UG-FF2) that was 
housed in a Belgian shelter. To search for explanations for this discrepancy, accessory 
proteins of the virus in faecal and tissue suspensions of that cat were sequenced (data not 
shown). As in all faecally shed FCoVs sequenced so far (Chang et al., 2010; Pedersen et al., 
2009; Pedersen et al., 2012), the faecal strain carried an intact 3c gene. In addition, this strain 
showed only 96% and 89% homology with the tissue strain based on 7a and 7b protein 
respectively. So it seems that this cat was co-infected with another, most probably enteric 
strain circulating in that shelter, explaining the shedding of enterotropic infectious virus in 
that cat. In 3/4 of the tissue samples from FIP cats (UG-TF5, UG-TF9 and UG-TF17), 
infectious virus was found by inoculation of monocyte-derived macrophages. However, these 
viruses seemed to have lost their tropism for intestinal epithelial cells since no infection was 
detected after inoculation of the intestinal epithelial cell cultures. The fact that FECV is the 
only pathotype that is well adapted for growth in intestinal epithelial cells shows that FECVs 
have the advantage over FIPVs to spread amongst cats. These findings are in agreement with 
previous observations on FCoV epidemiology, explaining the restricted transmission of 
FIPVs and hence low incidence of cats with FIP (Addie & Jarrett, 2001; Addie et al., 1995; 
Pedersen, 2009; Pedersen et al., 2012). 
Since no cell culture-propagated serotype I enteric strains are available, two of those strains, 
FECV UCD and UG-FH8, were further propagated in the established cultures. After 3 
passages, both virus strains were raised in titre with 3 log10 TCID50 / ml, making them usable 
for further in vitro experiments. It has been described that the 7b glycoprotein is not necessary 
for replication in cell cultures, and hence this gene is readily lost by in vitro propagation. 
Therefore, alterations in the 7b protein can be a sign for cell culture adaptation as seen in 
many of the cell culture propagated serotype I FIPVs (Herrewegh et al., 1995). In present 
study, no such signs of cell culture adaptation were detected for both 3th passage strains, 
which still carried intact ORF7 genes identical to the original faecal strains. All field enteric 
strains sequenced so far carried intact 3c genes (Chang et al., 2010; Pedersen et al., 2009; 
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Pedersen et al., 2012). To date, the only available avirulent, enteritis-inducing strain, WSU 
79-1683, has a mutated 3c gene and for that reason doubt has been cast on the use of this 
strain as a typical enteric pathotype (Pedersen, 2009; Pedersen et al., 2008). Both FECV UCD 
and UG-FH8 propagated in this study still carried an intact (and identical to the original 
strain) ORF3. In addition, the cell culture propagation of both strains did not extend their 
tropism to other non-enterocytic feline cells, making them useful as representatives of the 
enteric pathotype. 
In conclusion, we established cultures of both feline small and large intestinal epithelial cells, 
providing new and reliable in vitro models for studying enteric pathogenesis processes of 
FCoVs. These enterocyte cultures were susceptible to different enteric serotype I field strains, 
while FIPVs were clearly restricted in their replication in intestinal epithelial cells. Two of the 
enteric strains were further propagated, providing relevant enteric strains for future FCoV 
research. 
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Summary 
To initiate infections, many coronaviruses use sialic acids, either as receptor determinants or 
as attachment factors helping the virus find its receptor underneath the heavily glycosylated 
mucus layer. In the present study, the role of sialic acids in serotype I feline enteric 
coronavirus (FECV) infections was studied in feline intestinal epithelial cell cultures. 
Treatment of cells with neuraminidase (NA) enhanced infection efficiency, showing that 
terminal sialic acid residues on the cell surface are not receptor determinants and even hamper 
efficient virus-receptor engagement. Knowing that NA treatment of coronaviruses can 
unmask viral sialic acid binding activity, replication of untreated and NA-treated viruses was 
compared, showing that NA treatment of the virus enhanced infectivity in untreated cells but 
was detrimental in NA-treated cells. By using sialylated compounds as competitive inhibitors, 
it was demonstrated that sialyllactose (2,6-α-linked over 2,3-α-linked) notably reduced 
infectivity of NA-treated viruses, whereas bovine submaxillary mucin inhibited both treated 
and untreated viruses. In desialylated cells, however, viruses were less prone to competitive 
inhibition with sialylated compounds. In conclusion, this study demonstrated that FECV has a 
sialic acid binding capacity, which is partially masked by virus-associated sialic acids, and 
that attachment to sialylated compounds can facilitate enterocyte infections. However, sialic 
acid binding was not a prerequisite for the initiation of infection, and virus-receptor 
engagement was even more efficient after desialylation of cells, indicating that FECV 
requires sialidases for efficient enterocyte infections. 
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4.1.1  Introduction 
Feline enteric coronavirus (FECV) is an enzootic enteropathogen in cats. The enteritis caused 
by its replication in intestinal epithelial cells is mild and mostly unnoticed (Addie & Jarrett, 
1992; Pedersen et al., 1981). However, mutations in the viral genome can allow the virus to 
replicate efficiently in monocytes/macrophages, resulting in the fatal feline infectious 
peritonitis (FIP) (Dewerchin et al., 2005; Pedersen, 2009; Rottier et al., 2005; Stoddart & 
Scott, 1989; Vennema et al., 1998). Despite many attempts, treatment of FIP has remained 
palliative to date. In multi-cat environments, cat owners lose up to 12 % of their cats, and 
recurrent FIP deaths are still a major reason to stop breeding programs. Since FIP is the 
consequence of mutations arising in the viral genome during a common FECV infection, 
FECV is an attractive target in the fight against FIP. Despite the valuable information 
available from different in vivo studies (Meli et al., 2004; Pedersen et al., 2008; Pedersen et 
al., 1981; Poland et al., 1996; Vogel et al., 2010), very little is known about the FECV-
enterocyte interactions as these viruses had been uncultivable for many years. The 
propagation of these viruses in recently established feline intestinal epithelial cell cultures 
allows further unravelling of these FECV-enterocyte interactions in vitro (Desmarets et al., 
2013).  
Coronaviruses mediate their entry into host cells by their spike (S) proteins. Coronavirus S 
proteins have been shown to possess at least 2 receptor-binding domains (RBDs), the S1 N-
terminal RBD and the S1 C-terminal RBD. Whereas the C-terminal RBD of most 
coronaviruses is involved in protein binding, the N-terminal RBD can act as a lectin, 
recognizing various sialic acids (Peng et al., 2011). Sialic acid binding has been described for 
members of the alpha-, beta-, and gammacoronaviruses. However, whereas some of these 
viruses rely on sialic acid binding for the initiation of host cell infections, others use sialic 
acids as attachment factors, but rely solely on another protein receptor to initiate their 
infections (Schwegmann-Wessels & Herrler, 2006). 
Among alphacoronaviruses, a sialic acid binding capacity has been described for 
transmissible gastroenteritis virus (TGEV) and porcine epidemic diarrhoea virus (PEDV). For 
both viruses, this sialic acid binding activity becomes more pronounced when virions are 
pretreated with neuraminidase (NA), demonstrating that the sialic acid binding site is masked 
by virion-associated sialic acids (Park et al., 2010; Schultze et al., 1996). The role of this 
sialic acid binding during TGEV infections has been extensively studied. Sialic acid binding 
by TGEV Purdue is not essential in the initiation of in vitro infections as desialylation of cells 
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hardly affects its replication, and mutants lacking the sialic acid binding site replicate to the 
same extent in cell cultures (Krempl et al., 1997; Schultze et al., 1996). However, when the 
absorption time is reduced, sialic acid binding contributes to efficient infection, showing that 
the sialic acid binding activity helps TGEV infections under unfavourable conditions, as 
encountered during its passage through the intestinal tract (Schwegmann-Wessels et al., 
2011). Indeed, mutants lacking the sialic acid binding site were no longer capable of inducing 
enteropathy, showing that sialic acid binding is required to induce efficient intestinal 
infections in vivo (Bernard & Laude, 1995; Krempl et al., 1997), possibly by allowing the 
virus to interact with and pass through the mucus layer covering the epithelial cells 
(Schwegmann-Wessels et al., 2002). In contrast to TGEV Purdue, NA treatment renders cells 
more resistant to infection with TGEV Miller, bovine coronavirus (BCoV) (a 
betacoronavirus) and avian infectious bronchitis virus (IBV) (a gammacoronavirus), showing 
that these viruses use sialic acids as receptor determinants to initiate infection into host cells 
(Schultze & Herrler, 1992; Schwegmann-Wessels et al., 2011; Winter et al., 2006).  
The role of sialic acids in feline coronavirus (FCoV) infections is unknown. However, it has 
been shown that FIP cats have hyposialylated serum alpha1-acid glycoprotein (AGP), 
whereas healthy cats in the same environment tend to have hypersialylated AGP, suggesting 
that sialylated compounds can determine the outcome of a feline coronavirus infection, 
potentially by acting as a decoy for virus infections (Ceciliani et al., 2004; Paltrinieri et al., 
2008). In the present study, the sialic acid binding capacity of FECV and the role of sialic 
acids in FECV infections was investigated in 2 different intestinal epithelial cell cultures with 
2 different serotype I FECV strains. 
4.1.2 Materials and methods 
4.1.2.1 Viruses and cells 
Two serotype I FECV strains, UCD and UG-FH8, were propagated in feline colonocyte 
cultures in foetal bovine serum (FBS)-depleted medium, and third passage strains were used 
for all infection experiments. All experiments were performed in both feline ileocyte and 
colonocyte cultures. Cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM)/Ham's F12 Nutrient Mixture (1/1) supplemented with 100 U penicillin ml-1, 0.1 mg 
streptomycin ml-1, 0.1 mg gentamycin ml-1, 5 % FBS (Gibco BRL) and 1 % non-essential 
amino acids 100x (Gibco BRL). The origin of the viruses and cells has previously been 
described (Desmarets et al., 2013).  
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4.1.2.2 Neuraminidase treatment of cells 
To remove sialic acids from the enterocytes, monolayers of continuous ileocytes and 
colonocytes were washed 2 times with warm Ca2+- and Mg2+-enriched phosphate buffered 
saline (PBS). Then, cells were incubated with 50 mU ml-1 NA from Vibrio Cholerae (Roche 
Diagnostics) in Ca2+- and Mg2+-enriched PBS. Cells that were not treated with NA were 
incubated in Ca2+- and Mg2+-enriched PBS and underwent the same manipulations as the NA-
treated cells. After 1 h at 37 °C, cells were washed three times with medium to remove the 
neuraminidase. Viability of the cells was assessed by ethidium monoazide bromide (EMA) 
staining, ensuring > 99 % viability with the used NA concentration. 
4.1.2.3 Neuraminidase treatment of viruses 
To remove sialic acids from the virus, virus suspensions were incubated on a shaker for 1 h at 
37 °C with 50 mU ml-1 Glycocleave® neuraminidase (Vibrio Cholerae) enzyme beads 
(GALAB Technologies GmbH) in Ca2+- and Mg2+-enriched PBS. Beads were washed 2 times 
with Ca2+- and Mg2+-enriched PBS before incubation with the virus to remove buffers. Before 
inoculation, NA beads were separated from the virus by centrifugation (200 g, 10 min, 4 °C). 
Untreated virions were incubated in Ca2+- and Mg2+-enriched PBS without beads and 
underwent the same manipulations as the NA-treated virus. 
4.1.2.4 Infection experiments 
Cells were inoculated with either NA-treated or untreated virus (105.8 TCID50 ml-1 and 105.97 
TCID50 ml-1 for FECV UCD and UG-FH8, respectively). After 5 or 60 minutes at 37 °C, the 
unbound virus particles were removed by three washing steps with medium, and the cells 
were further incubated in medium for 12 h (37 °C, 5 % CO2). Then, cells were fixed with 4 % 
paraformaldehyde for 10 min at room temperature (RT). 
4.1.2.5 Immunofluorescence staining of infected enterocytes 
Cells were permeabilized with 0.1% Triton X-100 for 2 min at RT. Then, cells were incubated 
for 1 h at 37 °C with the monoclonal anti-nucleocapsid antibody 10A12 (produced and 
characterized in the laboratory of the authors) containing 10% normal goat serum, followed 
by incubation with goat anti-mouse FITC labelled antibodies (Molecular Probes) for 1 h at 37 
°C. Nuclei were stained with Hoechst 33342 (Molecular Probes) for 10 min at RT. Slides 
were mounted using glycerine-PBS solution (0.9:0.1, vol:vol) with 2.5 % 1,4-
diazabicyclo[2.2.2]octane (Janssen Chimica) and analysed by fluorescence microscopy (DM 
B fluorescence microscope, Leica Microsystems GmbH). 
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4.1.2.6 Infection inhibition assays 
Porcine gastric mucin, bovine submaxillary mucin, fetuin, lactoferrin, lactose, D-galactose, N-
acetyl-D-glucosamine, and N-acetyl-D-galactosamine were purchased from Sigma-Aldrich, 
α2,3-sialyllactose and α2,6-sialyllactose from Carbosynth Limited. NA-treated and untreated 
viruses were pre-incubated with different concentrations of each compound for 30 min at 37 
°C. These virus-compound mixtures were used to inoculate feline colonocyte cultures. After 1 
h at 37 °C, unbound virus particles were removed by 3 washing steps with medium and the 
cells were further incubated in medium for 12 h. Then, cells were fixed with 4 % 
paraformaldehyde and stained as described above. Viability of the cells was assessed by EMA 
staining, ensuring > 99 % viability with the used concentrations. 
4.1.2.7 Statistical analysis 
Experiments were independently repeated 4 times, and results were compared with the Mann-
Whitney U test. Statistical analysis was performed using GraphPad Prism version 5.0c 
(GraphPad software, San Diego, CA, USA). P values ≤ 0.05 were considered significantly 
different. 
4.1.3 Results 
4.1.3.1 Effect of NA treatment of cells on FECV infection 
To assess the role of sialic acids as receptor determinants, cells were pretreated with 50 mU 
ml-1 NA prior to inoculation with FECV strains UCD or UG-FH8. Surprisingly, removal of 
sialic acids greatly enhanced infectivity of both strains, even after 5 minutes absorption time 
(Figure 4.1.1). By determination of the percentage of infected cells 12 h p.i., it was shown 
that NA pretreatment of cells significantly (p = 0.05) enhanced infection efficiency from 0.05 
± 0.05 % to 3.63 ± 1.21 % for UCD and from 0.59 ± 0.14 % to 19.07 ± 18.86 % for UG-FH8 
in ileocytes. For the colonocytes, NA treatment of the cells increased the percentage of 
infected cells from 0.29 ± 0.29 % to 3.36 ± 2.11 % for UCD, and from 0.80 ± 0.19 to 33.45 ± 
20.57 % for UG-FH8 (Figure 4.1.2, white bars). Although both strains were inoculated at 
comparable multiplicity of infection (m.o.i) (m.o.i. 0.25 and 0.35 as determined on NA-
treated cells for UCD and UG-FH8, respectively), consistently more cells (ranging from 2.8 
to 11.8 times more) were infected 12 h p.i. by UG-FH8 compared to UCD in both untreated 
and treated cells. These results imply that FECV does not depend on terminal sialic acid 
residues on the enterocyte surface for the initiation of its infection and that FECV requires 
sialidases to allow efficient virus-receptor engagement.  
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Figure 4.1.1. NA treatment of intestinal epithelial cells enhances FECV infection. Cells were pretreated with 
PBS or NA in PBS (50 mU ml-1) and inoculated with FECV UCD (m.o.i. 0.25) or UG-FH8 (m.o.i. 0.35) for 5 
minutes or 60 minutes at 37 °C. After 3 washings, cells were incubated in medium and infected cells were 
visualised 12 h p.i. by immunofluorescence staining. 
When sialic acids are removed by NA treatment of cells, subterminal sugar residues are 
exposed. To investigate if these sugars were involved in the enhanced infection efficiency of 
FECV in desialylated cells, subterminal sugar residues including D-galactose, N-acetyl-D-
glucosamine, and N-acetyl-D-galactosamine were used as competitive inhibitors. None of 
these sugars (in concentrations up to 50 mM) reduced FECV infection in NA-treated cells, 
showing that attachment to one of these exposed sugars is not the reason for the enhanced 
infectivity of FECV (data not shown).  
4.1.3.2  Effect of NA treatment of FECV on the replication in NA-treated and untreated 
cells 
Knowing that NA treatment of coronaviruses can unmask sialic acid binding activity, the 
replication of untreated and NA-pretreated viruses was compared in both untreated and NA-
treated cells. The effect of these treatments was analysed 12 h post inoculation (p.i.) in 
ileocyte and colonocyte cultures for both FECV strains (Fig. 4.1.2). Removal of sialic acids 
from the virus enhanced infectivity for both strains in both untreated cell cultures, though not 
significantly for UCD in colonocytes. For ileocytes, treatment of the virus increased the 
number of infected cells on average 7 times for UCD (p = 0.03) and 3.3 times for UG-FH8 (p 
=0.03), whereas for colonocytes percentage of infected cells was 1.6 times (p = 0.34) and 1.9 
(p = 0.03) times higher for UCD and UG-FH8, respectively.  
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Desialylation of the cells also enhanced infection efficiency of NA-treated viruses (black 
bars) (p = 0.03 for UCD and UG-FH8 in ileocytes, and p = 0.05 for UCD in colonocytes), 
although not significant for UG-FH8 in colonocytes (p = 0.2). In contrast to untreated cells, 
NA-treatment of the virus seemed to have a detrimental effect in NA-treated cells, although 
this reduction was only significant for UG-FH8 in colonocytes (p = 0.05). Considering all 
treatments, inoculation of NA-treated cells with untreated virus resulted in the most efficient 
infection. 
 
 
Figure 4.1.2. Effect of NA treatment of FECV on the replication in untreated and NA-treated cells. For 
both untreated and NA-treated FECV, percentage of infection was evaluated 12 h p.i. in both untreated and 
desialylated cells. Data are expressed as the means ± standard deviation of the results of 4 separate experiments. 
4.1.3.3 Effect of sialylated compounds on the replication of FECV in enterocytes 
To further analyse the FECV-sialic acid binding, and to investigate if the differences seen 
between untreated and NA-treated virions were due to sialic acid binding, the potential of 
different sialylated compounds (α2,3- and α2,6-sialyllactose, fetuin, porcine gastric mucin 
(PGM), bovine submaxillary mucin (BSM), and lactoferrin) to act as competitive inhibitor for 
FECV infection was studied. Therefore, both untreated and NA-treated virions were pre-
incubated for 30 minutes with different concentrations of each compound before inoculation 
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of colonocytes. Of all tested compounds, only sialyllactoses and BSM acted as inhibitors for 
FECV infection, whereas fetuin, lactoferrin, and PGM had no effect on FECV infectivity in 
concentrations up to 200 µg ml-1, 1 mg ml-1, and 50 mg ml-1, respectively.   
Figure 4.1.3 shows the relative percentage of infected cells 12 h p.i. after pre-incubation of 
both untreated and NA-treated viruses with different concentrations of α2,3-sialyllactose, 
α2,6-sialyllactose or lactose. In contrast to lactose, sialyllactoses significantly reduced 
infection of NA-treated viruses. For both strains, 2,6-α-linked sialic acids had a slightly more 
pronounced inhibitory activity compared to 2,3-α-linked sialic acids and reduced the absolute 
percentage of infected cells to a similar level as the untreated viruses. In contrast to the NA-
treated viruses, untreated viruses were hardly affected by the sialyllactoses. Only for the UG-
FH8 strain, α2,6-sialyllactose at the highest concentration (1000 µM) significantly reduced 
infection efficiency of the untreated virus. In desialylated cells, sialyllactoses did not have any 
effect on the replication of FECV (data not shown).  
 
 
Figure 4.1.3. Effect of sialyllactoses on the infectivity of untreated and NA-treated viruses in untreated 
colonocytes. Both untreated and NA-treated virions were pre-incubated for 30 minutes at 37 °C with α2,3-
sialyllactose, α2,6-sialyllactose or lactose before inoculation. One hour p.i., the inoculum was removed by 3 
washings, and the relative percentage of infected cells was assessed 12 h p.i. Data are expressed as the means ± 
standard deviation of the results of 4 different experiments. Significant differences (P ≤ 0.05) are indicated with 
an asterix. 
Role of sialic acids in FECV infections 97 
 
Whereas sialyllactoses especially inhibited infection of NA-treated virions, BSM was a very 
potent inhibitor of both NA-treated and untreated viruses, with almost complete inhibition of 
infection in untreated cells at a concentration of 1 mg ml-1 (Figure 4.1.4). Pre-incubation of 
only the cells with 2 mg ml-1 BSM had no effect on the viral replication, showing that BSM 
specifically interacted with the virus (data not shown). In addition, BSM also had an 
inhibiting effect on desialylated cells, though to a lesser extent than in untreated cells, 
indicating that it is more difficult for sialylated compounds to compete with the viral 
attachment in NA-pretreated cultures. The concentration needed to completely inhibit FECV 
infections in desialylated cells could not be determined, since toxicity was seen with BSM 
from 5 mg ml-1 onwards.  
 
 
Figure 4.1.4. Effect of BSM on the replication of untreated and NA-treated viruses in both untreated and 
desialylated cells. Both untreated and NA-treated virions were pre-incubated with different concentrations of 
BSM for 30 minutes at 37 °C before inoculation. One hour p.i., the inoculum was removed by 3 washings, and 
the relative percentage of infected cells was assessed 12 h p.i. Data are expressed as the means ± standard 
deviation of the results of 4 different experiments. Significant differences (P ≤ 0.05) are indicated with an 
asterix. 
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Taken together, these results show that FECV has a sialic acid binding capacity that is 
partially masked by virus-associated sialic acids and preferably recognizes 2,6-α-linked sialic 
acids over 2,3-α-linked sialic acids. In addition, attachment to sialylated compounds can 
facilitate FECV infection, especially in the untreated enterocyte cultures, which can explain 
the increased infectivity of NA-treated viruses. However, it seems that the receptor can be 
more efficiently reached when sialic acid binding is reduced/avoided by desialylation of the 
cells, indicating that attachment to terminal sialic acid residues is not a prerequisite for the 
initiation of infection in vitro.  
4.1.4 Discussion 
Coronaviruses are able to attach to host cells in 3 different ways: viral lectin-host 
carbohydrate (e.g. spike-sialic acids), protein-protein (e.g. spike-aminopeptidase N (APN)), 
and viral carbohydrate-host lectin (e.g. mannose-DC-SIGN) interactions. In the present study, 
the sialic acid binding capacity of FECV and the role of sialic acids in FECV infections of 
enterocytes was investigated. Sialic acid binding by the coronavirus S protein has been 
described for members of the alpha-, beta-, and gammacoronaviruses, including TGEV, 
PEDV, BCoV, human coronavirus (HCoV) OC43, and IBV (Kunkel & Herrler, 1993; Park et 
al., 2010; Schultze et al., 1992; Schultze et al., 1991; Schultze et al., 1996). In contrast to the 
alphacoronavirus TGEV, sialic acid binding is essential for initiating infection of host cells 
for members of both genera Beta- (BCoV and HCoV OC43) and Gammacoronavirus (IBV) 
(Schultze & Herrler, 1992; Schultze et al., 1996; Winter et al., 2006). For TGEV Purdue, it 
has been shown that NA treatment of the cells enhances APN-binding, but this seems to have 
no enhancing effect on the viral infectivity in vitro (Schwegmann-Wessels et al., 2002; 
Shahwan et al., 2013). In addition, when absorption time is reduced, desialylation of cells 
even reduces infectivity, clearly showing the role of sialic acid binding under unfavourable 
conditions as encountered in the intestinal tract (Schwegmann-Wessels et al., 2011). In the 
present study, it was demonstrated that removal of sialic acids from cells greatly enhanced 
FECV infections in the enterocyte cultures, even after only 5 minutes absorption time. This 
shows that terminal sialic acid residues are not receptor determinants and that FECV more 
efficiently interacts with its (still unknown) receptor after desialylation of the cells. These 
results are valuable for the future propagation, titration, and study of FECVs in cell cultures. 
Two different serotype I FECV strains were used in this study. It was noticed that UG-FH8 
behaved more virulent compared to UCD in the enterocyte cultures. In comparison with 
UCD, UG-FH8 seemed to replicate and/or spread much faster, resulting in up to 31 times 
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more infected cells 12 h p.i., although inoculated at comparable m.o.i.  The impact of this 
virulence during in vivo infections remains to be investigated. However, since FIPVs arise by 
mutations during FECV infections, strains as UG-FH8 are probably more prone to the 
introduction of pathotype-switching mutations. 
In contrast to betacoronaviruses, both alpha- and gammacoronaviruses lack a receptor-
destroying enzyme that keeps the sialic acid binding site free from competitive inhibitors to 
ensure efficient interaction with cell surface sialic acids. For these viruses, including TGEV, 
PEDV and IBV, it has been described that their sialic acid binding capacity becomes more 
pronounced when virions are pretreated with NA (Park et al., 2010; Schultze et al., 1992; 
Schultze et al., 1996). This masking effect has also been described before for mammalian 
siglecs such as sialoadhesin (Delputte & Nauwynck, 2004) and CD22 (Razi & Varki, 1998) 
and was also demonstrated for FECV in the present study. The effect of unmasking the viral 
sialic acid binding activity on viral infectivity has only been studied for TGEV. Whereas NA 
treatment of the virus enhanced sialic acid-mediated attachment to cells (Schwegmann-
Wessels et al., 2002), it had no effect on the infectivity of the viruses (Schultze et al., 1996). 
In contrast to TGEV, removal of sialic acids from FECV virions had an enhancing effect on 
the viral infectivity in vitro. By using sialyllactoses as competitive inhibitors, it was shown 
that this was due to an enhanced sialic acid binding (2,6-α-linked > 2,3-α-linked). By 
performing competitive inhibition experiments with the highly α2,6-sialylated macromolecule 
BSM (Tsuji & Osawa, 1986), which in contrast to sialyllactose allows multivalent binding, 
replication of both untreated and NA-treated viruses was almost completely inhibited at a 
concentration of 1 mg ml-1. This inhibition was not seen with another mucin, PGM, which 
especially contains neutral and sulphated oligosaccharides (Nordman et al., 1997). These 
results indicate that both untreated and NA-treated viruses use sialylated compounds as 
attachment factors in the enterocyte cultures. However, when sialic acid binding is 
reduced/avoided by desialylation of cells, the viral receptor can be more efficiently reached, 
resulting in an enhanced infectivity of both untreated and NA-treated viruses. In addition, 
viruses become less susceptible to competitive inhibition with sialylated compounds in 
desialylated cells (sialyllactoses had no effect, and the effect of BSM was less pronounced 
compared to untreated cells), showing that sialic acid binding is not a prerequisite for the 
initiation of FECV infections in vitro. This can explain why NA treatment of the virus is 
detrimental in desialylated cells, since its enhanced sialic acid binding activity potentially 
delays the virus in its receptor engagement by binding to remaining sialic acid residues. This 
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decoy activity of sialic acids in vitro can be explained by the fact that FECV has no receptor-
destroying activity mediating its detachment from non-receptor glycoproteins. Although the 
lack of a receptor-destroying enzyme seems to disadvantage the virus, allowing competitive 
inhibitors to cover the virus is possibly a major strategy of these viruses to enable intestinal 
infections. In contrast to non-enveloped viruses, which represent the majority of all enteritis-
inducing viruses, coronaviruses are more prone to inactivation by different unfavourable 
conditions and it is still unclear how the enteritis-inducing coronaviruses survive the harsh 
conditions (low pH, enzymes and bile salts) in the gastrointestinal tract. Since sialic acids can 
confer protection against enzymatic degradation (Schauer, 2000), additional covering with 
sialylated compounds such as mucins can help the virus to survive the unfavourable 
conditions in the upper part of the gastrointestinal tract (Schultze et al., 1996). 
Based on the results of the present study, a hypothetical model for the initiation of FECV 
infections in vivo can be proposed. In addition to the abundant intrinsic glycosylation (Siddell 
et al., 1983), FECV most probably becomes covered with sialylated compounds encountered 
during exit from infected host cells and/or during uptake in the oral cavity. This protects the 
virus and potentially masks the viral sialic acid binding site, allowing the virus to pass the 
stomach without degradation or distraction by attachment to gastric mucins. However, during 
this passage viruses are faced with acidic environments and host/bacterial sialidases, which 
mediate hydrolysis of sialic acids, resulting in the release of sialic acids from the viral surface. 
This induces the liberation of the virus’ sialic acid binding domain, allowing FECV to escape 
from the intestinal flow by attaching to the mucus and to engage with its functional receptor 
on the enterocyte membrane. Since FECV lacks its own receptor-destroying enzyme, passage 
through this mucus layer and efficient receptor engagement most likely depend on intestinal 
sialidases. 
For TGEV, it has been shown that its enterotropism is highly dependent on its sialic acid 
binding capacity (Krempl et al., 1997). The sialic acid binding activity of FIPV, and the role 
of sialic acid binding in the enterotropism of FCoVs remain to be investigated. In addition, it 
remains elusive if this sialic acid binding is also involved in further steps of the pathogenesis 
and the onset of FIP. In the present study, it was shown that sialylated compounds can act as 
inhibitors for at least FECV infections. This decoy activity has also been suggested before by 
Paltrinieri and co-workers, who proposed that the cat’s own sialylated acute phase protein 
AGP can confer protection against the development of FIP (Paltrinieri et al., 2008).  Whereas 
cats with FIP tend to have elevated, but hyposialylated serum AGP concentrations (Ceciliani 
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et al., 2004), healthy cats in the same environment have hypersialylated AGP (Paltrinieri et 
al., 2008). This hyposialylation of AGP in FIP cats included both 2,6-α-linked and 2,3-α-
linked sialic acids (Ceciliani et al., 2004). However, in contrast to the more pronounced decoy 
activity of 2,6-α-linked sialic acids observed in the present study, 2,3-α-linked sialic acids on 
AGP seemed to be more involved in the determination of the outcome of FCoV infections 
(Ceciliani et al., 2004; Paltrinieri et al., 2008). Since in the present study only FECV was 
considered, it would be interesting to investigate if changes in the viral sialic acid binding 
activity occur during the pathotype switch.  
In conclusion, this study shows that serotype I FECVs have a sialic acid binding capacity that 
is partially masked by virus-associated sialic acids. However, binding to terminal sialic acid 
residues on the enterocyte surface is not a prerequisite for infection, and these sialic acids 
even seem to hamper efficient receptor engagement during in vitro infections. Nevertheless, if 
the in vivo situation is taken into account, the rationale for such a lectin activity is more clear, 
since it gives the virus advantages in its confrontation with the harsh conditions and mucosal 
barriers in the intestinal tract. These insights provide new opportunities for antiviral 
intervention. 
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Summary 
Feline enteric coronavirus (FECV) is a worldwide distributed enteropathogen of cats that is 
important as the parent virus of the fatal feline infectious peritonitis virus. Since there is no 
information on fusion triggers/proteases required for FECV infections, lysosomotropic agents, 
serine-, cysteine-, aspartyl-, and metalloprotease inhibitors, and the furin inhibitor decanoyl-
RVKR-CMK, were assessed for their effect on serotype I FECV infections in enterocytes. In 
contrast to feline coronavirus (FCoV) 79-1683 and transmissible gastroenteritis virus (TGEV), 
which were taken as controls, serotype I FECV did not depend on low pH, cathepsin B and/or 
furin cleavage for its entry in enterocytes. The serine protease inhibitor AEBSF strongly reduced 
replication of all FCoVs and TGEV, when it was continuously present before and during 
replication or added after inoculation. Interestingly, this reduction resulted from the inhibition of 
a virion-associated serine protease because a similar inhibition was observed when only the 
virus was treated with AEBSF. As expected, since coronavirus’ polyprotein processing occurs 
by viral cysteine proteases, the cysteine protease inhibitor E64d also inhibited replication, when 
it was continuously present before and during replication or added after inoculation. Neither 
AEBSF nor E64d inhibited replication when only the cells were pre-treated. In conclusion, 
serotype I FECVs do not rely on low pH, cathepsin B or furin cleavage for entry, but the exact 
fusion trigger remains to be elucidated. In addition, it was shown that FECV and TGEV use a 
virion-associated serine protease to start the replication. 
 
 
 
 
 
Effect of lysosomotropic agents and 
protease inhibitors on feline enteric 
coronavirus infections in enterocytes 
4.2 
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4.2.1 Introduction 
Coronaviruses have been isolated from many animal species and humans and are associated 
with various diseases, ranging from mild/unnoticed to highly fatal intestinal, respiratory, or 
systemic infections. Coronaviruses are enveloped viruses that have to release their positive 
single stranded RNA in the cytoplasm to allow replication. This entry process requires cell 
attachment and subsequent fusion between the viral envelope and the host plasma- or endosomal 
membrane. The viral spike (S) protein carries out both steps in the entry process and is an 
essential determinant of host/tissue tropism and virulence (Belouzard et al., 2012; Rottier et al., 
2005). S proteins are class I fusion proteins, possessing common structural features with the 
fusion proteins of other enveloped viruses such as orthomyxo-, paramyxo-, retro-, filo-, and 
arenaviruses (Bosch et al., 2003; White et al., 2008). Typically, viral fusion proteins are 
synthesized as precursor proteins that undergo endoproteolytical cleavage by host proteases, 
generating a metastable complex of the globular receptor binding (S1 for coronaviruses) and the 
stalk-like fusion (S2 for coronaviruses) subunit. This brings the protein in a fusion competent 
state, allowing the rapid dissociation of both subunits and the insertion of the hydrophobic 
fusion peptide in the host membrane upon receptor binding, low pH exposure and/or, in case of 
(some) coronaviruses, additional proteolytical cleavage (Belouzard et al., 2012; Dimitrov, 2004; 
Heald-Sargent & Gallagher, 2012; White et al., 2008). Coronaviruses show great distinctions in 
their requirement for fusion activating triggers. Some coronaviruses, such as infectious 
bronchitis virus (IBV), murine hepatitis virus (MHV)-4 and MHV-A59, undergo proteolytical 
S1/S2 cleavage in virus-producing cells, mediated by furin-like cellular proteases encountered 
during exocytosis processes. For these viruses, receptor engagement and/or exposure to acid pH 
had been generally believed to be sufficient to allow genome release in the cell (Chu et al., 
2006; Eifart et al., 2007; Gallagher et al., 1991), but it has recently been questioned if these are 
the only triggers. Indeed, furin cleavage occurs not directly adjacent to the putative fusion 
peptide, and both MHV-A59 and IBV spikes seem to become additionally cleaved within their 
S2 subunit during entry (Wicht et al., 2014; Yamada & Liu, 2009). In contrast to IBV, MHV-4 
and MHV-A59, most coronaviruses carry uncleaved spikes and indisputably rely on 
proteolytical activation with non-furin proteases encountered during virus entry to allow 
infections. MHV-2, severe acute respiratory syndrome (SARS)-CoV, human CoV 229E, and 
Middle East respiratory syndrome (MERS)-CoV rely on low pH-dependent cathepsins, 
encountered during endocytosis (Gierer et al., 2013; Huang et al., 2006; Qiu et al., 2006; 
Simmons et al., 2005). However, it seems that at least some of them have evolved to use 
multiple cell entry routes, depending on the physiological conditions in the target tissue. Indeed, 
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SARS-CoV entry becomes completely independent of low pH and cathepsins when exposed to 
trypsin, thermolysin, or elastase after receptor engagement or by expression of serine proteases 
such as TMPRSS2 on the cell surface (Belouzard et al., 2010; Bertram et al., 2011; Glowacka et 
al., 2011; Matsuyama et al., 2005; Shulla et al., 2011). Cleavage with these proteases occurs 
both at the S1/S2 boundary and within S2, directly N-proximal of the fusion peptide (Belouzard 
et al., 2009; Belouzard et al., 2012; Matsuyama et al., 2005; Simmons et al., 2004). This mode 
of entry is about 100 times more efficient than the cathepsin-dependent entry, and can explain 
the virulence of SARS-CoV in the lung where these transmembrane serine proteases are 
available (Matsuyama et al., 2005). Consequently, fusion processes seem to largely influence 
virus tropism and pathogenicity, and can explain why 2 viruses or strains using the same 
receptor can show such great distinction in cell tropism.  
Feline coronaviruses (FCoVs) occur as 2 pathotypes for which the disease-causing potential is 
determined by their cell tropism. Feline enteric coronavirus (FECV) is an enzootic 
enteropathogenic virus, replicating in intestinal epithelial cells after oral uptake (Addie & 
Jarrett, 1992; Herrewegh et al., 1997; Meli et al., 2004; Pedersen et al., 1981). FECV infections 
mainly manifest subclinically (Hickman et al., 1995; Pedersen et al., 1981; Vogel et al., 2010), 
but mutations in the viral genome can allow this mutational variant, designated feline infectious 
peritonitis virus (FIPV), to efficiently replicate in monocytes/macrophages (Dewerchin et al., 
2005; Rottier et al., 2005; Stoddart & Scott, 1989), resulting in a fatal and incurable 
pyogranulomatous phlebitis and serositis. Each pathotype exists as 2 different serotypes (Fiscus 
& Teramoto, 1987a, b; Hohdatsu et al., 1991). Serotype II viruses are the result of double 
recombination events between serotype I FCoVs and canine coronaviruses (Herrewegh et al., 
1998; Lin et al., 2013). The determinants of the FCoV tropism have fascinated researcher for 
years, and the S2 fusion subunit of the spike protein is considered of key importance in the 
FCoV pathotype switch (Chang et al., 2012; Licitra et al., 2013; Rottier et al., 2005). As 
serotype II viruses readily propagate in cell cultures, entry processes of these viruses have been 
abundantly studied. Endocytosis has been identified as the main entry route for serotype II 
FCoVs (Van Hamme et al., 2007). After aminopeptidase N engagement, FIPV 79-1146 
undergoes clathrin- and caveolae- independent, but dynamin-dependent endocystosis (Van 
Hamme et al., 2008). Proteolytical cleavage is mediated by cathepsin B, and is only mildly 
affected by low pH. In contrast, the avirulent 79-1683 strain depends on both cathepsin B and 
low pH-activated cathepsin L activity for infection in cell culture. Based on the molecular 
weight of the cleavage products, it has been suggested that cleavage of serotype II spikes by 
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cathepsins occurs most probably directly adjacent to the fusion peptide, and not at the S1/S2 
boundary (Belouzard et al., 2012; Regan et al., 2008). Whereas serotype II FCoVs have been 
studied in quite detail, the more prevalent and clinically important serotype I viruses are less 
well understood, and it remains elusive if results obtained for serotype II viruses can be 
extrapolated to the real life situation. Therefore, many scientists have redirected their research to 
serotype I viruses in recent years. Genome analysis have revealed 2 regions in the spike protein 
that are very often affected by mutations when comparing faecal with tissue strains, one which 
is located at the S1/S2 boundary comprising the furin cleavage site, and the other which is 
located in the S2 subunit (Chang et al., 2012; Licitra et al., 2013). Although serotype I viruses 
have become genetically well characterized, the biology of these viruses is still largely 
unclarified. Therefore, the aim of this study was to contribute to the complex puzzle of FCoV 
biology by providing information on fusion triggers and proteases necessary for serotype I 
FECV infections in enterocytes. The effect of lysosomotropic agents and various protease 
inhibitors on FECV infection was evaluated for two serotype I FECV strains (UCD and UG-
FH8) in feline enterocyte cultures. Since during replication viral proteases are involved in viral 
polyprotein processing, and these viral proteases can be attractive targets for the development of 
therapeutics, protease inhibitors were tested for both their effect on cellular and viral proteases. 
Since entry processes for FCoV 79-1683 and TGEV Purdue have been (partially) characterized, 
and both viruses can infect feline enterocytes, these strains were included as controls.  
4.2.2 Materials and methods 
4.2.2.1  Cells and viruses 
Feline colonocyte cultures were grown in Dulbecco’s modified Eagle’s medium 
(DMEM)/Ham's F12 Nutrient Mixture (1/1) supplemented with 100 U penicillin ml-1 
(Continental Pharma Inc.), 0.1 mg streptomycin ml-1 (Certa), 0.1 mg gentamycin ml-1 (Gibco 
BRL), 5 % FBS (Gibco BRL) and 1 % non-essential amino acids 100x (Gibco BRL). These 
cells were used to provide a third passage of two serotype I FECV strains, UCD and UG-FH8. 
The origin of the viruses and cells has previously been described (Desmarets et al., 2013). The 
FCoV strain 79-1683, purchased from the American Type Culture Collection (ATCC), was 
grown in Crandell feline kidney (CrFK) cells and a third passage was used. Swine testicular 
cells were used to obtain a third passage of TGEV Purdue. 
4.2.2.2  Infection inhibition assay using lysosomotropic agents 
The weak bases ammonium chloride (NH4Cl) and chloroquine diphosphate, and the ionophore 
monensin were purchased from Sigma. NH4Cl was used at a range of 0-30 mM, chloroquine 
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diphosphate at 0-70 µM, and monensin at 0-20 µM. Monolayers were treated for 1 h with 
neuraminidase (NA) from Vibrio Cholerae (Roche Diagnostics) in Ca2+- and Mg2+-enriched 
PBS to improve virus infection (Desmarets et al., 2014). Then, cells were pre-incubated for 2 h 
with FBS-depleted medium (= control) or different concentrations of each pH drop inhibitor 
diluted in FBS-depleted medium, after which they were inoculated with FECV UCD (105.8 
TCID50 ml-1), UG-FH8 (105.8 TCID50 ml-1), FCoV 79-1683 (106.8 TCID50 ml-1), or TGEV 
Purdue (105.8 TCID50 ml-1), in presence of the inhibitor. Subsequently, cells were washed 3 
times and further incubated with lysosomotropic agents. Twelve hours p.i., cells were fixed with 
4 % paraformaldehyde for 10 min at room temperature (RT) and stained for infection (see 
below). Viability of the cells was assessed by ethidium monoazide bromide (EMA) staining, 
ensuring > 99 % viability at the highest concentration of each inhibitor. 
4.2.2.3  Infection inhibition assay using serine-, cysteine-, aspartyl-, and metalloprotease 
inhibitors 
All protease inhibitors were purchased from Sigma, except for the cathepsin B inhibitor CA-
074Me, which was purchased from Calbiochem. The serine protease inhibitor 4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF) was tested in a range of 0-100 µM, the 
aspartyl protease inhibitor pepstatin A between 0 and 0.75 µM, the metalloprotease inhibitor 
phosphoramidon between 0 and 15 µM, the membrane permeable cysteine protease inhibitor 
(2S,3S)-trans epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E-64d) between 0 and 8 
µM,  the serine/cysteine protease inhibitor leupeptin at a range of 0-100 µM, and the cathepsin 
B inhibitor CA-074Me between 0 and 10 µM. Viability of the cells was assessed by ethidium 
monoazide bromide (EMA) staining, ensuring > 99 % viability at the highest concentration of 
the inhibitor. All inhibitors were tested for their inhibiting effect on FECV replication as 
described for the lysosomotropic agents, namely by pre-incubation for 2 h, followed by 
continuous incubation during and after inoculation. Inhibitors with effect on viral replication 
were additionally tested for their potential to inhibit replication by 1) only pre-incubating the 
cells (2h, 37°C), 2) by treating the inoculum (see below), or 3) by addition of the inhibitor after 
inoculation (see below). Twelve hours p.i., cells were fixed with 4 % paraformaldehyde for 10 
min at room temperature (RT) and stained for infection (see below).  
4.2.2.4  Immunofluorescence staining of infected enterocytes 
Cells were permeabilized with 0.1% Triton X-100 for 2 min at RT. Then, cells were incubated 
for 1 h at 37 °C with the monoclonal anti-nucleocapsid antibody 10A12 (produced and 
characterized in the laboratory) containing 10% normal goat serum, followed by incubation with 
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goat anti-mouse FITC labelled antibodies (Molecular Probes) for 1 h at 37 °C. Nuclei were 
stained with Hoechst 33342 (Molecular Probes) for 10 min at RT. Slides were mounted using 
glycerine-PBS solution (0.9:0.1, vol:vol) with 2.5 % 1,4-diazabicyclo[2.2.2]octane (Janssen 
Chimica) and analysed by fluorescence microscopy (Leica Microsystems GmbH). 
4.2.2.5  Determination of the target protease of AEBSF and E64d 
To assess the target protease of AEBSF and E64d, 2 additional experiments were performed. 
First, virus inoculum, containing FECV UCD or UG-FH8, was treated for 2 h with 0 µM 
(control) or 100 µM AEBSF / 8 µM E64d at 37°C. Then, these virus-AEBSF/E64d mixtures 
were used to inoculate NA-treated cells for 5 min, after which inoculum was removed by three 
washings, and cells were further incubated in medium. Nine hours p.i., cells were fixed and 
stained as described above. In a second experiment, the time point at which the protease was 
involved in the replication cycle was assessed. Therefore, NA-treated cells were inoculated with 
FECV UCD or UG-FH8 at 105.8 TCID50 ml-1 for 5 min, after which inoculum was removed by 
three washings, and medium was added. At different time points p.i. (5, 30, 60, 90, 120, and 180 
min), medium was replaced by medium containing 0 µM (control) or 100 µM AEBSF / 8 µM 
E64d. Cells were fixed at 9 h p.i. to determine the percentage of infected cells as described 
above. 
4.2.2.6  Assessment of the requirement of furin cleavage for FECV infectivity 
The furin inhibitor decanoyl-RVKR-CMK was purchased from Calbiochem. To investigate the 
effect of furin cleavage during entry, cells were treated with 10 µM 2 h before and during 
inoculation (1 h). Then, the inoculum was removed by 3 washings and medium without inhibitor 
was added. Twelve hours p.i., cells were fixed. To study the effect of furin cleavage inhibition 
on the infectivity of progeny virus, cells were treated for 8 h after inoculation with 10 µM 
decanoyl-RVKR-CMK, after which both intra- and extracellular virus was collected and 
infectivity of the virus was assessed by determination of 50% tissue culture infective dose 
(TCID50). 
4.2.2.7  Infectivity titration 
Monolayers of colonocytes, seeded in collagen I coated 96-well plates, were inoculated with 50 
µl of serially diluted (1/10) virus suspensions. After 1 h (37 °C, 5% CO2), medium was added 
and the cells were further incubated for 72 h. Then, plates were washed with PBS, air-dried (1 h 
37°C) and frozen (-20°C). The 50% tissue culture infective dose was determined by means of 
immunoperoxidase monolayer assay (IPMA). Therefore, cells were fixed and permeabilized by 
incubation with PF 4% (10 min, RT), followed by incubation with methanol containing 1% 
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H2O2 (5 min, RT). Then, cells were incubated with PBS containing 10% normal goat serum and 
0.1% Tween 80 for 30 minutes at 37°C. Subsequently, cells were incubated with monoclonal 
antibodies against the N-protein, followed by goat anti-mouse HRP-labelled antibodies. Infected 
cells were visualized by adding sodium-acetate buffer containing amino-ethylcarbazole (AEC) 
and H2O2 for 10 minutes at RT. The fifty percent end-point was calculated according to the 
method of Reed and Muench (Reed & Muench, 1938). 
4.2.2.8  Statistics 
Experiments were independently repeated 3 times, and results were compared with the Mann-
Whitney U test. Statistical analysis was performed using GraphPad Prism version 5.0c 
(GraphPad software, San Diego, CA, USA). 
4.2.3 Results 
4.2.3.1  Serotype I FECV does not depend on acidic pH for its entry 
Figure 4.2.1 shows the effect of the endosomal/lysosomal acidification inhibitors ammonium 
chloride (NH4Cl), monensin, and chloroquine on FECV infection. FECV UCD and UG-FH8 
were not affected by NH4Cl or chloroquine, and marginally (but not significantly) affected by 
monensin. In contrast, FCoV 79-1683 and TGEV, known to depend on acid pH (Hansen et al., 
1998; Regan et al., 2008), were clearly affected by all of these pH drop inhibitors. These results 
imply that serotype I FECVs enter enterocytes via an acid-independent process. 
 
 
Figure 4.2.1. Effect of lysosomotropic agents on the infection of FECV UCD, FECV UG-FH8, FCoV 79-1683 
and TGEV in feline enterocytes. Cells were incubated 2 h before, during and after inoculation with different 
concentrations of NH4Cl, monensin or chloroquine diphosphate. Cells were fixed 12 h p.i., and the percentage of 
infected cells was determined relative to the control.  
4.2.3.2  Effect of continuous exposure of cells to various protease inhibitors on the replication 
of serotype I FECVs, serotype II FCoV 79-1683 and TGEV in enterocytes 
Several protease inhibitors were tested for the potential to inhibit serotype I FECV strains UCD 
and UG-FH8, FCoV 79-1683, and TGEV replication. For all inhibitors, the effect on infectivity 
was first evaluated by continuous incubation of the inhibitor in the medium before and during 
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replication, i.e. until 12 h p.i. As shown in Figure 4.2.2, the serine protease inhibitor AEBSF 
was a very potent inhibitor of all 4 viruses, with almost complete inhibition of infection at a 
concentration of 100 µM. The cell-permeable cysteine protease inhibitor E64d affected all feline 
coronaviruses, but not TGEV, which is in consistence with a previous report (Kim et al., 2013). 
Since serotype II feline coronaviruses are known to depend on cathepsin B, CA-074Me was 
tested for its inhibiting effect on the serotype I viruses. Serotype II FCoV 79-1683 was affected 
by cathepsin B inhibitor CA-074Me, but this effect was not as obvious as previously reported in 
other cell cultures (Regan et al., 2008), as only 71.5 ± 10.2 % infection relative to the control (p 
= 0.0636) was seen in the enterocyte cultures. In contrast to serotype II FCoV 79-1683, no effect 
was seen with cathepsin B inhibitor CA-074Me on infection of serotype I FECVs and TGEV. 
None of the viruses was inhibited by leupeptin, pepstatin A, and phosphoramidon. Also bestatin 
had no effect on the replication in concentrations up to 60 µM (data not shown). 
 
 
Figure 4.2.2. Effect of various protease inhibitors on the replication of FECV UCD, FECV UG-FH8, FCoV 
79-1683, and TGEV. Cells were incubated 2 h before, during and after inoculation with different concentrations of 
protease inhibitors. Cells were fixed 12 h p.i., and the percentage of infected cells was determined relative to the 
control.  
 
As inhibitors were continuously present during replication of the virus, these results cannot give 
a clue on the target protease (host and/or viral) and the stage of the replication cycle that was 
inhibited by AEBSF and E64d. To assess if cellular serine and/or cysteine proteases were 
involved in the entry, it was investigated whether only pre-treatment of cells with the inhibitors 
would similarly decrease the virus replication (Figure 4.2.3). When only pre-incubating with 
AEBSF, no inhibition was seen for all viruses, whereas E64d affected FCoV 79-1683, but not 
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serotype I FECVs or TGEV. Also a combination of AEBSF and E64d did not affect serotype I 
FECV replication. As both AEBSF and E64d are irreversible blockers, these data suggest an 
effect of both inhibitors on viral rather than on cellular proteases, except for serotype II FCoV 
79-1683, which used cellular cysteine proteases.  
 
 
Figure 4.2.3. Effect of pre-treatment of cells with protease inhibitors AEBSF and/or E64d on the replication 
of FECV UCD, FECV UG-FH8, FCoV 79-1683, and TGEV. Cells were incubated 2 h before inoculation (pre-
treatment) with 100 µM AEBSF, 8 µM E64d, or a combination of AEBSF and E64d. Cells were fixed 12 h p.i., and 
the percentage of infected cells was determined relative to the control.  
Taken together, these experiments showed that inhibition of cellular proteases by AEBSF or 
E64d was not able to reduce serotype I FECV infection, but both reduced viral replication, most 
probably by inhibiting viral protease activity. In addition, it was demonstrated that AEBSF had a 
potent antiviral activity against both feline coronaviruses and TGEV. 
4.2.3.3  AEBSF inhibits a virion-associated serine protease that works between 60 and 120 
min p.i., and E64d targets non-virion associated cysteine protease(s) that also work(s) before 
120 min p.i. 
Coronaviruses are known to encode for cysteine proteases involved in polyprotein processing, 
but no coronaviral serine protease activity has been described. To further identify the target 
protease, AEBSF and E64d were used to either treat the inoculum, or were added at different 
time points post inoculation to identify which step in the replication cycle was blocked. Figure 
4.2.4 shows the results of AEBSF or E64d treatment of the inoculum. Since inhibitors could not 
be separated from the virus after pre-treatment of the inoculum, it was decided to inoculate the 
virus-inhibitor mixtures for only 5 min, in order to be sure that AEBSF could not block anything 
but the virus, and a control was taken by adding this AEBSF-virus mixture for 5 min without 
any pre-treatment of the virus. Interestingly, if only the inoculum was treated with AEBSF, the 
same inhibition was seen as when AEBSF was continuously present during the experiment, 
indicating that the viral protease that is blocked by AEBSF is incorporated in the virion. For 
E64d, pre-treatment of the inoculum did not inhibit the FECV replication. 
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Figure 4.2.4. AEBSF, but not E64d treatment of viruses reduces their replication capacity. FECV UG-FH8 
and UCD were treated for 2 h with 100 µM AEBSF or 8 µM E64d or medium (control). Then, virus-inhibitor 
mixtures were inoculated for 5 min, after which the inoculum was removed by three washings. An extra control 
consisting of the addition of AEBSF or E64d during 5 min inoculation without pre-treatment was also included. 
Cells were further incubated in medium and percentage of infected cells was assessed 9 h p.i. 
Subsequently, a kinetic study was performed to assess at which time points p.i. this viral serine 
protease fulfilled its function, and the same was done for E64d to get an idea about the potential 
role of the protease. Therefore, cells were inoculated for 5 min with the virus, after which the 
inoculum was removed by three washings and medium was added. At different time point p.i. 
(5, 30, 60, 90, 120, and 180 min), medium was changed to medium containing 0 µM (control) or 
100 µM AEBSF / 8 µM E64d, and the percentage of infected cells was determined at 9 h p.i. 
Figure 4.2.5 shows that until 1 h p.i., the replication remained blocked by AEBSF addition, 
indicating that the protease had not yet completed its function by 1 h p.i. From 90 min p.i., viral 
replication became less affected by the addition of AEBSF, indicating that the viral serine 
protease fulfilled its function between 60 and 90-120 min after addition of the virus to the cells. 
E64d had a slight inhibitory effect on the FECV replication when added to the medium at all 
time points before 120 min p.i., although there was slightly less inhibition when added after 60 
or 90 min p.i. compared to 5 or 30 min p.i. 
 
Figure 4.2.5. Effect of addition of AEBSF or E64d at several time points p.i. Cells were inoculated with FECV 
UG-FH8 or UCD for 5 min, after which inoculum was removed by three washings and medium was added. At 
different time points post inoculation (5, 30, 60, 90, 120, and 180 min), medium was replaced by medium 
containing no (control) or 100 µM AEBSF/8 µM E64d and cells were fixed 9 h p.i. Graphs represent the percentage 
of infected cells relative to the control (dashed line) for each of the assessed time points.  
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4.2.3.4  Effect of furin inhibitor decanoyl-RVKR-CMK on the entry and infectivity of serotype 
I FECVs 
Serotype I FECVs are known to have a highly conserved furin cleavage site at the S1/S2 
boundary (de Haan et al., 2008; Licitra et al., 2013). Therefore, it was investigated if furin 
cleavage of the FECV spike would be a determining factor in its infectivity for enterocytes. As 
furin cleavage can occur either during entry or during exit, the effect of both incubation with 
furin inhibitor before/during inoculation (pre-treatment) and after inoculation (post-treatment) 
was studied. Figure 4.2.6 shows the relative percentage of infected cells 12 h p.i. after treatment 
of cells 2 h before and during inoculation (1 h) with 10 µM decanoyl-RVKR-CMK. Neither of 
the two serotype I FECVs was affected by this treatment, whereas infectivity of serotype II 
strain 79-1683 and TGEV was reduced to 73.7 ± 3.2 % and 68.4 ± 8.4 %, respectively (p = 
0.0636). As furin cleavage inhibition had no effect on the entry of serotype I FECVs, the effect 
of furin cleavage inhibition during production of new progeny virus was investigated. Figure 
4.2.7 shows the results of infectivity titration 9 h p.i. after treatment of cells with 10 µM furin 
inhibitor decanoyl-RVKR-CMK for 8 h p.i. Neither of the two serotype I viruses showed 
decreased infectivity when assessing both intra- and extracellular titre, and there was also no 
effect when 25 µM of inhibitor was used or when the furin inhibitor was refreshed at 4 h p.i. 
(data not shown). These results indicate that furin cleavage is not a prerequisite for FECV 
infectivity in enterocytes. In addition, viruses released from post-treated cells, which are 
supposed to have uncleaved spikes, were not more susceptible to chloroquine or furin pre-
treatment compared to the control, indicating that these viruses did not started to use furin 
encountered during entry nor another entry pathway, which could have explained the lack of 
effect on infectivity (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.6. Effect of pre-treatment of cells with furin inhibitor decanoyl-RVKR-CMK. Cells were treated 
with 10 µM furin inhibitor decanoyl-RVKR-CMK 2 h before and during inoculation and the percentage of infected 
cells was assessed relative to control 12 h p.i.  
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Figure 4.2.7. Effect of furin inhibitor decanoyl-RVKR-CMK on the infectivity of progeny FECV. Cells were 
inoculated with FECV UCD and FECV UG-FH8 (m.o.i. 0.2). After 1 h, the inoculum was removed by 3 washings 
and cells were further incubated with 10 µM decanoyl-RVKR-CMK for 8 h, after which both intra- and 
extracellular infectious titres were assessed. 
4.2.4 Discussion 
As all enveloped viruses, coronaviruses require fusion processes to deliver their genome into the 
cytosol. This fusion process is mediated by the spike, a class I fusion protein which protrudes 
from the viral surface as a homotrimer complex (Bosch et al., 2003). Viral class I fusion 
proteins are typically synthesized as inactive precursor proteins and require proteolytical 
activation to acquire their fusion competent state. In addition, other triggers such as low pH 
and/or receptor binding are needed to finally allow the fusion of the viral envelope and the host 
membrane (Dimitrov, 2004; White et al., 2008). Depending on the required fusion triggers, 
genome release occurs at the plasma- or at the endosomal membrane. Fusion triggers and entry 
pathways differ greatly among coronaviruses, and depend on the virus, strain, or even the cell 
type a certain virus/strain is faced with (Belouzard et al., 2012; Heald-Sargent & Gallagher, 
2012). In addition to the receptor distribution, these differences are of key importance in the 
determination of virus tropism and pathogenicity. Cell tropism switch is a crucial event in FIP 
pathogenesis, but so far nothing is known about fusion triggers required for the abundantly 
present and clinically relevant serotype I FCoVs. In the present study, fusion triggers required 
for serotype I FECV infection in enterocytes were investigated by using various endosomal 
acidification- and protease inhibitors. Serotype II FCoV 79-1683 and TGEV Purdue were taken 
along the experiments as control for the activity of the products, since these viruses can infect 
feline enterocytes and their fusion triggers have been (partially) characterized. 
In contrast to TGEV and FCoV 79-1683 for which we and others (Hansen et al., 1998; Regan et 
al., 2008) showed that they depend on endosomal acidification, serotype I FECV did not require 
a low pH step to initiate infection in enterocytes. This indicates that serotype I FECV most 
probably enters cells via fusion at the plasma- or early endosomal membrane. To elucidate 
0
2
4
6
8
Control Furin inhibitor
decanoyl-RVKR-
CMK
Lo
g 1
0 T
CI
D
50
 / 
10
6  c
el
ls
0
2
4
6
8
Intracellular titre
Extracellular titre
Control Furin inhibitor
decanoyl-RVKR-
CMK
Lo
g 1
0 T
CI
D
50
 / 
10
6  c
el
ls
FECV UCD FECV UG-FH8
Proteases involved in FECV infections 117 
 
 
whether FECV fuses at the plasma- or endosomal membrane, further research using chemical 
inhibitors of internalization pathways, dominant-negative proteins involved in the internalization 
and/or co-localization studies need to be performed, as previously described for FIPV 79-1146, 
amongst others (Van Hamme et al., 2008). Acid-independent entry has been described for 
MHV-4 and FIPV 79-1146 (Gallagher et al., 1991; Regan et al., 2008). In contrast to FIPV 79-
1146 (and other serotype II FCoVs) (Regan et al., 2008), serotype I FECV entry did not depend 
on the (acid-independent) cathepsin B, or on any other host cysteine protease that could be 
inhibited by the broad-spectrum cysteine protease inhibitor E64d. However, a reduction of viral 
replication was seen when E64d was present in the medium until 12 h p.i. The same inhibition 
pattern (i.e. no effect when cells were only pre-treated, but substantial reduction when the 
inhibitor was present in the medium during the entire course of the infection) was noticed with 
the broad-spectrum serine protease inhibitor AEBSF, which, in contrast to E64d, not only 
affected FCoVs (serotype I and II), but also potently inhibited TGEV infection. Both E64d and 
AEBSF are irreversible blockers, and hence should block all host proteases when only pre-
treating cells before inoculation. Consequently, the inhibitory effect seen when leaving both 
compounds in the medium during replication was most probably due to the inactivation of viral 
proteases. Indeed, coronaviruses undergo autoproteolytical processing of 2 precursor proteins, 
polyprotein (pp) 1a and 1ab, which are directly synthesized from the genome upon genome 
release. This proteolytical cleavage results in the formation of 16 mature proteins and is 
mediated by at least 2 or 3 viral protease encoded by nsp3 and nsp5. However, despite the 
chymotrypsin-like structure of nsp5-encoded proteases, all viral proteases known to be involved 
in polyprotein processing are cysteine proteases, as the papain-like proteases encoded by nsp3 
employ the catalytic cysteine-histidine-aspartic acid triad, and the main proteases encoded by 
nsp5 the cysteine-histidine catalytic dyad (Hegyi et al., 2002; Lu et al., 1995; Wojdyla et al., 
2010; Ziebuhr et al., 2000). Consequently, this viral protease-mediated genome processing 
could explain the reduction seen with E64d, which is in consistence with previous reports (Kim 
et al., 1995; Kim et al., 2013), but not the strong reduction induced by AEBSF for all tested 
viruses. Therefore, it was further determined which stage of the replication cycle was targeted 
by AEBSF. Interestingly, similar reduction in infection was noticed when only the inoculum 
was treated with AEBSF or when AEBSF was added to the medium after inoculation at 5, 30, or 
60 min p.i. From 90 min p.i., virus replication was less affected by the addition of AEBSF, 
indicating that the proteolysis had already occurred in a substantial amount of cells by then. So 
far, inhibition of coronavirus replication with AEBSF has only been reported for IBV and 
PEDV, but for both viruses, this effect was attributed to inhibition of host serine proteases 
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during entry (Park et al., 2014; Yamada & Liu, 2009). However, in both studies, AEBSF was 
present in the inoculum for 1 (PEDV) or 2 hours (IBV), and hence inhibition of a viral protease 
cannot be excluded in these studies. Results obtained in the present study give an indication that 
beside cysteine protease activity encoded by the pp1a, coronaviruses also encode a serine 
protease, which, in contrast to the cysteine proteases, resides in the virion. However, it cannot be 
excluded that this protease activity results from the incorporation of a cellular serine protease in 
the virion. Based on the kinetic study that was performed with AEBSF and E64d, this serine 
protease is most likely involved in the initiation of the replication during a post-entry step, but 
the identity and function remain to be elucidated. Nonetheless, the fact that all these 
coronaviruses could be blocked by AEBSF makes this information highly valuable for future 
coronavirus research and multi-coronavirus drug development.  
At least two distinct cleavage sites (CS) for proteolytical activation of coronavirus S proteins 
have been described. CS1 is located at the S1/S2 boundary, and CS2 is found within S2, 
adjacent to the putative fusion peptide (Belouzard et al., 2009; Belouzard et al., 2010; Belouzard 
et al., 2012; Heald-Sargent & Gallagher, 2012; Yamada & Liu, 2009). Some coronaviruses, 
such as IBV, MHV-A59, MHV-4, and serotype I FECV are believed to carry a pre-cleaved 
spike by cleavage at CS1 mediated by furin, encountered during the exocytosis process (de 
Haan et al., 2008). Furin is a Ca2+-dependent serine protease and is one of the mammalian 
proprotein convertases (PCs). Furin is ubiquitously found in endocytic and exocytic pathways 
by its circulation from the trans-Golgi network to the plasma membrane, and back via the 
endocytic pathway (Seidah & Prat, 2012). Typically, furin cleavage preferably occurs after the 
C-terminal arginine residue in the consensus motif RXR(K)R/, where X represents any amino 
acid, but cleavage after the motif RXXR/ has also been described (Molloy et al., 1992). This 
multi-basic motif is found at CS1 in some coronaviruses, including serotype I FECVs, but 
seems to be absent in most other coronaviruses, and its exact role in in vivo coronavirus 
infections is still not completely clarified. CS1 cleavage by furin is not a determinant of 
infectivity in cell culture (de Haan et al., 2004; Gombold et al., 1993; Yamada & Liu, 2009), but 
it does promote cell-cell fusion, and, at least for SARS-CoV, also promotes CS2 cleavage 
(Belouzard et al., 2009). In addition, cleavage at the S1/S2 boundary occurs too far from the 
fusion peptide and therefore can potentially not liberate the internal fusion peptide. 
Consequently, cleavage at CS2, and not at CS1, is considered as the key fusion-determining 
factor of coronaviruses. The need for CS2 and not CS1 cleavage for virus entry has been clearly 
demonstrated for IBV Beaudette strain. Indeed, S proteins of IBV Beaudette (and related 
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strains) have 2 furin cleavage sites, one at amino acid position 531-538 (CS1) and the other at 
amino acid position 684-692 (CS2). By mutational analysis and the use of the broad spectrum 
PC inhibitor decanoyl-RVKR-CMK, Yamada and Liu showed that whereas the first cleavage 
site can promote fusion, only CS2 cleavage is the key determinant for induction of both virus-
cell and cell-cell fusion. At that position, FCoV 79-1683, TGEV, CCoV, and bat HKU5-1 also 
have a furin cleavable motif (RKYR), whereas other coronaviruses have a highly conserved 
trypsin cleavable site (Yamada & Liu, 2009). In the present study, the requirement for furin-like 
enzymes has only been studied for virus-cell fusion processes, and not for cell-cell fusion, as the 
enterocyte cultures are not prone to syncytium formation with any of the viruses used in this 
study. It was shown that both FCoV 79-1683 and TGEV rely on PC (potentially furin) cleavage 
during their entry in enterocytes, most probably by cleavage at the CS2 site as suggested by 
Yamada and Liu (2009), although this was not further confirmed in the present study. In 
contrast, serotype I FECVs were not at all affected by pre-treatment of cells with decanoyl-
RVKR-CMK, indicating that PCs are not involved during entry. According to the ProP server, 
no PC cleavage site was present at CS2 of FECV UCD (http://www.cbs.dtu.dk/services/ProP/) 
(Duckert et al., 2004). In addition, viruses released from decanoyl-RVKR-CMK treated cells 
were not less infectious than those released from non-treated cells, indicating that furin cleavage 
at the CS1 site is not a prerequisite for FECV infectivity. This is in consistence with all previous 
reports on other coronaviruses with a furin cleavable CS1 site (de Haan et al., 2004; Gombold et 
al., 1993; Yamada & Liu, 2009), but should be further confirmed by mutational analysis of this 
motif in serotype I FECVs. In addtion, none of the other tested protease inhibitors, including 
AEBSF, E64d, leupeptin, pepstatin A, cathepsin B inhibitor, phosphoramidon, bestatin (data not 
shown), chymostatin (data not shown), phenylmethylsulfonyl fluoride (PMSF) (data not shown) 
and tosyl phenylalanyl chloromethyl ketone (TPCK) (data not shown), affected serotype I 
FECV entry. These inhibitors target the main classes of proteases, although leupeptin was the 
only inhibitor that could potentially inhibit threonine proteases. Leupeptin works on a wide 
range of cysteine, threonine and trypsin-like serine proteases and has been shown to affect 
replication of many coronaviruses, such as SARS-CoV, MERS-CoV, HCoV 229E, and PEDV 
(Appleyard & Tisdale, 1985; Shirato et al., 2013; Shirato et al., 2011; Simmons et al., 2005). 
This inhibition had been attributed to both its effect on endosomal cysteine proteases and/or to 
its effect on type II transmembrane serine proteases. However, although FCoV 79-1683 is 
known to use endosomal cysteine proteases, no effect of leupeptin was seen in the present study. 
This can be attributed to the questionable cell permeability of leupeptin and is in consistence 
with a previous report, showing that leupeptin had no effect on the cathepsin B-dependent FIPV 
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79-1146 replication (Appleyard & Tisdale, 1985). This observation implies that other threonine 
protease inhibitors than leupeptin should be tested to reveal whether or not this class of 
proteases is involved. In addition, it cannot be assured that all proteases within a certain class 
were targeted with the inhibitors that were used. Consequently, although FECV serotype I entry 
was not affected by the tested inhibitors targeting the main classes of proteases, this does not 
exclude that the spike is cleaved by cellular proteases during entry. Indeed, a recent study 
reporting the use of a conditional biotinylation assay showed that MHV-A59 spike is 
proteolytically cleaved during entry, but the exact protease could also not be identified, as this 
process was not susceptible to inhibitors targeting serine-, cysteine-, aspartyl-, and 
metalloproteases (Wicht et al., 2014). So far, it remains unknown whether serotype I FECV 
warrants proteolytical cleavage by cellular protease during entry. 
In conclusion, present study demonstrated that, in contrast to serotype II FCoVs, serotype I 
FECVs did not rely on acidic pH or cathepsin B for entry, confirming that care should be taken 
when extrapolating results obtained with the serotype II viruses to the in vivo situation, 
especially when it concerns viral entry. In addition, the furin inhibitor decanoyl-RVKR-CMK 
did not affect serotype I FECV entry or infectivity of progeny virus, but did inhibit FCoV 79-
1683 and TGEV entry. Moreover, it was shown that serotype I FECVs (and some other 
alphacoronaviruses) potentially carry a virion-associated serine protease, which fulfils its 
function between 60 and 120 min p.i., thereby identifying a new target for drug development. 
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Summary 
Feline enteric coronavirus (FECV) is a worldwide distributed, harmless intestinal virus of 
cats. However, occasionally, mutations occur that transform FECV into the deadly feline 
infectious peritonitis virus (FIPV). In order to better understand the feline coronavirus 
pathogenesis, three specific pathogen free cats were experimentally infected with the serotype 
I FECV UCD. Virus shedding was quantified in faeces and oral fluid by 2 different RT-
qPCRs (one recognising the 3’ of all genomic and subgenomic mRNAs (3’ qPCR), and the 
other recognising the ORF1b of the genomic RNA (5’ qPCR)), and by virus titration in 
enterocyte cultures. Blood samples were used to assess viraemia, neutralizing antibodies, and 
different subsets of leukocytes. The three cats remained clinical healthy during the course of 
the experiment, although some loss of appetite and slight weight loss was noticed in 2 cats 
(cat 1 and cat 3) in the beginning of the experiment. In these 2 cats, viral RNA was detected 
in faeces from day 2 (3’ qPCR) or day 4 (5’ qPCR) post inoculation (p.i.), and remained 
detectable for 2 months p.i. Infectious virus was found from day 4 until day 28 p.i. It was 
shown that the 3’ qPCR gave a viral genome overestimation of 3-4.3 log10. Neutralizing 
antibodies were detectable from day 9 p.i, and a cell-associated viraemia was detected at 
infrequent time points after the onset of faecal shedding. No abnormal leukocyte numbers 
were noticed, except for a granulocytopenia in cat 1. Interestingly, the other cat (cat 2) 
showed a deviating infection pattern, characterized by absence of clinical signs, a delayed 
faecal shedding (from day 14 p.i.), which was not infectious in cell cultures, a delayed rise in 
antibody titres (from day 21 p.i.), and a viraemia that was detected far before any intestinal 
replication. No abnormalities or differences could be seen in leukocyte numbers compared to 
the other two cats, with the exception of CD8+ regulatory T cells, but if and how these cells 
played a role remains elusive.   
Clinical, virological, and immunological 
parameters during experimental feline 
enteric coronavirus infection 
5.1 
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5.1.1  Introduction 
Feline coronaviruses (FCoVs) occur as two pathotypes, associated with either enteric or 
systemic diseases in cats. Feline enteric coronavirus (FECV) is an enteropathogenic virus that 
is ubiquitously present throughout the cat population worldwide (Addie & Jarrett, 1992; 
Pedersen et al., 1981b). The mild enteritis caused by its intestinal replication can be 
manifested by transient mild anorexia, weight loss and/or diarrhoea, but this is often too mild 
to be noticed (Hickman et al., 1995; Pedersen et al., 1981b; Vogel et al., 2010). Feline 
infectious peritonitis virus (FIPV) arises most likely by mutation from FECV in individually 
infected cats (Chang et al., 2011; Chang et al., 2010; Herrewegh et al., 1995; Pedersen et al., 
2009; Pedersen et al., 2012; Poland et al., 1996; Vennema et al., 1998). These yet unknown 
mutations provide the virus with tools to productively replicate in monocytes/macrophages, 
causing a highly fatal systemic disease (FIP) characterized by a diffuse vasculitis, 
polyserositis and severe lymphopenia (Addie et al., 2009; Horzinek & Osterhaus, 1979; Kipar 
et al., 1998). Both pathotypes occur as 2 serotypes. Serotype II viruses arise by double 
recombination events between serotype I FCoVs and canine coronaviruses but represent only 
a minority of all strains worldwide (Addie et al., 2003; Benetka et al., 2004; Herrewegh et al., 
1998; Hohdatsu et al., 1992; Kummrow et al., 2005; Lin et al., 2009; Vennema, 1999).  
In vivo experiments are indispensable to study pathogenesis events. Due to its pathogenicity, 
most studies have been done with FIPV in order to investigate its complex epidemiology, 
pathogenesis and its interplay with the host’s immune system. Although FECV is the source 
of every FIPV and consequently an important target in the control of FIP, experimental 
studies with FECV are rather scarce (Meli et al., 2004; Pedersen et al., 2008; Pedersen et al., 
1981b; Poland et al., 1996; Vogel et al., 2010). These studies mainly focussed on disease 
causing potential, faecal excretion patterns, and humoral immune responses during FECV 
infections. However, up until now, very little is known about the oral shedding of the virus, 
the viral infectivity of oral and faecal excretions, the presence of neutralizing antibodies, and 
the dynamics of the several leukocyte subsets during FECV infections. In addition, 
information on the relationship between PCR-assessed shedding and infectivity is scarce, as 
this has only been investigated once by infecting specific pathogen free (SPF) cats with either 
PCR-negative, weak-positive or strong-positive faecal samples (Foley et al., 1997). 
Quantification of infectious virus and its correlation to RT-qPCR results have never been 
investigated, as there had been no susceptible cell cultures available. The recently established 
feline intestinal cell cultures (Desmarets et al., 2013) can further shed light on these missing 
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links. Therefore, this study aimed at further broadening our knowledge on FECV 
pathogenesis, by providing information on viral infectivity, neutralizing antibody titres, and 
the dynamics of different leukocyte subsets during FECV infection by inoculation of 3 SPF 
cats with FECV UCD. For all cats, clinical, virological, and immunological parameters were 
followed during 3 months after inoculation. Surprisingly, 1 of the cats showed an aberrant 
excretion pattern compared to the other cats. Differences and potential causes for this 
abnormality are discussed. 
5.1.2 Materials and methods 
5.1.2.1  Virus 
A faecal suspension containing an unknown titre of the FECV strain UCD (originally isolated 
at UC Davis, (Pedersen et al., 1981b)) were kindly provided by Dr. P. Rottier (Utrecht 
University, The Netherlands). This suspension was diluted 1/10 in phosphate buffered saline 
and stored at -70 °C until use. The RNA content was determined using an RT-qPCR based on 
SYBR Green detection (see below). The suspension was centrifuged at 16200 g for 10 min to 
remove bacterial or host cells, and animals were infected with the suspension supernatant. 
5.1.2.2  Inoculation and monitoring 
Three 14 to 18 months old SPF cats (feline leukaemia virus-, feline immunodeficiency virus-, 
and FCoV-negative) (Harlan laboratories, Indianapolis, IN, USA) were orally infected with 
800 µl of faecal suspension supernatant, containing 1011.3 viral RNA copies, while stimulating 
the swallowing reflex. Cats were housed in the same room but were separated from each other 
to avoid any physical contact between the animals. Additionally, precautions were taken to 
prevent exposure to any source of contaminating coronavirus. Briefly, with each handling, 
sterile clothing and footwear was ensured while litter trays, food trays and water bowls were 
cleaned and decontaminated daily. To ensure no contamination could arise from the litter 
being used, fine sand was washed extensively and autoclaved to serve as litter. The cats were 
monitored each day during the first week after infection and subsequently on day 9, 14, 21, 
28, 56, and 84. Each time, the rectal temperature was measured, lymph nodes were palpated, 
an oral swab was taken and faeces were collected. If faeces were not available, faecal 
shedding was monitored by inserting a cotton tipped swab (Copan diagnostics, CA, USA) into 
the rectum. Swabs were suspended in 1 ml DMEM supplemented with 1000 U ml-1 penicillin 
(Continental Pharma Inc., Puurs, Belgium), 0.4 mg ml-1 gentamycin (Gibco BRL, Merelbeke, 
Belgium) and 10% fetal bovine serum (FBS, Gibco BRL). Faeces were diluted 1:5 (w:v) in 
the same medium. Suspensions were centrifuged at 2000 g for 10 min and supernatant was 
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frozen (-70°C) until determination of the viral load. Additionally, on day 0, 3, 5, 7, 9, 14, 21, 
28, 56 and 84, cats were weighed, and 5 ml blood was taken from the vena jugularis in 
heparin (15 U ml-1) (Leo, Zaventem, Belgium). 
5.1.2.3  One step RT-qPCR for the quantification of the viral RNA load 
5.1.2.3.1  RT-qPCR for the detection of total viral RNA 
RNA was extracted from the faecal suspension using the QIAamp Viral RNA Mini Kit 
(Qiagen, Benelux BV, Belgium). A one step real-time RT-PCR based on SYBR Green 
detection was performed with primers described by Gut et al. (1999), targeting a 102 bp 
fragment at the 3’ end of the genome (Gut et al., 1999). A 15 µl PCR mixture was used per 
reaction and contained 0.3 µl Superscript™ III RT/ Platinum® Taq Mix, 7.5 µl 2x SYBR® 
Green Reaction Mix with ROX (Superscript™ III Platinum® SYBR® Green One-Step qRT-
PCR Kit with ROX, Invitrogen), 0.5µM forward primer FCoV1128f, 0.5 µM reverse primer 
FCoV1229r and 3 µl FECV UCD RNA or diluted standard RNA (see below). A reverse 
transcription step of 20 min at 50°C and a denaturation step at 95°C for 5 min were followed 
by 45 cycles each 15 s at 95°C and 30 s at 60°C. A first-derivative melting curve analysis was 
performed by heating the mixture to 95°C for 15 s and then cooling to 60°C for 1 min and 
heating back to 95°C at 0.3°C increments. Reverse transcription, amplification, monitoring 
and melting curve analysis were carried out in a Step One Plus™ real-time PCR system 
(Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA). 
Synthetic RNA standards were generated by extracting RNA from FECV 79-1683 using the 
QIAamp Viral RNA Mini Kit (Qiagen). The RNA was reverse-transcribed into cDNA using 
the SuperScript™ III First-Strand Synthesis System for RT-PCR (Invitrogen). Briefly, 250 ng 
RNA was incubated for 5 min at 65°C with 2 µM reverse primer FCoV1229r and 10mM 
dNTP mix. Afterwards, an equal volume of cDNA synthesis mix, containing 10x RT buffer, 
25mM MgCl2, 0.1 M DTT, 40 U µl-1 RNase OUT and 200 U µl-1 Superscript III RT was 
added and incubated for 50 min at 50°C. The reaction was terminated at 85°C for 5 min. RNA 
was removed by incubation with RNase H for 20 min at 37°C. The 50 µl PCR mixture for the 
amplification of the cDNA contained 5x Herculase II reaction buffer, 25mM dNTP mix, 200 
ng DNA template, 0.25µM forward primer FCoV1128f modified with a T7 promotor 
sequence at its 5’ end, 0.25µM reverse primer FCoV1229r and 0.5 µl Herculase II fusion 
DNA polymerase (Agilent Technologies Inc., Santa Clara, CA, USA). After a denaturation 
step for 1 min at 95°C, 30 cycli of amplification, each 20 s at 95°C, 30 s at 60°C and 1 min at 
68°C, were followed by a terminal elongation of 4 min at 68°C. cRNA standards were 
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transcribed by inbubation for 1 h at 37°C with 10x transcription buffer, 500µM rNTPs and 20 
U T7 RNA polymerase-Plus Enzyme Mix (Applied Biosystems). Transcription reactions were 
DNase treated and the amount of RNA was determined using the Nanodrop 200 system. Ten-
fold serial dilutions were made over a range of 6 log units (1010-105) for the generation of the 
standard curve. 
5.1.2.3.2  RT-qPCR for the detection of genomic RNA 
RNA was extracted from the faecal suspensions using the QIAamp Viral RNA Mini Kit 
(Qiagen, Benelux BV, Belgium). Primer design and PCR conditions have previously been 
described (see chapter 3) (Desmarets et al., 2013). 
5.1.2.4  Infectivity titration 
Monolayers of colonocytes, seeded in collagen I coated 96-well plates, were inoculated with 
50 µl of serially diluted (1/10) faecal suspensions (ranging from 100 to 10-7). After 1 h (37°C, 
5% CO2), medium was added and the cells were further incubated for 72 h. To avoid cell loss 
due to faecal toxicity, undiluted suspensions were removed from the wells 1 h p.i., and the 
cells were washed 2 times before they were further incubated in medium. Then, plates were 
washed with PBS, air-dried (1 h 37°C) and frozen (-20°C). The 50% tissue culture infective 
dose (TCID50) was determined by means of immunoperoxidase monolayer assay (IPMA). 
Therefore, cells were fixed and permeabilized by incubation with PF 4% (10 min, RT), 
followed by incubation with methanol containing 1% H2O2 (5 min, RT). Then, cells were 
incubated with PBS containing 10% negative goat serum and 0.1% Tween 80 for 30 min at 
37°C. Subsequently, cells were incubated with monoclonal antibodies against the N-protein 
(produced and characterized in the lab), followed by goat anti-mouse HRP-labelled 
antibodies. Infected cells were visualized by adding sodium-acetate buffer containing amino-
ethylcarbazole (AEC) and H2O2 for 10 min at RT. The fifty percent end-point was calculated 
according to the method of Reed and Muench (Reed & Muench, 1938). 
5.1.2.5  Determination of neutralizing serum antibody titres 
Sera were incubated at 56°C for 30 min to inactivate complement. Two-fold serial dilutions of 
the sera were mixed with an equal volume of a virus suspension containing 100 TCID50 
FECV UCD and incubated for 1 h (37°C, 5% CO2). Then, colonocytes were added and 
further incubated with the virus-serum suspensions for 3 days. Infection was visualized by 
means of IPMA as described for the assessment of the infectious titre. The virus neutralizing 
titres were expressed as the reciprocal of the serum dilution that neutralized infection in 50% 
of the monolayers. 
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5.1.2.6  Leukocyte isolation 
Blood mononuclear cells were separated on Ficoll-Paque (GE Healthcare, Little Chalfont, 
Buckinghamshire, United Kingdom). After isolation, cells were counted and frozen. Briefly, 
maximum 2 x 107 cells ml-1 were resuspended in RPMI supplemented with 30% fetal bovine 
serum (FBS), 100 U penicillin ml-1, 0.1 mg streptomycin ml-1, and 10% dimethyl sulfoxide 
(DMSO). Subsequently, cells were frozen by lowering the temperature with 1°C min-1 until -
30°C, followed by a 15 min incubation period at -30°C and finally lowering the temperature 
to -150°C at a rate of 1°C s-1 (PTLPD81, Orthodyne, Alleur, Belgium). After freezing, cells 
were stored in liquid nitrogen. 
5.1.2.7  Antibodies used for leukocyte staining 
Monoclonal antibodies against the epsilon chain of feline CD3 (NZM1) and against feline 
CD56 (SZK1) were kindly provided by Dr. Yorihiro Nishimura (Tokyo University, Japan) 
(Shimojima et al., 2003). Monoclonal antibodies FE5.4D2, and CA2.1D6 recognizing feline 
CD8β, and canine CD21, respectively, were purchased from AbD Serotec (Dusseldorf, 
Germany). A monoclonal antibody (FJK-16s), directly conjugated with Alexa fluor 647 
(AF647) and crossreacting with feline Foxp3 was purchased from eBioscience (San Diego, 
USA). Monoclonal antibody CAT30A against feline CD4 was purchased from Veterinary 
Medical Research and Development (VMRD, Pullman, USA). Conjugated secondary 
antibodies [Molecular Probes (Invitrogen, Carlsbad, USA)] were goat anti-rat Alexa Fluor 
488, goat anti-mouse IgG R-Phycoerythrin (R-PE), goat anti-mouse IgG2a Alexa Fluor 488, 
goat anti-mouse IgG1 Alexa Fluor 647 and goat anti-mouse IgG3 fluorescein isothiocyanate 
(FITC). When primary antibodies from the same IgG1 isotype were used, one primary 
antibody was labeled with Zenon Alexa Fluor 488 Mouse IgG1 (Invitrogen, Carlsbad, USA). 
5.1.2.8  Leukocyte staining 
Phenotyping of cells from all compartments was performed simultaneously. All analyzed 
cells were first stored in liquid nitrogen, facilitating analysis workflow. Several precautions 
were taken in order to preserve immunophenotypic properties as was done in previous 
research (Vermeulen et al., 2012). Briefly, cells were frozen directly after isolation, they were 
stored at -196°C for the entire storage period and viability of thawed cells was routinely 80-
90%. A minimum of 1 × 106 of frozen cells were stained for phenotypic analysis in RPMI 
supplemented with 1 mM Ethylenediaminetetraacetic acid (EDTA). Cells were incubated for 
20 min at 4°C while gently shaking, both with the primary and dye-conjugated secondary 
antibodies. Cells were washed with cold RPMI containing EDTA and centrifuged at 300 g for 
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10 min at 4°C. During regulatory T cell staining, surface molecules were first stained, after 
which cells were fixed with the fixation/permeabilization kit optimized for staining of 
intracellular Foxp3 (eBioscience, San Diego, USA). Cells were then stained with anti-Foxp3 
antibody, directly conjugated with AF647. Analysis was done on a FACSCanto flow 
cytometer using FACSDiva software (BD Biosciences, Mountain View, California, USA). 
After singlet gating, a minimum of 2 × 105 events was analyzed.  
5.1.2.9  Animal welfare 
This study was performed according to animal welfare guidelines. Under the application 
EC2012/043, this research was positively evaluated by the Ethical Committee of the Faculty 
of Veterinary Medicine, Ghent University.   
5.1.3 Results 
5.1.3.1  Clinical signs, viral shedding, and viraemia in 3 cats inoculated with FECV UCD 
Mild clinical symptoms were seen in 2 of the 3 cats (cat 1 and cat 3) during the first week p.i. 
(Figure 5.1.1). Symptoms consisted of a diminished appetite and moderate weight loss, to 
95.4 and 88.4% of the initial weight for cat 1 and 3, respectively. Cat 1 also showed an 
increased body temperature at day 4 (39.5 °C) and day 6 (39.7°C) p.i. No diarrhoea or 
changes in faeces consistency were noticed. From day 9, both cats started to recover and 
reached their original weight at 21 days p.i. Cat 2 showed no signs of loss of appetite, weight 
loss or abnormal faeces consistency during the entire infection course, but slightly swollen 
submandibular lymph nodes were noticed at day 3 p.i., and a slightly raised temperature 
(39.3°C) at day 7 p.i. 
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Figure 5.1.1. Clinical parameters followed during the entire FECV UCD infection course. (A) Rectal 
temperature was monitored daily during the first week, and on day 9, 14, 21, 28, 56, and 84 p.i. (B) Body weight 
was measured at day 0, 3, 5, 7, 9, 14, 21, 28, 56, and 84, and expressed relative to the weight before inoculation. 
Oral and faecal shedding were quantified in all animals by 2 different RT-qPCRs, and by 
virus titration in feline enterocyte cultures (Figure 5.1.2). These 2 RT-qPCRs were taken 
along to assess the overestimation of virus particles by the generally used 3’ qPCR (Gut et al., 
1999), as this qPCR detects not only genomic RNA, but also all subgenomic mRNAs. 
Directly after inoculation, only a fraction of the viral inoculum was found in the mouth, 
indicating that all cats had swallowed most of the inoculum. The next day, viral RNA was 
still detected in oral fluid of cat 2 and 3 with the 3’ qPCR, whereas only in cat 3 genomic 
RNA (5’ qPCR) and infectious virus were detected. Total RNA (3’ qPCR) remained 
detectable for cat 2 and 3 at day 2 p.i., whereas genomic viral RNA was detected for cat 1 and 
3. During the remainder of the infection course, oral viral RNA load and days of detection 
varied considerably. Overall, the amount of oral RNA nearly always approached detection 
levels, which can explain the inconsistency seen between both qPCRs. Infectious virus could 
not be found in oral fluid, except for cat 3 at day 0 and day 1. 
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Figure 5.1.2.  Quantification of oral and faecal shedding by 2 different real time RT-PCRs and virus 
titration. Oral swabs and faeces (or faecal swabs if no faeces were available) were taken at regular time points 
p.i., and the total amount of viral RNA was quantified by RT-qPCR using either primers targeting the 3’ part of 
the genome and subgenomic mRNAs (3’ qPCR) or primers against the ORF1b to detect only genomic RNA (5’ 
qPCR). The amount of infectious virus was determined by titration in feline enterocyte cultures. 
Faecal RNA shedding was detected for cat 1 and 3 from day 2 (3’ qPCR) or day 4 (5’ qPCR) 
p.i. onwards. For these 2 cats, faecal shedding peaked at day 5 p.i., whereupon shedding 
slightly dropped but remained at high levels until 28 days p.i. Thereafter, virus shedding 
dropped and both cats had ceased shedding by day 84 p.i. Infectious virus was found in cell 
culture from day 4 until day 21 (cat 1) or day 28 (cat 3) p.i. In contrast to cat 1 and 3, an 
aberrant excretion pattern was found in cat 2. At day 2, viral RNA was detected with the 3’ 
qPCR, but not with the 5’ qPCR. Thereafter, viral RNA excretion disappeared and was not 
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detected anymore until day 14 p.i. From then, faecal RNA shedding remained high during the 
remainder of the experiment. However, infectious virus could not be detected for this cat at 
any of the time points. 
Concerning the faecal shedding, the 3’ qPCR gave viral RNA quantities that were 3-4.3 log10 
higher than the 5’ qPCR, indicating that only 1/1000 to 1/20000 of all copies detected with 
the 3’ qPCR are viral genomic RNA copies. This can explain why total RNA copies detected 
with the 3’ qPCR were 6-8 log10 higher compared to the infectious virus titre. Overall, the 5’ 
qPCR gave total viral titres that were more correlated with the results of infectious virus 
titres. Indeed, the amount of infectious particles was typically 3-4 log10 times lower compared 
to the total amount of particles in the first week p.i. From day 9 p.i., infectivity titres 
progressively declined to undetectable levels, whereas PCR titres remained high for an 
additional 1-2 months. 
Both cell-free and cell-associated viraemia were assessed at regular time points for all cats, 
using the 5’ qPCR (Table 5.1.1). A cell-associated viraemia was detected at infrequent time 
points for all cats. In contrast to cat 1 and 3, viraemia in cat 2 was detected before the onset of 
faecal shedding (day 3 and 5 p.i.), and no longer thereafter.  
 
Table 5.1.1. Detection of viraemia during the entire infection course. 
 
 
 
 
 
 
 
 
5.1.3.2  Immunological parameters 
5.1.3.2.1  Neutralizing antibody response 
Figure 5.1.3 shows the amount neutralizing antibodies detected in the serum of the three cats 
during the infection experiment. For cat 1 and 3, which displayed an active intestinal 
replication during the first week p.i., neutralizing antibodies were detected from day 9 p.i. and 
peaked at day 21 (cat 3) or day 28 (cat 1) p.i. In cat 2 with the delayed shedding pattern, 
 Cat 1 Cat 2 Cat 3 
Day 
p.i. Plasma 
Cell- 
associated Plasma 
Cell- 
associated Plasma 
Cell- 
associated 
0 - - - - - - 
3 - - - + - - 
5 - - - + - + 
7 - + - - - - 
9 - + - - - + 
14 - + - - - + 
21 - - - - - - 
28 - - - - - + 
56 - - - - - - 
84 - - - - - - 
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similar signs of seroconversion occurred only after the onset of intestinal replication, with the 
first detectable antibodies appearing at day 21 p.i. In all cats, antibody titres remained at high 
levels during the remainder of the experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.3. Neutralizing serum antibody responses during FECV infection. Neutralizing antibody titres 
were assessed in the serum on day 0, 3, 5, 7, 9, 14, 21, 28, 56, and 84 p.i. by virus neutralization assay in 
enterocytes using FECV UCD. 
5.1.3.2.2  Dynamics of leukocyte subsets during FECV infection 
Figure 5.1.4 shows the absolute number of T cells, B cells, monocytes, and granulocytes 
determined in blood taken at regular time points p.i. No abnormal leukocyte numbers were 
noticed in any of the three cats, except for a depletion of peripheral granulocytes in cat 1 
during the first 3 weeks p.i. For each cat, T and B cell numbers followed a similar trend. All 
cats showed a small decrease in lymphocyte numbers, which started to resolve from day 21 
p.i., but this recovery phase was much more pronounced in cat 1 and 3 compared to cat 2. 
Indeed, whereas lymphocyte numbers remained at pre-infection levels for cat 2, both cat 1 
and 3 showed a considerable rise in lymphocyte numbers, characterized by a slight 
lymphocytosis, which coincided with cessation of the shedding in both cats. Monocytes of cat 
1 and 2 slightly declined to raise back to pre-infection levels at day 28 p.i., but numbers 
always remained within the normal limits.  
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Figure 5.1.4. Absolute quantity of different leukocyte subsets during FECV infection. Analysed cells were 
A) T cells, B) B cells, C) monocytes, and D) granulocytes. Two horizontal dashed lines represent reference 
values in healthy animals. 
Quantification of regulatory leukocytes (natural killer (NK) and regulatory T cells (Tregs)) is 
shown in Figure 5.1.5. As for other leukocytes, no abnormal high or low NK cell- or Treg 
numbers were noticed during the infection course. However, some trends were visible. In all 
cats, NK cells slowly declined with the lowest amount at 14 or 21 days p.i., whereupon NK 
cell count rose again to pre-infection level at day 56 p.i. Treg counts similarly declined and 
rose in all cats. When analysing a subset of Tregs (CD8+ Tregs), which has been associated 
with suppression of gut immune responses, it was noticed that the delayed shedder had higher 
numbers of CD8+ Tregs, which increased until day 7 p.i., whereas the number of CD8+ Tregs 
was slightly decreased during the first week for the other 2 cats. 
 
Figure 5.1.5. Number of regulatory cells during FECV infection. Analysed cells include: (A) NK-cells, (B) 
Tregs, and (C) CD8+ Tregs.  
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5.1.4 Discussion 
Due to its pathogenic behaviour, FIPV has received considerable attention, and clinical, 
virological and immunological parameters during both natural and experimental FIPV 
infections have frequently been studied. The last decade, comprehensive studies on the FIPV 
parent virus, FECV, have extensively contributed to our current understanding of 
epizootiology and pathogenesis (Addie et al., 2003; Meli et al., 2004; Pedersen et al., 2008; 
Vogel et al., 2010), but too many unidentified parameters have hampered the unravelling of 
the highly complex FCoV pathogenesis so far. The aim of this study was to contribute to the 
current understanding of FECV infections by filling some of the missing links, such as viral 
infectivity of oral and faecal excretions, the generation of neutralizing antibodies, and the 
dynamics of the several leukocyte subsets during experimental FECV infections.  
In accordance with previous reports on experimental FECV infections (Meli et al., 2004; 
Pedersen et al., 2008; Vogel et al., 2010), two of the three cats started shedding between day 
2 and 4 p.i. Faecally shed RNA peaked at day 5 p.i., showed a plateau until day 28 p.i., and 
then diminished to become undetectable at day 84 p.i. Both cats showed mild clinical signs, 
including loss of appetite and mild weight loss, but diarrhoea was never observed. In these 
cats, infectious virus was found from day 4 until day 21 (cat 1) or day 28 (cat 3) p.i. The 
antibody response was detectable from day 9 p.i., which is also in accordance with earlier 
reports (Pedersen, 1995; Pedersen et al., 1981a; Vogel et al., 2010). However, the 
neutralizing capacity had never been determined due to the lack of an appropriate cell line to 
perform the neutralization assay on. By using feline enterocyte cultures, it was shown in the 
present study that serum antibodies mounted during FECV infections are highly neutralizing. 
Interestingly, one of the infected cats (cat 2) showed an infection pattern that deviated from 
the other cats. In contrast to cat 1 and 3, no anorexia or weight loss was noticed during the 
entire study. In addition, shedding in cat 2 was remarkably delayed (until day 14 p.i.), as was 
the onset of the antibody response, which started to become detectable from 21 days p.i. 
onwards. A delay in faecal shedding and seroconversion has been described before in 1 study, 
reporting no faecal shedding before day 10 p.i., and a detectable seroconversion only after 21 
days (Foley et al., 1997). In that study, this infection pattern was typically seen in cats 
infected with weak-positive faecal extracts. However, in the present study all cats were 
infected with a high dose (1011.3 RNA copies), and a previous study reported the successful 
inoculation of cats with FECV UCD at a dose as low as 105.7 RNA copies, without noticing 
this delay (Vogel et al., 2010). Another possible explanation for this pattern is that the 
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original inoculation failed, and that this cat became infected later on by inadvertent 
transmission of the virus shed by one of the other cats. However, this explanation seems also 
very unlikely, as 1) cats were housed separately and precautions were taken to avoid 
inadvertent transmission, 2) FCoV RNA was found in oral secretions until 2 days after 
inoculation, 3) viral RNA was found in faeces at day 2, indicating passage of the virus 
without any further infection, and 4) a cell-associated viraemia was detected in this cat at day 
3 and 5 p.i. Notably the latter observation raises the presumption that FECV could have 
reached the intestine via the blood. How this can be achieved remains enigmatic, but based on 
the swollen submandibular lymph nodes at day 3 p.i., it can be hypothesized that FECV was 
potentially taken up by permissive (most likely monocytic) cells in the oral cavity from which 
the virus could further spread systemically to finally reach the intestine, from which 
subsequent shedding occurred. Interestingly, despite this systemic infection, the 
immunological response was delayed until the intestinal replication was detected, indicating 
that only intestinal replication succeeded to create sufficient antigenic mass to activate the 
immune response. This is in accordance with what can be seen during natural infections, as it 
has been shown that not all viraemic cats have antibodies (Gunn-Moore et al., 1998). The 
alternative route of infection seems plausible, since it is known that intraperitoneal 
inoculation of FECV can occasionally result in faecal shedding, which has been attributed to 
the circulation of FECV-loaded monocytic cells from the periphery to the intestine (Foley et 
al., 1997; Pedersen et al., 2012). Surprisingly, virus that was shed by this cat was no longer 
infectious in enterocyte cultures in vitro, suggesting that during its circulation the virus has 
changed. Full genome sequencing of the excreted viruses is currently being performed to 
reveal if this lack of infectivity has a genetic background. Another possible explanation for 
the lack of in vitro infectivity is that intestinal shedding in this cat occurred from non-
enterocytes, which could have changed the virus glycosylation and in that way tropism for 
enterocytes, but this needs to be further assessed. 
In the present study, shedding was quantified by two different RT-qPCR assays, and by 
infectious titration in previously established enterocyte cultures (Desmarets et al., 2013). The 
3’ qPCR is commonly used for monitoring of faecal shedding and targets a conserved region 
at the 3’ end of the viral genome, which is also present in all subgenomic mRNAs (Gut et al., 
1999), whereas the 5’ qPCR recognises a conserved region within ORF1b, that is only present 
in full genome RNA molecules. Comparison of both qPCRs revealed that virus quantification 
in faeces was 3-4.3 log10 times overestimated if the 3’ qPCR was used. In addition, shedding 
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quantities and patterns observed with the 5’ qPCR correlated much better to what was found 
on infectivity titration, making the latter qPCR more valuable for management purposes. 
Infectivity titres were typically 3-4 log10 times lower during the first week p.i., which is 
reasonable, taken into consideration that a proportion of all viruses will be defective and that 
infectious titration of faecal samples can give an underestimation due to toxicity in cell 
culture. In addition, all titrations were performed before it was noticed that neuraminidase 
treatment could enhance FECV infectivity in the cell cultures (Desmarets et al., 2014), which 
can also contribute to underestimation. As infection progressed, the difference between total 
genomic RNA copies and infectious titre even further increased. Since this coincided with the 
onset of neutralizing antibodies, it is possible that neutralizing antibodies in faeces caused an 
increased underestimation of infectious virus in cell culture, but the presence of intestinal 
neutralizing antibodies was not further investigated. Whereas faecal RNA was detected from 
day 2 p.i. with the 3’ qPCR, faecal shedding was never noticed before day 4 p.i. with the 5’ 
qPCR or in enterocyte cultures. In addition, faecal RNA was also found at day 2 p.i. in cat 2 
with the 3’ qPCR, but no signs of active intestinal replication were seen in this cat until day 
14 p.i. These observations raise the question whether the early detection with the 3’ qPCR 
results from active shedding or rather from the shedding of the remainder of the (by then 
degraded) inoculum. Oral shedding was noticed at inconsistent time points, which is in 
accordance with what is observed in natural infections (Addie & Jarrett, 2001), and depended 
on the cat and on the PCR that was used. Whether this oral RNA resulted from active 
replication in the tonsils, as previously proposed for FIPV (Stoddart et al., 1988), or was 
rather the result from the licking behaviour of the cats is unknown. However, at least some 
time points cannot be explained by the latter as oral RNA was found for cat 2 and 3 before 
any faecal shedding was noticed, making a restricted replication of FECV in the throat 
possible at these time points. 
When analysing general peripheral leukocyte subsets, no major changes were noticed, except 
for a granulocytopenia in cat 1 during the first 3 weeks p.i, and a slight T and B cell 
lymphocytosis at day 56 p.i. for cat 1 and 3. Concerning the regulatory cells, FECV infection 
was characterized by a transient NK cell reduction in peripheral blood, which was most 
probably the result of migration of NK cells to the intestine or associated lymphoid tissue, 
since NK cells had an elevated CD11b and CD62L expression (data not shown). FECV 
infection also appeared to be characterized by a transient lowered amount of peripheral Tregs, 
which can most probably also be explained by specific trafficking to the gut or associated 
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lymphoid tissue. Acute or chronic virus infections are very often associated with an increase 
in peripheral Treg frequency or function, a feature that was not noticed in the present study. 
However, gut immunology seems to differ quite a lot from systemic immunity, notably given 
the fact that the gut has regulatory systems in place to induce tolerance against commensal 
bacteria and food antigens, systems where Tregs play a vital role. Manipulation of Tregs 
through accumulation or activation at sites of infection can also cause immune tolerance 
against pathogenic micro-organisms, as exemplified by protozoan (Leishmania Major), 
nematodic (Heligmosomoides polygyrus) and bacterial (Helicobacter pylori) infections 
(Belkaid, 2007; Bilate & Lafaille, 2012). Whether these cells also contribute to the long-
lasting or persistent shedding of FECV remains to be investigated. In addition, cat 2 showed a 
deviating pattern in peripheral circulating CD8+ Tregs compared to the other cats. This subset 
has recently gained a lot of interest in the context of gut immunity to colorectal cancer, graft-
to-host disease and rectal HIV/SIV infection, where they are associated with suppressed 
immunity (Beres et al., 2012; Chaput et al., 2009; Nigam et al., 2010). However, if and how 
these cells played a role in the aberrant infection pattern of this cat remains elusive, as not 
much is known about the exact function of these cells.  
In conclusion, present study reports the simultaneous assessment of different virological  
(presence of viral RNA and/or infectious virus in faeces, oral fluid, and blood), and 
immunological parameters (neutralizing antibodies and several leukocyte subsets) during 
experimental FECV infections in three cats. Two of the three cats showed mild clinical signs; 
a faecal shedding that started within a few days p.i. and was infectious in vitro for 3-4 weeks; 
a cell-associated viraemia and oral shedding at inconsistent time points; highly neutralizing 
antibody responses from day 9 p.i.; and no abnormalities in leukocyte subsets. Remarkably, a 
deviating infection pattern was noticed in one cat, characterized by an early cell-associated 
viraemia (day 3 and 5 p.i.), a delayed faecal shedding (starting from day 14 p.i) and antibody 
response (detectable from day 21 p.i.), and a loss of infectivity of the excreted virus in 
enterocytes cultures. No differences could be seen in leukocyte numbers compared to the 
other cats, with the exception of CD8+ regulatory T cells, but their role remains elusive so far. 
Consequently, whether this deviating infection pattern was due to mutational variants or 
rather was a cat-dependent factor requires further investigation. 
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Summary 
In multi-cat environments, feline infectious peritonitis (FIP) is a major cause of financial and 
emotional losses by killing up to 12% of the young cat population. FIP is the result of 
mutations occurring in the viral genome during common FECV infections, which reside in 
virtually all multi-cat households. To date, adapting the management/housing to restrict these 
FECV infections is the only way to deal with FIP. However, reports that describe how the 
management can be adapted using currently available diagnostic PCR techniques and, more 
importantly, if these efforts are feasible and cost-effective in the prevention of FIP, are still 
lacking. Therefore, 2 breeding catteries (<15 cats) were followed for 3 years (household 1), 
and 1 year (household 2). In both households, faecal shedding of individual cats was regularly 
monitored, and cats were grouped according to the results in order to avoid FECV 
transmission. Grouping was performed by housing cats in separate rooms, without any other 
restrictions concerning handling of cats, clothing or people movement, in order not to 
compromise practical feasibility. In household 1, all but one of the cats had ceased shedding 9 
months after the start of the monitoring. The cattery was even totally cleared from shedders 
after removal of this persistently shedding cat, and two negative litters were raised. As a result 
of the regular import of new cats, this cattery could not be kept negative, but due to the 
grouping, it was prevented that the virus spread again throughout the complete cat population. 
In household 2, grouping of cats was also successful to make a non-shedding population, but 
in contrast to household 1, 7/14 cats were still shedding 1 year after the start of the 
monitoring. It was concluded that making an FECV-negative population is practically feasible 
by regularly monitoring of shedding and grouping of cats, but that cost-effectiveness of this 
strategy depended on the household. 
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5.2.1 Introduction 
In the sixties, feline infectious peritonitis (FIP) was first named and described as a new viral 
disease entity in cats (Holzworth, 1963; Wolfe & Griesemer, 1966; Zook et al., 1968). In 
1970, the causative agent of FIP was found to be coronavirus, designated feline infectious 
peritonitis virus (FIPV) (Ward, 1970). However, whereas many healthy cats tended to have 
anti-FIPV antibodies, and FIPV seemed to be highly infectious upon experimental 
inoculation, only a minority of all cats actually succumbed to FIP. This inconsistency between 
seroprevalence and disease was solved in the eighties, when Pedersen and colleagues 
discovered that many healthy cats shed a seemingly harmless coronavirus in their faeces, and 
that FIPV most probably arose by mutation from this feline enteric coronavirus (FECV) 
(Pedersen et al., 1984; Pedersen et al., 1981). This mutational pathotype switch was later on 
confirmed, and it is now widely accepted that the majority of all FIP cases are the 
consequence of mutations arising in the viral genome during a common FECV infection 
(Chang et al., 2010; Pedersen et al., 2009; Pedersen et al., 2012; Poland et al., 1996). With 
the observations that infection with the easily transmittable FECV precedes the development 
of FIP, it became rapidly clear that managing the faecal-oral transmission in multi-cat 
environments is of key importance in FIP prevention. Indeed, recommendations from the 
workshops on FCoV control in catteries that were held at the first and second international 
feline coronavirus/feline infectious peritonitis symposium stated that control of FIP must 
preferably be directed at the control of the underlying FECV infections, and should that fail, 
at the FIPV itself (Addie et al., 2004; Pedersen et al., 1995). 
FECV is found in virtually all multi-cat environments worldwide (Addie & Jarrett, 1992; 
Pedersen et al., 1981), except for the Falkland Islands, which have remained FCoV 
seronegative so far by extensive testing of incoming cats (Addie et al., 2012). Faeces from 
shedders are highly contagious, resulting in a very fast and efficient faecal-oral transmission 
of the virus to susceptible cats, which in turn start to shed high amounts of FECV in their 
faeces within one week after uptake (Pedersen et al., 2008; Pedersen et al., 2004; Pedersen et 
al., 1981; Vogel et al., 2010). Infected cats shed the virus for many weeks, months, or in case 
of persistent shedders, years. These cats are a continuous source of infection or reinfection of 
negative cats, the latter being the result of the readily declining local immunity after the 
infection has been cleared (Addie & Jarrett, 2001; Addie et al., 2003; Pedersen, 2009; 
Pedersen et al., 2008). Therefore, if one wants to prevent FECV infection, the most important 
measure to be taken is to prevent any contact between shedders and naive animals. In the past, 
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this separation policy has been successfully applied to either completely eradicate FCoVs 
(Hickman et al., 1995), or to control transmission to the most susceptible population in 
breeding catteries, which comprise the several weeks old kittens after they have lost their 
protection from maternal immunity (Addie & Jarrett, 1992). Hickman and colleagues reported 
the introduction of FECV in a closed specific pathogen free (SPF) facility, which had been 
unnoticed until several cats started to die from FIP. As these cats were of high value, the 
researchers decided to completely eradicate FCoVs from the colony by serological testing and 
grouping based on antibody titres, since no diagnostic PCR tests were available at that time. 
Only seronegative animals were kept to create offspring, and cats that remained seropositive 
were removed from the colony. By regular testing and strict quarantine measures, the 
researchers were able to recreate a FCoV-negative SPF population (Hickman et al., 1995). In 
practice, however, this method has many drawbacks and is hardly feasible. Indeed, by using 
PCR to measure faecal shedding, many researchers reported inconsistent conclusions on the 
correlation between antibody titre and shedding, indicating that it is very difficult to reliably 
isolate shedders from non-shedders based on their serum antibody titre (Addie et al., 2003; 
Foley et al., 1997; Harpold et al., 1999; Pedersen et al., 2008). In addition, eradication was 
highly simplified in the study of Hickman and colleagues by the fact that only few animals 
were saved and kept for further breeding programs, and by the availability of high quality 
isolation facilities to prevent any further transmission of the virus. Consequently, complete 
eradication of FCoVs based on antibody titre is hardly feasible in practice. In addition, even if 
this would succeed, it is quite challenging to remain FCoV-negative, as FCoV infections are 
present in virtually all multi-cat environments from where new cats are frequently imported. 
For these reasons, work groups recommended to direct the control of FIP towards the control 
of transmission from shedders to the highly susceptible young animals (Addie et al., 2004; 
Pedersen et al., 1995). FIP is typically seen in kittens in the post-weaning period and most 
kittens are protected by maternally derived antibodies until 5-10 weeks of age (Addie et al., 
2009; Foley et al., 1997; Harpold et al., 1999; Pedersen et al., 2008). Therefore, it has been 
recommended to control the transmission of FECV from shedders to the kittens by isolating 
the queens 2-3 weeks prior to parturition, taking the kittens away from their mother at 4-6 
weeks of age (= early weaning) and raise them in complete isolation (Addie et al., 2004). 
Although clearly demonstrated that early weaning can strongly decrease the incidence of FIP 
(Addie & Jarrett, 1992), the success rate is variable and depends on the isolation procedure 
and the shedding state of the queen (Addie et al., 2004). When kittens are faced with a high 
infection pressure, viruses break through the maternal immunity, and kittens can become 
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infected as soon as 2 weeks of age (Lutz et al., 2002). In addition, early weaning has been 
questioned by its negative impact on the socialisation of kittens, and is therefore not regularly 
applied in practice. 
FECV remains enzootic by continuous transmission of the virus from shedders to susceptible 
animals, and FECV shedding can be easily detected with currently available high sensitive 
PCR techniques (Addie et al., 2003; Foley et al., 1997; Pedersen et al., 2008). Consequently, 
grouping of cats based on their shedding state has been proposed to avoid (re)infections, but 
no reports on the successful isolation of shedders from non-shedders have yet been published. 
However, this strategy would allow the prevention of FECV exposure to kittens without the 
need for early weaning and complete isolation, as this would allow selection of negative 
animals for breeding and/or socialisation of kittens. In the present study, the feasibility of this 
strategy was evaluated in 2 breeding catteries. These catteries were followed over a period of 
3 years (household 1) or 1 year (household 2). Faecal shedding was monitored every 2-4 
months, and after every testing, decisions were made for grouping of animals according to the 
test results. The practical feasibility, advantages, and costs (time and money) are discussed. 
5.2.2 Materials and methods 
5.2.2.1  Households 
Household 1 represents a Siamese and Oriental Shorthair breeding cattery, established in a 
normal two-storey house, in which cats were held in groups at both floors. We were contacted 
by this cattery at the end of 2011, since a lot of FIP deaths had occurred in their kitten 
population. Indeed, from August 2011, 8 out of 21 kittens born in that cattery in 2011 finally 
succumbed to FIP (6 pathologically confirmed cases, 2 highly suspected cases). From 
October 2011, faecal shedding was monitored regularly over a period of 3 years in order to 
control the FECV transmission. Table 5.2.1 gives an overview of the cattery cats and their 
fate from June 2010 until August 2014. Kittens are indicated by the letter of the litter, 
followed by a number (e.g. A1 = cat 1 from litter A), and the identity of the parents is given in 
between brackets (tomcat x queen). In this cattery, cats were regularly imported and 
sporadically exported for breeding. 
Household 2 represents a British Shorthair and Selkirk Rex breeding cattery, established in a 
normal two-storey house, in which cats only had access to the ground floor. In contrast to 
household 1, this cattery had never had FIP cases in the kitten population, but had had 4 adult 
cats that had succumbed to FIP in 2 years. After the fourth FIP case (2013), the owner started 
to fear for FIP in any future newborn litter and started to monitor shedding of cats to control 
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transmission of FECV. Table 5.2.2 gives an overview of the cattery cats and their fate from 
2007 until August 2014. Litters are indicated with a letter (A to M), and kittens that were kept 
in the cattery are identified with a letter and a number (e.g. A1). The identity of the parents is 
given in between brackets (tomcat x queen). In this cattery, breeding occurred with in-house 
animals. 
5.2.2.2  Sampling 
For evaluating individual faecal shedding of group-housed cats, cotton tipped swabs (Copan 
diagnostics, CA, USA) were inserted about 5 cm in the rectum. Subsequently, swabs were 
suspended in 1 ml transport medium, consisting of Dulbecco’s modified Eagle’s medium 
(DMEM) containing 100 U ml-1 penicillin (Continental Pharma Inc., Puurs, Belgium) and 
transported at 4°C to the lab. For sampling of kittens or individually housed animals, faeces 
were collected/pooled and upon arrival, 20% suspensions were made in the same transport 
medium.  
5.2.2.3  Assessment of the viral RNA load 
After centrifugation (10 min, 2000 g) of the sample, viral RNA was extracted from the 
supernatant using the viral RNA mini kit (Qiagen, Benelux BV, Belgium). Assessment of the 
viral load was done by RT-qPCR against the viral ORF1b, as previously described 
(Desmarets et al., 2013). In this study, the amount of viral genomic copies was only semi-
quantitatively assessed, as absolute quantification is too expensive for routine follow up of 
cattery cats. Therefore, shedding of each cat was expressed as a Cq value. Since Cq value 37 
represents <1 RNA copy in our reactions, all signals rising after Cq = 37 were considered as 
negative. 
5.2.2.4  Grouping of cats 
Cats were grouped in the house according to their shedding state, generating separated non-
shedding- and one or more shedding groups. Precautions taken to avoid inadvertent 
transmission from the shedding to the non-shedding group included daily cleaning of litter 
trays, thereby first cleaning the litter trays of the negative group, and regular cleaning and 
disinfecting of surfaces. As owners wanted to continue normal daily tasks in their house, no 
special precautions were taken considering people movement, handling of cats, or clothing. 
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Table 5.2.1. Overview of cats present in household 1 and their fate from 2010 until 2014. 
Abbreviations and symbols: † = death, M = male, F = female, FHV= feline herpes virus. Dark shading represents 
absence in cattery at the given time point. 
a Cat 11-16 represent British Shorthair cats that joined the cattery from March 2014. 
Cat id Sex 
Birth 
date 2010 2011 2012 2013 2014 
1 M 03/2006      
2 M 05/2006  11/2011 † no FIP    
3 F 01/2006  12/2011 Adopted    
4 F 08/2008  12/2011 Sold    
A1(1x4) F 02/2010      
A2(1x4) F 02/2010      
A3(1x4) F 02/2010      
A4(1x4) M 02/2010 † no FIP   
5 M 05/2006 Import 12/2010 † FIP 
    
6 M 05/2008 Import  01/2012 †Amyloidosis 
  
7 F 06/2006 Import     
8 F 03/2009 Import     
9 F 06/2008 Import     
B1(5x7) M 01/2011      
B2(5x7) F 01/2011      
B3(5x7) F 01/2011  08/2011 †FIP suspected 
  
B4 (5x7) F 01/2011  09/2011 †FIP  
C1-5(5x4)  02/2011  03/2011 † FHV- pneumonia 
 
C6 (5x4) M 02/2011    
D1(5x9) M 02/2011  04/2011 † no FIP  
D2(5x9) M 02/2011  10/2011 †FIP  
D3(5x9) F 02/2011    
D4(5x9) M 02/2011  11/2011 †FIP  
E1(6x8) M 02/2011  10/2011 †FIP suspected 
 
E2(6x8) M 02/2011  08/2011 †FIP  
E3(6x8) M 02/2011  11/2011 †FIP  
E4(6x8) F 02/2011  08/2011 †FIP  
E5(6x8) F 02/2011      
E6-7(6x8)  02/2011  † no FIP    
F1(A1xB1) M 03/2013      
F2-5 
(A1xB1) 
 03/2013      
10 F 01/2013    Import  
G1(B1x8) F 05/2013      
G2-6(B1x8)  05/2013      
G7(B1x8) M 05/2013    08/2013 † no FIP 
 
H1-4(B1x8)  02/2014      
I1(B1xA1) F 02/2014     07/2014 †FIP 
I2(B1xA1) M 02/2014      
I3-6(B1xA1)  02/2014      
11a F      Import 
12a F      Import 
13a M      Import 
14a F      Import 
15a M      Import 
16a M 02/2014     Import 
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Table 5.2.2. Overview of cats present in household 2 and their fate from 2007 until 2014. 
Abbreviations and symbols: † = death, M = male, F = female, FHV= feline herpes virus. Dark shading represents 
absence in cattery. 
a Cat 13 and 14 are European Shorthair cats that were found outside and were imported in the cattery. 
5.2.2.5  Serum antibody titre 
As there is still some controversy on the correlation between antibody titres and faecal 
shedding, serum antibody titres were assessed in household 1 from October 2011 until 
February 2013. Therefore, porcine respiratory coronavirus-infected swine testicular cells, 
seeded in 96-well plates, were incubated with serial dilutions of the serum samples (50 
µl/well). After 1 h (37°C), cells were washed with PBS containing 0.0025% Tween 80, 
followed by incubation with HRP-labeled rat anti-cat antibodies (1 h, 37°C). Visualization 
was done by adding sodium-acetate buffer containing amino-ethylcarbazole (AEC) and H2O2 
Cat id Sex Birth date 2007 2008 2009 2010 2011 2012 2013 2014 
1 M 02/2006      01/2012 † FIP   
2 F 07/2004 Import      † no FIP  
3 F 07/2004 Import        
4 F 03/2007 Import        
A(1x3)  09/2007         
A1 F 09/2007         
5 M 04/2007  Import     04/2013 † FIP  
B(1x2)  02/2008         
6 F 05/2008  Import       
7 F 08/2005  Import  Temporary adoption  
C(5xA1)  12/2008         
8 M 05/2008   Import 01/2010 † FIP     
D(1x3)  04/2009         
9 F 05/2009   Import 11/2010 † FIP     
E(5x7)  08/2009         
F(8x4)  01/2010         
G(8xA1)  02/2010         
10 F 07/2005    Import     
11 F 02/2010    Import     
H(15x9)  09/2010         
H1(15x9) F 09/2010         
H2(15x9) F 09/2010         
I(5x3)  09/2010         
12 M 11/2010     Import    
J(5x3)  08/2011         
K(15xA1)  03/2012         
K1 
(15xA1) F 03/2012         
L(12xH1)  04/2012         
L1(12xH1) M 04/2012         
M(12xH2)  10/2012         
13a F ?       Import  
14a M ?       Import  
15 M 07/2009       † no FIP  
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for 10 minutes at RT. The antibody titer was the highest dilution at which infection could still 
be visualized.  
5.2.3 Results 
5.2.3.1  Household 1 
In October 2011, the faecal shedding of all cats present in the house was monitored for the 
first time. At that time, most of the kittens born in 2011 had been sold, and 8/21 died from 
FIP in their new home. Two of the three affected litters had the same father (cat 5) that died of 
FIP itself in December 2010, but had a different mother (cat 7 and 9 for litter B and D, 
respectively). Litter E was the results of the mating of queen 8 with tomcat 6. At the first 
sample taking, 9 cats were still present in the house, and both faecal shedding and antibody 
titres were assessed for each of them (Figure 5.2.1).  
 
 
Figure 5.2.1. Semi-quantitative assessment of faecal shedding (A) and antibody titres (B) of all cats 
present in household 1 at the first sampling (October 2011). 
 
Although all cats had serum antibodies, two cats (cat 7 and cat A1) did not shed FECV. Two 
other cats (cat 3 and cat 4) showed a moderate shedding, whereas the remainder of cats shed 
more than 4 million copies per swab. Cat 7 had the lowest antibody titre (400), followed by 
cat 3, A1, and B2 with a titre of 1600; cat 4, 8, and 9 with a titre of 3200; and cat 6 and B1 
with a titre of 6400. Consequently, antibody titres did not correlate with the amount of faecal 
shedding, and would not have been a good parameter for grouping. Indeed, if grouping would 
have been based on antibody titre, the negative cat A1 could have been put together with the 
moderate shedding cat 3 and/or the high shedder B2. 
After having received the test results, the owner decided to lower infection pressure as fast as 
possible by removing some of its less valuable cats from the cattery. Therefore, cat 4 was 
sold, and cat 3 and B2 were given for adoption to family members, one of which was a 
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sporadic caretaker of the cats in household 1. Cat 3 and B2 remained available for further 
testing of shedding and antibody titres. The other cats were grouped in the house as shown in 
Figure 5.2.2. In January 2012, shedding was monitored again. The negative group (cat 7 and 
A1) was still negative, and cat B1 and B2 had become negative. All cats from the positive 
group (cat 6, 8, and 9) at the first floor were still shedding, as was cat 3. Cat B1 is a tomcat, 
and hence this cat could not be grouped together with the negative (female) cats. 
Consequently, all groups remained as they were. Shortly after the second sampling, cat 6 
developed severe disease, characterized by waves of lethargy, anorexia and icterus. This cat 
finally succumbed, but whereas it was highly FIP suspected, pathological examination 
diagnosed the cat with hepatic amyloidosis, and not FIP.  
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April 2012 
 
 
July 2012 
 
 
October 2012 
 
Figure 5.2.2. Shedding and grouping of cats in household 1 from October 2011 until October 2012. Figures 
represent the grouping of the cats after the shedding was monitored at the indicated time points. 
B1
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
Ground floor 
7 A1
12
15
18
21
24
27
30
33
36
Cat identity
C
q 
va
lu
e
8 9
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
First floor 
B1
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
Ground floor First floor 
7 A1 8
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
9
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
B1
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
Ground floor First floor 
7 A1 8
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
9
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
B2
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
B2 
3
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
3 
8 
9 
B1 
B1 
7 A1 
7 A1 8 
9 
B2
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
B2 
3
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
3 
7 A1 8 
B1 
9 
B2
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
B2 
3
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
3 
Control of FECV transmission in catteries 157 
 
 
In April 2012, all cats, except for the 2 remaining cats of the positive group, had become 
negative, and groups remained as they were. In July 2012, cat 8 had ceased shedding and was 
removed from the positive group to the negative group. Cat 9 was the only cat that remained 
shedding, and this was still the case in October 2012, one year after the first sampling. 
Consequently, this cat was identified as a persistent shedder and was kept isolated from the 
other cats.  
As most of the cats were now non-shedders, breeding program was taken up again, and queen 
A1 was mated with tomcat B1 in January 2013. In February 2013, the next sampling was 
performed to make sure that all cats had indeed remained negative before the kittens would be 
born, as there was still a continuous risk for inadvertent transmission of FECV from the 
persistent shedder to the other cats (since no special precautions were taken to avoid such 
transmissions). All cats remained negative, except for the persistently shedding cat 9, which 
continued to shed the virus at moderate levels (Figure 5.2.3).  
 
February 2013 
Figure 5.2.3. Shedding and grouping of cats in household 1 in February 2013. Figures represent the 
grouping of the cats after the shedding was monitored. 
In addition to faecal shedding, antibody titres of the cats were assessed from October 2011 to 
February 2013. After the sampling in February 2013, it was decided to stop monitoring these 
antibody titres, as it became rapidly clear that this rather invasive parameter did not add any 
value in the management of FCoVs. Figure 5.2.4 overviews the evolution of both shedding 
and antibody titres for all seven remaining cats from October 2011 until February 2013. 
Whereas there was a clear correlation between low/absent antibodies and lack of shedding, 
higher antibody tires were much more difficult to interpret, as cats with higher antibody titres 
were not necessarily shedders. In addition, antibody titres declined much slower compared to 
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shedding (except for cat B2), clearly demonstrating the advantage of monitoring shedding 
over serum antibody titres. Despite the absence of shedding in cat A1, antibodies showed a 
small rise in titre in July 2012. Whether this is the result from restricted systemic replication, 
or rather results from variation of the antibody test, was not further determined.   
 
 
Figure 5.2.4. Evolution of shedding (red line) and antibody titres (black line) in 7 cats from household 1. 
 
By the end of February, cat A1 was isolated for parturition, and in March 2013, the first litter 
(F-litter) was born since the start of the study. From April 2013, when kittens were 4 weeks of 
age, shedding of all cats, kittens inclusive, was monitored every 1-2 weeks to assure their 
negative status. At the time of sampling, kittens were housed in one room together with their 
mother and cat 7. Cat 8 and B1 were housed together for mating, and the persistently 
shedding cat 9 was still housed separately. All cats, except for cat 9, were negative. April 16th, 
a new cat (cat 10) was imported in the cattery. This cat was immediately isolated and tested 
for shedding, together with the remainder of the cattery cats. As expected given the 
widespread distribution of FCoVs, cat 10 was positive, and it was decided to house this cat 
with the persistent shedder for the welfare of the animals (Figure 5.2.5). During two 
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samplings in April, cat 7 showed a very weak positive signal, but this was so low that is was 
decided to keep this cat within the negative group, and this had indeed no further 
consequences, showing that this cat was not infectious for other cats (and kittens). 
 
April 16 2013 
 
Figure 5.2.5. Shedding and grouping of cats after the introduction of new cat (10) in household 1. The 
figure represents the grouping of the cats after the shedding was monitored. 
At the end of May, a new litter (G-litter) was born, resulting from the mating of cat 8 with 
tomcat B1. These kittens were born in a bench in the same room as cats A1, cat 7 and the F-
litter, and were finally allowed to mix with each other (after having confirmed that all cats in 
the room were still negative), resulting in a total of 12 kittens and 3 adults in that room in 
June 2013. At that time, cat 9 and 10 were still shedding (Figure 5.2.6). 
 
June 2013 
Figure 5.2.6. Shedding and grouping of cats of household 1 in June 2013. The figure represents the grouping 
of the cats after the shedding was monitored. 
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By the end of July 2013, 4 kittens of the F-litter had been sold, and all of them were negative 
before they went out and are all healthy at this time. One male kitten of the F-litter was kept 
for future breeding and housed together with the other tomcat B1. By then, cat 10 had become 
negative and was separated from the persistent shedder. As there were still kittens in the room 
of the negative group, cat 10 was kept in a separate room for 1 additional week, whereafter its 
faeces was monitored again for shedding to be absolutely certain that this cat was indeed 
negative. After having confirmed its negative status, this cat was allowed to mix with the 
negative group (Figure 5.2.7).  
 
August 2013 
 
Figure 5.2.7. Shedding and grouping of cats of household 1 in August 2013. The figure represents the 
grouping of the cats after the shedding was monitored. 
 
In August 2013, there was an outbreak of gastroenteritis, including anorexia, diarrhoea, and 
vomiting in all kittens, and one of those kittens finally succumbed to it. Faeces of all cats 
were still negative for coronavirus, but despite many other parasitological, bacteriological, 
and virological tests, the exact aetiology could not be discovered. In September 2013, queen 
A1 was exported for mating to another cattery. When she was imported again, she was 
isolated from the other cats for 4 weeks, in order to avoid outbreak of various infectious 
diseases. Upon arrival and after 4 weeks, she was tested for FECV shedding. Since she was 
negative, she was allowed to mix again with the others. All kittens of the G-litter, except for 
1, were sold, and were negative when they went out, and are still healthy at this time. The 
other female kitten (G1) was housed with the negative cats. In November 2013, the persistent 
shedder died due to chronic kidney failure (which was not caused by FIP). Since the external 
mating of cat A1 had not been successful, she was mated again in the cattery with tomcat B1 
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in November 2013, as was cat 8. At that time, the entire cat population in household 1 was 
negative. 
In February 2014, 2 litters of a total of 10 kittens were born from these matings. 
Unfortunately, 1 of the 2 queens (cat A1) did not survive the caesarean. As cat 8 also had 4 
kittens (H-litter), it was decided to place 4 of the kittens from cat A1 (I-litter) with cat 8, and 
the other 2 (cat I1 and I2) were raised with an adoption mother that had just 3 new kittens in a 
British Shorthair cattery. In March 2014, when the kittens were 4-5 weeks of age, both 
catteries were screened for FCoV shedding in all cats. Whereas all cats, kittens inclusive, 
were negative in household 1, two adult cats from the adoption cattery (inclusive the adoption 
queen) were moderate shedders, one was shedding at low levels and the other was negative. 
More importantly, due to the shedding of the mother, kittens had already become positive 
before they were 5 weeks of age and were shedding enormous amounts (> 5 x 109 copies / 
gram, determined on pooled faeces of all kittens) of FCoV (Figure 5.2.8). At that time, kitten 
I1 suffered from anorexia and did not gain normal weight, but this resolved after 1 week. 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.8. Shedding of cats and kittens in the adoption cattery in March 2014. 
 
In March 2014, household 1 fused with another cattery, which consisted of 4 adult British 
Shorthair cats. The 4 cats (cat 11-14) were housed in a room at the first floor, and were 
monitored for shedding, together with the other cats at the ground floor. At that time, cat 7 
and 8 were housed together with the kittens, and cat 10 and G1 in another room, as were 
tomcats B1 and F1. All cats at the ground floor were still negative, whereas all British 
Shorthair cats were positive, with 1 cat shedding at high levels, and the other 3 at low levels 
(Figure 5.2.9).  
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March 2014 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.9. Shedding and grouping of cats and kittens in household 1 in March 2014. The figure 
represents the grouping of the cats after the shedding was monitored. 
In April 2014, the 2 kittens (I1 and I2) were withdrawn from the adoption cattery, but since 
there was no more room available in household 1, they were kept in the house of a family 
member where also cat 3 was housed, but kittens were kept in a separate room. Both kittens 
were still shedding, although at substantial lower level compared to the initial screening 
(Figure 5.2.10). Kitten I1 suffered again for about 1 week from anorexia and weight loss at 
the age of 7 weeks (April 2014) and 11 weeks (May 2014), and nothing but coronavirus could 
be diagnosed in the faeces (bacteriological and parasitic examinations were negative). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.10. Shedding of the 2 positive kittens withdrawn from the adoption cattery in April and May 
2014. 
In the beginning of May 2014, new sampling was done for all cats in household 1. All cats at 
the ground floor were still negative, and 3 out of 4 cats at the first floor had become negative. 
Therefore, the only remaining shedder, cat 14, was separated from the others (Figure 5.2.11). 
At that time, a new puppy was introduced in the house. In addition, although kittens I1 and I2 
were still shedding, it was decided to mix them with cat 3 for their socialisation.  
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May 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.11. Grouping and shedding of cats in household 1 at the beginning of May 2014. The figure 
represents the grouping of the cats after the shedding was monitored. 
 
At the end of May, 2 new British Shorthair cats (cat 15 and 16) were imported in household 1, 
and cat 13 was removed. The two new cats were kept separated from each other and from the 
other cats until they were tested. Cat 15 was a male adult cat and the other was a male kitten 
of around 14 weeks. The adult cat was housed at the first floor, and the kitten at the ground 
floor. Due to this import, all cats were tested again at the end of May (Figure 5.2.12). The 
new adult male cat (cat 15) was negative, but the new kitten (cat 16) was shedding moderate 
amounts of virus. Unfortunately, all kittens of the H-and I litter (then aged 13 weeks) and the 
two adult cats that were housed in the same room had also become positive, indicating an 
inadvertent transmission of the virus from 1 room to the other, for which kitten 16 had most 
probably been the source (based on the melting curve analysis). All the other cats at the 
ground floor that were housed separately from the kitten-group remained negative. Once the 
test results were known, owners realized that most probably the new puppy was the reason for 
the inadvertent transmission, since this dog had been allowed to cross the two rooms, 
comprising the kitchen and the living room, and had lately been playing around with the 
kittens and in the litter trays of both the new kitten and the negative kitten-group. This can 
also explain why the other groups remained negative, since the dog was not allowed to enter 
the rooms where these cats were housed. All of those kittens are still healthy to date. In 
contrast, 1 of the kittens that was infected at the age of 4 weeks in the adoption cattery, started 
to develop signs of FIP, including anorexia, weight loss, fever, and icterus shortly after it was 
sold. This cat was euthanized at the end of July 2014, and FIP was confirmed on necropsy.  
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 End of May 2014 
 
 
 
 
 
 
Figure 5.2.12. Grouping and shedding of cats in household 1 at the end of May 2014. The figure represents 
the grouping of the cats after the shedding was monitored. 
5.2.3.2  Household 2 
The first sampling in household 2 was done in June 2013 (Figure 5.2.13). At that moment, the 
cattery consisted of 10 female adults, 2 intact males (cat 12 and L1), and 1 neutered European 
Shorthair male (cat 14). All female cats were housed together in 1 room, the 2 intact males in 
another room. The neutered male was allowed to cross both rooms. 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 5.2.13. Shedding of cats at the first sampling in household 2 in June 2013. 
 
Based on these results, cats were housed in 3 groups: the tomcat group, the negative group 
(composed of cat 3 and 6) and the positive female cat group (Figure 5.2.14). Cat 14 was 
allowed to cross the rooms of the tomcat- and the positive female cat group. 
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June 2013 
 
Figure 5.2.14. Shedding and grouping of cats in household 2 in June 2013. The figure represents the 
grouping of the cats after the shedding was monitored. 
Thereafter, cats were tested regularly every 2-5 months and groups were adjusted based on 
the shedding state (Figure 5.2.15). By the end of august 2013, 1 additional cat (cat A1) had 
become negative and was grouped with the other 2 negative cats. By December 2013, 1 extra 
female cat (cat 13) had ceased shedding and was switched from group. Tomcat 12 had 
become negative, and tomcat L1 was shedding only very low amounts of virus. In March 
2014, a new cat (cat 7) was imported in the cattery. This cat had been removed from the 
cattery in the past due to behavioural problems and had been housed in a single cat 
environment since then. As she was negative, she was allowed to mix with the negative 
group. By March 2014, both tomcats had become negative and the neutered male (cat 14) was 
no longer allowed to mix with these cats, since he was still shedding. After the sampling in 
March, the owner decided to switch the housing of the groups, since the positive group started 
to become too big to house in the room they were initially in. Therefore, the positive group 
was divided into 2 subgroups, and separated over 2 rooms, and the negative group became 
housed in the room where the positive cats had been housed. By July 2014, nothing was 
changed in the shedding of all cats, implying that half of the cats in household 2 were still 
shedding the virus 1 year after the first sampling. This is in sharp contrast to household 1, 
where all cats but the persistent shedder had ceased shedding within 9 months. As all young 
breeding animals were in the positive group, the owner decided to postpone the breeding 
program with the animals. Further follow up is necessary to find out which cats will 
eventually stop shedding, and which of them are persistently infected.  
3 6
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
12 L1
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
4 A1 10 11 H1 H2 K1 13 14
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ueA1 
4 
10 
11 H1 H2 
K1 
13 
14 
6 3 12 
L1 
166 
 
August 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
March 2014 
 
 
 
 
 
 
 
 
 
 
 
3 6 A1
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
12 L1
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
4 10 11 H1 H2 K1 13 14
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
12 L1
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
4 10 11 H1 H2 K1 14
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
A1 
4 
10 
11 H1 H2 
K1 
13 
14 
A1 6 3 12 
L1 
A1 
4 
10 
11 H1 H2 
K1 14 
12 L1 
3 6 A1 7 13
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
12 L1
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
10 11 H2
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
4 H1 K1 14
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
12 
L1 
6 3 
13 
A1 7 
0 11 H2 
4 H1 K1 14 
3 6 A1 13
12
15
18
21
24
27
30
33
36
Cat identity
C q
 v
al
ue
13 A1 6 3 
Control of FECV transmission in catteries 167 
 
 
July 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.15. Shedding and grouping of cats in household 2 from August 2013 until July 2014. Figures 
represent the grouping of the cats after the shedding was monitored at the indicated time points. 
5.2.4 Discussion 
Despite the enormous progress made on epizootiology and pathogenesis since its discovery 5 
decades ago, FIP has remained one of the few insurmountable and highly feared cat diseases 
to date. It is widely accepted that the majority of all FIP cases are the consequence of 
mutations arising in the viral genome during a common FECV infection (Chang et al., 2010; 
Pedersen et al., 2009; Pedersen et al., 2012; Poland et al., 1996), although this internal 
mutation theory has been questioned during infrequently observed epizootics of FIP, i.e. when 
FIP deaths greatly exceed the normally encountered 5-12% of all seropositive cats (Addie & 
Jarrett, 1992; Kipar & Meli, 2014; Pedersen, 2009; Wang et al., 2013). The huge FECV 
infection pressure in multi-cat environments together with the often genetically predisposition 
of those pure bred cats favour the development of FIP, especially in the young cats. Due to 
the high demand for control measures to avoid these enormous financial and emotional losses, 
the aim of this study was to evaluate if it is practically feasible and cost-effective to control 
faecal-oral transmission of FECV by regularly monitoring of the faecal shedding and 
grouping of cats. 
Two medium sized catteries (<15 cats) that faced FIP deaths in the past were followed for 3 
years (household 1) or 1 year (household 2). In 2011, household 1 had faced over 30% FIP 
deaths in its kitten population. Two out of three affected litters (B- and D-litter) had the same 
father, which died of FIP itself at the age of 4.5 years (cat 5). Although the other affected 
litter (E-litter) had a completely different genetic background, also 4/7 kittens finally 
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succumbed to FIP. Consequently, the high incidence of FIP at that time was most probably 
the unfortunate coincidence of the high infection pressure (16 kittens were present at the same 
time and allowed to mix), combined with the higher genetic predisposition to develop FIP. In 
order to control the infection pressure, it was decided to breed only with negative animals in 
the future, as this seemed reasonably feasible to obtain in this cattery, which does not 
necessarily has to export/import cats for mating. By grouping of cats based on their shedding 
status, all but one of the cats had ceased shedding by July 2012, which is 9 months after the 
start of the monitoring in October 2011. By then, 4 samplings had been performed, with a 
total cost of €510 (VAT exclusive) to test all cats 4 times. At that time, the owner could have 
started the breeding program, since all but one of the female cats and the tomcat were 
negative. However, he decided to wait in the hope that the last cat would also cease shedding, 
taking away any further threat for the kittens. Unfortunately, this cat was still positive at the 
next sampling and remained persistently shedding the virus during the remainder of the 
follow up. In January 2013, 2 years after the birth of the last litter, breeding program was 
taken up again, as all cats but the persistent shedder remained negative. By assuring that all 
breeding and in contact animals were negative before the kittens were born, all 12 kittens 
from the 2 litters did not have to be isolated from the other cats and remained FCoV-negative 
until they were sold at the age of 13-14 weeks. If they became infected thereafter was not 
investigated. For many cattery owners the question arises whether the effort to avoid exposure 
in their cattery is worthwhile, as kittens can indeed be infected later in life when rehomed. 
Many kittens raised in catteries are sold to private owners and will no longer be housed in a 
multi-cat environment, making the risk that they will ever develop FIP almost negligible. In 
addition, for kittens that are sold to other catteries, one should take into consideration that 
delaying FECV infection decreases the FIP incidence, since older kittens have lower 
replication rates and a more mature immune system to combat the mutant viruses if these 
arise, which is the reason why it is worthwhile and highly recommended to delay exposure as 
much as possible (Addie et al., 2004; Pedersen et al., 2008). Indeed, it was shown in this 
study that 1 of the 2 kittens that were exposed at 4 weeks of age developed FIP, whereas the 
other 4 kittens from the same litter, and 4 kittens from another litter with the same father that 
were exposed at 12-13 weeks remained healthy to date, although all these kittens were 
potentially prone to the development of FIP due to the extensive FIP history in the fathers 
line. The exposure of these kittens at the age of 12-13 weeks was the result of an inadvertent 
transmission of FECV from the adjacent room where a newly imported positive kitten was 
housed to the room of the negative kitten group. Inadvertent transmission of FECV has 
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previously been described as an event that readily occurs from 1 room to another by pieces of 
litter on the body, clothing, or shoes, and has been recognized as a major problem in the 
management of FCoVs (Hickman et al., 1995; Pedersen et al., 1981). However, inadvertent 
transmission had never been noticed in the present study in neither of the 2 households, 
although no special precautions were taken considering clothing, people movement and 
handling of cats, and despite the fact that caretakers were running back and forth from 
positive and negative animals within and outside (including cat 3, B2, I1, and I2 of household 
1) the cattery. As the inadvertent transmission noticed at the end of May 2014 in household 1 
had never occurred before and was confined to only 1 room, it was thought not to result from 
people movement, but had been attributed to the dog, for which owners later realized that this 
puppy had been playing around with the kittens and in the litter trays of both groups. In 
addition, melting curve analysis revealed identical melting peaks for the strain of the newly 
imported positive kitten and the other kittens, suggesting that this new kitten was indeed the 
source of the inadvertent transmission. Whether or not the dog was indeed the reason for the 
transmission remains unknown, but these data emphasize that care should be taken at any 
time to avoid such accidental infections. Import cats are often only a few months of age and it 
is known that young animals shed very high amounts of virus (Pedersen et al., 2008). 
Consequently, these cats are highly contagious and a major risk for such inadvertent 
transmissions. Therefore, it is recommended to thoroughly monitor the shedding of every 
imported cat and to separate these cats as far as possible in the house from negative cats, as 
was done in the present study with cat 10 in household 1. This separation included the 
housing in a non-adjacent room, which was sufficient to maintain a negative kitten population 
without the need for unfeasible quarantine measures. In contrast, by housing the newly 
imported kitten (cat 16) in the adjacent room, transmission of the virus to the negative kittens 
could not be avoided. Fortunately, the exposure of the kittens was postponed until the age of 
12-13 weeks, and has so far not had any consequences, as all 8 kittens are still healthy. In 
addition, there was no further spread from the kittens to other animals in the cattery (except 
for 2 adults cats that were housed with the kittens), which will make it possible for the owners 
to continue breeding with negative animals.  
The present follow up studies showed that it is practically feasible to restrict the FECV 
transmission, and hence FIP incidence, in multi-cat environments by regularly monitoring and 
grouping of cats. In household 1, the complete 3 years follow up had a total cost of around 
€1500 (VAT exclusive), which was certainly worthwhile the effort and cost since the FIP 
170 
 
losses in 2011 succeeded more than €4000 of costs on top of the fact that kittens of this 
cattery became less wanted. This cattery had the advantage that the management procedures 
were highly feasible by the availability of many rooms (and family that wanted to take care of 
some cats if they could not be housed in the cattery for some time), and by the fact that taking 
negative cats for breeding was highly facilitated, given that no import or export was needed 
for mating, which certainly could have complicated the whole procedure. Indeed, exporting 
queens/importing tomcats for mating increases the risk that queens become (re)infected, and 
should be accompanied by screening the shedding state of the tomcat if one wants to prevent 
this. Other efforts that had to be considered were especially hygienic ones, such as daily 
cleaning and disinfecting of litter trays, and regular cleaning and disinfecting surfaces in the 
house, thereby first cleaning the room of negative cats. No special precautions were taken 
considering people movement, handling of cats or clothing, which made the grouping 
procedure practically feasible according to the owners. For household 2 on the other hand, 
which never faced FIP deaths in the kitten population, this management procedure has been 
less cost-effective so far, as only half of the population ceased shedding after 1 year of 
sampling, which has cost €730 so far to screen all 14 cats 4 times. Extreme long-lasting 
shedding (> 1 year) occurred both in purebred cats as in a European Shorthair cat in this 
household, and could be the result of the strain (Addie et al., 2003), or the infection dose 
(Vogel et al., 2010), as previously reported for natural and experimental infections, 
respectively. Whether this persistent infection is also the cause of the many FIP problems in 
the adult cats in household 2 remains elusive. Nevertheless, it is clear that the major costs are 
determined by the duration of shedding, which is known to be cat- and strain-dependent and 
unfortunately cannot be predicted at the start of the control program. Generally taken, one 
should count for at least 1 year to obtain sufficient negative breeding animals. In addition, 
feasibility of grouping highly depends on the number of animals and the available rooms in 
the household, and will be less feasible and even much more time- and money-consuming in 
large multi-cat households (>20 animals) compared to the households discussed in the present 
study. This further supports the need to invest in the development of efficient tools for the 
prevention or treatment of FCoV infections. 
In consistency with previous reports, no clinical signs were seen in cats that were infected 
with FECV (Meli et al., 2004; Pedersen et al., 2008; Pedersen et al., 1981; Vogel et al., 
2010). Even most kittens from the adoption cattery that were shedding enormous amounts of 
FECV at the age of 4-5 weeks remained healthy. However, one of those kittens showed bouts 
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of anorexia and weight loss/lack of weight gain, first noticed at 4 weeks of age, and later seen 
at 7 and 11 weeks of age. This cat finally succumbed to FIP when she was less than 6 months, 
so it remains unknown whether these waves of illness were due to the enteric infection or 
rather were the result from the gradual development of systemic disease, which is known to 
occur in waves (de Groot-Mijnes et al., 2005). Nonetheless, the swift development of FIP in 
this cat allows us to assume that the FIPV strain can only be generated from the initial enteric 
infection, and full genome sequencing will allow genetic comparison of this FECV/FIPV 
tandem. In addition, as faecal shedding from this kitten and her healthy brother was 
monitored several times before she succumbed to FIP, it would be very interesting to 
investigate whether or not viruses found in the faeces of these two cats show any difference, 
and how these enteric viruses evolved over time. Clinical signs of gastroenteritis were noticed 
in FECV-negative kittens, and one of the kittens even succumbed to it. Despite many efforts 
to identify bacterial, parasitological, and other viral aetiology, no diagnosis could be made. In 
any other cattery where FCoV viruses are endemic, this diarrhoea would probably have been 
falsely dedicated to the intestinal coronavirus infections, implying that it is often hard to 
reliably identify the real aetiology of diarrhoea in cats in FCoV endemic environments. 
It has been stated that false negative results due to intermittent shedding of the cats can raise 
problems in grouping of animals, and that 5 consecutive negative monthly tests are necessary 
to confirm the cats’ negative shedding state (Addie & Jarrett, 2001). In the present study, 
intermittent shedding was indeed noticed in a minority of the cats (cat 7 and 12 in household 
1), but only in cats that were recovering from FECV infection, which is in consistence with a 
previous report (Herrewegh et al., 1997). These cats were shedding such low amounts of virus 
that this could have been missed, even if it was assured that swabs were taken deep enough in 
the rectum and a highly sensitive RT-qPCR was used. However, this ‘intermittent shedding’ 
did not at all hamper the grouping, as these cats were no longer infectious to other cats and 
even kittens. This implies that these cats can be safely grouped with the non-shedders, 
provided that sampling has been correctly performed and PCR test are highly validated. This 
is in agreement with a previous study, reporting that low-level positive faecal samples may 
not be infectious (Foley et al., 1997). However, if one wants to add a new cat in a negative 
group where very young animals reside, which should be avoided as much as possible, it is 
indeed recommended to additionally confirm that no false negative results were generated by 
the sampling or the test, as was done in this study for cat 10 in household 1. Indeed, it was 
noticed in the present study that shedding in the positive cats could fluctuate between low and 
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high during different samplings. If for reasons stated above (bad sample taking or inadequate 
PCR) the low shedding would have been missed, this could indeed have lead to improper 
grouping of the cats. 
Since the discovery that serum antibody tests cannot distinguish between FECV infections 
and FIP, the value of these tests has been questioned (Pedersen, 1995). Their use for 
management purposes has also been questioned, but this is still regularly performed in 
practice, notably prompted by the occurrence of FIP cases. In accordance with previous 
reports, the present study confirms that antibody tests are a waste of money if performed for 
the management of FCoV infections in catteries, since they cannot be properly interpreted. 
Indeed, low/absent antibody titres appear in cats that recovered from FECV infection, but 
have also been seen in cats that were infected within 10 days before testing (see chapter 5.1), 
and hence shed enormous amounts of virus. In addition, very high antibody titres are seen in 
both healthy shedders and non-shedders, making them not at all useful for grouping of 
animals, and certainly not for the prediction of FIP development. If one wants to spent money 
on FIP prevention, present study shows that it is certainly more worthwhile to consider 
grouping based on shedding instead of antibody titres. The motivation for this grouping is that 
FCoV transmission to kittens can be effectively avoided if one makes sure that the queen and 
all in contact animals are negative before the kittens are born. To obtain such a non-shedding 
population, it is recommended to monitor the faecal shedding of all cats every 2-3 months, 
and to group them in at least one positive and a negative group in separate, and if possible 
non-adjacent rooms. Care should be taken that swabs are inserted deep enough into the 
rectum (to avoid false negative testing), and that inadvertent transmission of the virus to the 
negative group is minimalized (e.g. by regular cleaning/disinfection (sodium hypochlorite), 
thereby first cleaning the litter trays/room of the negative group), but no strict quarantine 
measures are needed. In addition, the shedding of every newly imported cat should be 
thoroughly screened before decisions are made on the housing of the cat. 
In conclusion, present study reports the successful control of FECV transmission from 
shedders to naive animals by regularly monitoring of shedding and grouping of cats in small 
to medium-sized catteries (<15 animals), without the need for strict measures concerning 
people movement, clothing, or handling of cats. Cost-effectiveness of this strategy depended 
on the household, showing that especially in multi-cat environments with major FIP problems 
it is worthwhile to thoroughly monitor FECV transmission, as this will prevent enormous 
financial losses by kitten mortality. Although effective, monitoring is (and will always be) a 
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time- and money-consuming approach, due to the worldwide distribution, the long-lasting 
shedding and the highly contagious character of FECV. This further supports the need to 
invest in the development of efficient tools for the prevention and/or treatment of FCoV 
infections. 
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Coronaviruses have been reported as a serious threat in many animal species since the mid 
twentieth century, but only began to gain particular public and scientific interest when 
threatening the human species during the severe acute respiratory syndrome (SARS) outbreak 
in 2002-2003. This was further strengthened when a new fatal coronavirus, Middle East 
respiratory syndrome virus, from camel origin emerged in humans in 2012. But despite this 
increased research interest, it has remained quite challenging to find effective curative and/or 
preventive measures to combat coronaviruses, and FCoVs are undoubtedly one of the most 
fascinating examples of this failure. About 5 decades of research have led to several dozen 
potential vaccines/treatments, which all have been proven unsuccessful so far (Pedersen, 
2009, 2014). Coronaviruses are known to be prone to recombination and mutation events in 
their RNA genome, and both features seem to have indirectly hampered feline coronavirus 
(FCoV) research. Recombination events between FCoVs and canine coronaviruses (CCoVs) 
have led to the classification of FCoVs in two serotypes, serotype II viruses being the result of 
recombination between original feline serotype I viruses and CCoVs (Fiscus & Teramoto, 
1987a, b; Herrewegh et al., 1998; Hohdatsu et al., 1991; Lin et al., 2013). These serotype II 
viruses represent only a minority of all FCoVs (Addie et al., 2003; Benetka et al., 2004; 
Hohdatsu et al., 1992; Kummrow et al., 2005; Lin et al., 2009; Vennema, 1999), but have 
been quite extensively used in the search for effective vaccines/antivirals, as these have been 
the only viruses that could be easily propagated and studied in vitro. However, some of the 
genes, including the gene encoding for the tropism- and immunity-determining spike protein, 
are considerably different from the more clinically relevant serotype I FCoVs, which can be 
one of the reasons for the lack of in vivo efficacy of at least some of the generated 
treatments/vaccines, especially when they target the entry process. With this in mind, many 
scientists have redirected their research to serotype I viruses in recent years. Genome analysis 
and comparison have aimed at identifying the other genetic event that readily occurs in feline 
coronavirus genomes, namely the mutational switch from an avirulent enteric virus (FECV) to 
the deadly systemic FIPV (Chang et al., 2010; Chang et al., 2012; Licitra et al., 2013; 
Pedersen et al., 2009; Pedersen et al., 2012; Porter et al., 2014). However, this search has 
been seriously hampered by the fact that, due to high mutation rate, FECV exists in so many 
different strains, characterized by distinct single nucleotide polymorphisms and 
insertion/deletions, and by the fact that (almost) every FIPV has its own specific mutations as 
it originates de novo during infection with FECV (Pedersen, 2009). This makes comparison 
between FIPV strains and the search for the pathotype-switching mutations very difficult. In 
addition, as long as serotype I viruses cannot be properly grown and studied in vitro, it will 
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remain difficult to assess if mutations/deletions are indeed the cause of the pathotype switch, 
and to generate appropriate antiviral measures. 
Due to its low pathogenic character and the inability to grow the virus in vitro, FECV has not 
yet received much attention in the search for effective preventive measures or antivirals. 
However, given that FECV infection precedes the development of FIP, this virus is an 
attractive target in the fight against FIP. Therefore, this thesis aimed to focus on this root of 
all troubles, by providing cell cultures to grow and study (serotype I) FECVs, by extending 
the knowledge on FECV pathogenesis and enterocyte interactions, and by providing some 
(future) directions to combat this virus in the fight against FIP. 
6.1 The initiation of feline coronavirus infections: what about the intestinal phase?  
It is widely accepted that most FIP cases are the consequence of mutations arising in the viral 
genome during a common intestinal FECV infection (Chang et al., 2011; Chang et al., 2010; 
Pedersen, 2009; Pedersen et al., 2012; Poland et al., 1996). FECV is easily transmitted 
between cats by the faecal-oral route, and maintained within a cat population by continuous 
transmission from shedders to susceptible animals, the latter including all cats that have lost 
local, passively (=maternal) or actively acquired immunity (Addie et al., 2009; Addie et al., 
2003; Foley et al., 1997; Pedersen et al., 2008). Experimental infections and in vivo follow-up 
studies have added considerable understanding of how FECV infections are established and 
maintained within a cat population (Addie & Jarrett, 1992; Addie et al., 2003; Meli et al., 
2004; Pedersen et al., 2008; Pedersen et al., 1981; Poland et al., 1996; Vogel et al., 2010), but 
many insights are still lacking to completely understand how this virus interacts with its target 
cell and its host. To address some of these missing links, both in vitro studies and 
experimental FECV infections were conducted. 
6.1.1  Establishment of intestinal epithelial cell cultures to propagate serotype I FECVs and 
study FECV-enterocyte interactions (Chapter 3) 
At the start of this project, neither a representative in vitro model nor FECV strain was 
available to study FECV-enterocyte interactions. Therefore, the first part of this thesis 
focussed on the establishment of enterocyte cultures that would allow the propagation of the 
clinically relevant serotype I viruses and the study of FECV-cell interactions. A technique 
was optimized for the isolation and cultivation of primary intestinal epithelial cells from the 
ileum (= ileocytes) and colon (= colonocytes), as both intestinal segments are known to 
sustain FECV replication (Herrewegh et al., 1997; Kipar et al., 2010; Meli et al., 2004; 
Pedersen et al., 1981; Vogel et al., 2010). Isolation of primary intestinal epithelial cells is 
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often complicated by induction of programmed cell death after detachment from the 
extracellular matrix (designated as anoikis), the uncontrolled contamination with stromal cells 
and/or bacteria, and the still unknown homeostatic components needed to maintain these 
cultures (Kaeffer, 2002). To avoid anoikis during isolation of primary enterocytes, intestinal 
epithelial cells were isolated in cell clusters, still attached to each other and to the laminin part 
of the basement membrane. This was obtained by using a combination of dispase and 
collagenase, which digest the fibronectin and collagen but not the laminin layer of the 
basement membrane. Another advantage of the isolation of cells in clusters is that 
contaminating mesenchymal cells, which occur as single cells, can be separated from the 
much larger epithelial cell clusters based on their density, which was done in the present 
thesis by using 2% sorbitol solution to wash the digested mucosa several times. This protocol 
allowed the successful isolation of primary ileocytes and colonocytes, characterized by the 
expression of the epithelial cell marker cytokeratin, and absence of the mesenchyme cell 
marker vimentin. 
Primary epithelial cell cultures are ideal tools to reliably investigate virus-host interactions. 
However, their isolation is labour-intensive, the cultures are often contaminated with a 
various amount of mesenchymal cells, and the yield is variable and rather low. In addition, 
primary feline intestinal epithelial cells underwent no (ileocytes) or only a restricted number 
of replications (colonocytes) to finally end up in replicative senescence, making these primary 
cells useless for future long-term, standardized studies. To overcome this barrier of replicative 
senescence, primary ileocytes and colonocytes were immortalized by inducing SV40 T-
antigen- and hTERT-expression. The epithelial nature of the generated continuous cell lines 
was confirmed by the cobblestone morphology, dome formation and cytokeratin expression. 
However, in contrast to the primary cells, these cultures were characterized by a co-
expression of both cytokeratin and vimentin, a feature that is typically seen in dedifferentiated 
epithelial cells (Baer & Bereiter-Hahn, 2012). Therefore, the reliability of these cultures as in 
vitro model for enteric FCoV infections was investigated. This was done by comparing 
replication capacity of the serotype II FCoV WSU 79-1683 and FCoV WSU 79-1146, since 
these strains were the only viruses that could be propagated at that time, and hence were 
available to perform standardized, comparative studies between enteric and systemic FCoVs. 
FCoV WSU 79-1683 is an enteritis-inducing strain, but is believed to rather be an avirulent 
FIPV than a real FECV, as this strain shows a 3c deletion, a genetic hallmark that has so far 
only been observed in FIPVs (Chang et al., 2010; Pedersen, 2009; Pedersen et al., 2012). In 
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contrast, FCoV WSU 79-1146 is one of the most virulent FIP-inducing strains described so 
far. Two major conclusions were drawn from these experiments: 1) the avirulent, enterotropic 
FCoV strain 79-1683 infected enterocytes much more efficient compared to the FIP-inducing 
strain 79-1146, and 2) both viruses infected enterocyte cultures similarly to what was 
observed for primary cells, making these continuous cell cultures reliable as in vitro model to 
study enteric coronavirus infections.  
After having established this in vitro model, it was investigated whether we would also be 
able to propagate and study field strains in order to make future research more reliable. By 
then, cultivation of an enteric strain had never been achieved, and only few serotype I FIPV 
strains had been adapted to grow in continuous cell cultures. Seventeen faecal samples from 
healthy cats (1 including the prototype FECV strain UCD (Pedersen et al., 1981)), and faecal 
and tissue samples from 4 FIP cats were collected, and the amount of FCoV genomic RNA 
was quantified by RT-qPCR. For each sample, the presence and amount of enterotropic 
infectious virus was determined by immunofluorescence and IPMA, respectively. Of the 14 
positive faecal samples collected from healthy cats, 8 were found to contain virus that was 
able to infect the enterocyte cultures. Of the 7 positive samples collected from FIP cats, only 
1 faecal sample was found to contain enterotropic virus. A previous report mentioned that 
faeces from FIP cats is no longer infectious for other cats, as it could neither induce FIP nor 
intestinal infections upon inoculation of SPF cats (Pedersen et al., 2012). This prompted us to 
sequence a part of the genome (ORF 3 and 7) and compare the sequence with the strain found 
in the affected tissues of that FIP cat, showing that the enteric strain and the tissue strain were 
completely different. This observation indicated that this cat was not shedding an FIPV strain, 
but rather an FECV strain by which this cat had became superinfected in the shelter in which 
it was housed. Two viruses with the highest initial infectious titre, including the American 
FECV UCD strain and the own isolated UG-FH8 strain, were further propagated in the cell 
cultures to increase their titre, and were used in all subsequent experiments at passage 3.  
Based on the data generated in chapter 3, it was concluded that 1) FIPVs were clearly 
restricted in their replication in enterocytes, giving an explanation why FECV is the only 
pathotype circulating amongst cats; 2) the established enterocyte cultures provide a new, 
reliable in vitro model to propagate and study feline enteric coronaviruses. 
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6.1.2  Initiation of enteric infections by FECV-sialic acid interactions (Chapter 4.1) 
Enteric viruses have to overcome two important barriers before they can reach their target 
cell, the enterocyte. Firstly, they have to survive the harsh digestive environment, including 
low pH, proteases, lipases, bile salts, and carbohydrases that are normally involved in the 
break down of proteins, lipids, and sugars in food. In contrast to non-enveloped viruses, 
which represent the majority of all enteritis-inducing viruses, coronaviruses are highly prone 
to inactivation by different unfavourable conditions, and it is still unclear how the enteritis-
inducing coronaviruses survive the harsh conditions in the gastrointestinal tract after they 
have been swallowed. In addition, intestinal epithelial cells are covered by an enormous layer 
of mucus, a gellish network mainly formed by heavily glycosylated glycoproteins, called 
mucins, which act as a second barrier that has to be overcome by the virus to reach the cell 
surface. Since the carbohydrate moieties of the mucins are the first to be encountered during 
mucosal infections, it is not surprising that many viruses have evolved to interact with sugars 
at the mucosal surfaces of the host (Van Breedam et al., 2013). In addition, recognition of a 
specific glycan composition often determines tropism and pathogenicity of pathogens 
(Bomsel & Alfsen, 2003). As for other viruses, also many coronaviruses, such as 
transmissible gastroenteritis virus (TGEV), bovine coronavirus (BCoV), and infectious 
bronchitis virus (IBV) attach to sugars, notably sialic acids, to initiate their infections 
(Schultze & Herrler, 1992; Schultze et al., 1996; Schwegmann-Wessels & Herrler, 2006; 
Schwegmann-Wessels et al., 2011; Winter et al., 2006). In contrast to BCoVs and IBV, 
TGEV solely relies on a protein receptor for its entry, but uses its sialic acid binding capacity 
to interact with a mucoglycoprotein (Schwegmann-Wessels et al., 2003; Schwegmann-
Wessels et al., 2011). Although dispensable in cell culture, this sialic acid binding capacity is 
a key-determining factor for the enterotropism of TGEV, potentially by allowing the virus to 
interact with and pass through the intestinal mucus layer (Bernard & Laude, 1995; Krempl et 
al., 1997). All these observations prompted us to unravel if FECV can also interact with sialic 
acids/mucins, and how these interactions are involved in the initiation of FECV infections.   
The role of sialic acids during FECV infections was studied in vitro by investigating the effect 
of 1) neuraminidase (NA) treatment of enterocyte cultures, 2) NA treatment of the virus, and 
3) the addition of sialylated compounds to the inoculum, on the infectivity of FECV. It was 
demonstrated that desialylation of cells spectacularly enhanced (up to 72 times) FECV 
infectivity, showing that sialic acids on the cell surface can hamper efficient FECV-enterocyte 
interactions in vitro. This observation also clearly affected the propagation and titration of 
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FECV in vitro, as both FECV UCD and UG-FH8 were grown to titres of around 107 TCID50 
/ml when cells were desialylated before inoculation (data not shown), instead of around 105-
106 as initially reported in chapter 3. This also implies that infectious titres described in 
chapter 3 were potentially slightly underestimated. Nonetheless, these data clearly show that 
in contrast to BCoVs and IBV, sialic acids are no receptor determinants during FECV 
infections (at least not the terminal sialic acid residues, as internal sialic acids residues are not 
affected by the neuraminidase used in our studies). Given that neuraminidase treatment of 
viruses can unmask sialic acid binding capacity (Park et al., 2011; Schultze et al., 1992; 
Schultze et al., 1996), it was subsequently investigated if neuraminidase treatment of the virus 
would impact its infectivity in cell cultures, showing that desialylated virus infected the cells 
up to 7 times better compared to untreated virus. This increased infectivity was reduced/lost if 
these viruses were pre-incubated with sialyllactose, for which the effect was more pronounced 
when using α2,6- than α2,3-sialyllactose. Based on these experiments, two major conclusion 
were made: 1) FECV has a sialic acid binding capacity (α2,6- over α2,3-linked) that is 
(partially) masked by virion associated sialic acids, and 2) unmasking the sialic acid binding 
capacity can give the virus advantages in its interaction with enterocytes, although sialic acids 
were clearly shown not to be receptor determinants.  
The hypothesis that sialic acids might probably serve as ‘attachment’ factors could also 
explain the seemingly conflicting data on their involvement in FECV infections that were 
obtained when evaluating the infectivity of NA-treated viruses in desialylated cells (Figure 
6.1). Indeed, if cell-associated sialic acids can help the virus to more efficiently stick to the 
cell surface, it is logical that this can result in an increased number of infected cells if viruses 
have a more pronounced sialic acid binding capacity obtained by NA treatment of the virus 
(Figure 6.1; 1). On the other hand, it is also logical that if the virus can no longer stick to 
these sialic acids by treatment of the cells, that the virus-receptor interaction is even more 
efficient, as there is less chance that viruses get trapped by non-receptor glycoproteins. The 
latter can explain both the increase in infectivity upon desialylation of cells (Figure 6.1; 2a 
and 2b), and the reduced infectivity of virus with an increased sialic acid binding capacity 
(NA-treated viruses) in these cells (Figure 6.1; 3). Indeed, the less attachment to sialic acids 
that can occur in vitro, the less viruses will get ‘trapped’ by non-receptor glycoproteins or 
glycolipids, and hence the better they can interact with the receptor. 
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Figure 6.1. Effect of neuraminidase treatment of cells and/or FECV in vitro. 1) Enhancement of infection by 
NA treatment of FECV. Removal of sialic acids (red dots) from the viral surface liberates a sialic acid binding 
domain (green domain) that allows the virus to more efficiently interact with the sialylated (red dots) glycocalyx. 
2) Enhancement of infection by NA treatment of cells for both untreated (2a) and NA-treated viruses (2b). 
Removal of sialic acids (red dots) from the cell surface results in less repulsion by/distraction from the sialylated 
glycocalyx, and hence leads to a more efficient infection. 3) Reduction of infection by NA treatment of virus in 
NA-treated cells. Allowing more attachment to sialic acids by the liberation of the viral sialic acid binding 
domain (green domain) results in more distraction by non-receptor-related sialic acids compared to the non-
treated virus, and hence leads to less efficient infection.  
These data suggest that FECV resembles TGEV in its requirement for sialic acids in the 
initiation of infection, and hence that sialic acid binding can be a strategy for this virus to 
attach to highly sialylated mucins. The FECV-mucin interaction was studied by performing 
competitive inhibition experiments with 2 different, commercially available mucins, porcine 
gastric mucin (PGM) and bovine submaxillary mucin (BSM). Whereas PGM could not affect 
FECV infectivity at concentrations up to 50 mg/ml, BSM potently inhibited FECV infections 
from 0.5 mg/ml onwards. The fact that this effect was much less pronounced on desialylated 
cells confirmed previous conclusions that sialic acid binding occurs in non-treated cell 
cultures, but is not a prerequisite for the initiation of FECV infections in vitro. In contrast to 
sialyllactoses, also non-treated viruses had a mucin binding capacity, which can be explained 
by the multivalent binding to mucins compared to sialylactoses. These data show that FECV 
is capable of interacting with mucins, and that it prefers mucins rich in (α2,6-linked) sialic 
acids (such as BSM), and not other mucins such as PGM, which is mainly composed of 
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neutral and sulphated oligosaccharides. In addition to these experiments, we have also 
performed experiments with feline saliva and found that this could also reduce FECV 
infectivity (data not shown). This interaction with salivary mucins raised the hypothesis that 
the sialic acid binding capacity is probably not only a way to allow attachment and 
subsequent passage through the mucus layer, but also a way to deal with the harmful digestive 
juices the viruses are faced with. This hypothetical model is depicted in Figure 6.2. Indeed, if 
FECV can cover itself with sialylated compounds/mucins, the virus can be protected against 
digestion, which can explain how these enveloped viruses manage to reach the intestine. 
During its passage, the virus is faced with acidic pH and bacterial and/or cellular sialidases, 
which will finally desialylate the virus. This desialylation will liberate the sialic acid binding 
domain of the virus, allowing it to escape from the intestinal flow by attachment to the 
intestinal mucus layer. The need for this ‘digestion’ would also explain why the proximal part 
of the duodenum seems not to become infected by the virus (Pedersen et al., 1981). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Hypothetical model for the initiation of intestinal FECV infections. (1) Virion protected by a 
carbohydrate/mucin shell, formed by intrinsic glycosylation and additional binding to sialylated 
compounds/mucins, encountered during exit from infected cells or during uptake in the oral cavity (e.g. salivary 
mucins). (2) This protects the virus from degradation when faced with the unfavourable conditions (enzymes, 
pH) in the uppert part of the gastro-intestinal tract. (3) Exposure of the virions to low pH and/or bacterial/cellular 
sialidases liberates the viral sialic acid binding site (green domain), (4) allowing the virus to attach to sialic acids 
(α2,6- > α2,3-linked sialic acids) in mucus. (5) Passage through the mucus layer, most probably facilitated by 
intestinal sialidases, finally allows FECV to engage with its functional receptor (6) expressed on the enterocyte 
membrane.  
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Taken together, chapter 4.1 demonstrated that FECV has a sialic acid binding capacity, but 
that attachment to sialic acids is not a prerequisite for the initiation of in vitro infections, and 
even hampers efficient enterocyte infections. Nonetheless, it seems reasonable for the virus to 
possess this property, as it can give the virus advantages in its confrontation with the harsh 
conditions and mucosal barriers during its passage through the intestinal tract. However, 
passage through the stomach seems not to be the only way by which FECV can reach the 
intestine… 
6.1.3  Alternative route to initiate enteric infections? (Chapter 5.1) 
In an attempt to learn more about in vivo FECV infections by experimental inoculation of 
cats, it was found that one of the cats showed a remarkably different infection pattern 
compared to the other cats. This infection pattern was characterized by a delayed faecal 
shedding (starting from day 14 instead of day 2-4 p.i.), absence of infectivity in enterocyte 
cultures of the excreted virus, a delayed raise in antibody titres, and viraemia that was 
detected far before any intestinal replication. The only reasonable explanation that could link 
the early viraemia with the delay in intestinal shedding was that FECV could have reached the 
intestine by the systemic route. The initiation of intestinal infections by the systemic route has 
been reported before, when it was noticed that intraperitoneal FECV inoculation of cats can 
result in faecal shedding (Foley et al., 1997; Pedersen et al., 2012). However, in contrast to 
our results, intraperitoneal inoculation of FECV gave no aberrant excretion pattern, as onset 
and level of shedding were comparable to the orally inoculated cats, indicating that FECV 
was carried very fast from the periphery to the intestine in that study. In our study, the oral 
RNA shedding during the first 3 days and the swollen submandibular lymph nodes at day 3 
p.i. raised the hypothesis that FECV could have encountered susceptible, most probably 
monocytic cells, in the tonsils, from where subsequent viraemia occurred. For FIPV, infection 
of monocytic cells in tonsils has been described upon oral inoculation, making this site of 
infection quite plausible (Stoddart et al., 1988). As a result of the viraemia, these infected 
cells should then have extravasated in the intestinal mucosa, explaining the sudden detection 
of shedding in that cat at 14 days p.i. However, although this alternative route for the 
initiation of enteric FECV infections can link the oral shedding, swollen submandibular 
lymph nodes, and early viraemia with the delayed shedding, it cannot give an explanation for 
the lack of infectivity of this virus. Indeed, the virus shed by this cat was no longer infectious 
for enterocytes, at least not in vitro, as no additional inoculation studies were done with the 
faecal suspensions of this cat to confirm this feature. Nevertheless, the huge differences in 
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infectivity compared to the virus excreted from the other 2 cats raised the question whether 
this virus was indeed shed by enterocytes, and not by another cell type (from the monocytic 
lineage?) residing in the intestinal mucosa. Two possible explanations can be considered for 
this feature. First, it is possible that viral genetics have changed by its adaptation 
to/replication in this cell type, which would give the virus a more FIPV-like phenotype, for 
which we showed that they replicate very inefficient in enterocytes (chapter 3). Full genome 
sequences of the excreted viruses of all cats and the inoculum are currently being assessed to 
find any of those genetic differences. If these would not reveal any differences, another 
explanation for the lack of enterotropism would be that by its adaptation to/replication in cells 
of the monocytic lineage, the glycosylation of the virus has extensively changed, as it is 
known that cell-specific post-translational glycosylations can determine the cell tropism of the 
progeny virus (Dejnirattisai et al., 2011; Lin et al., 2003). However, coronaviruses are known 
to use their sugar coat to bind to lectins expressed on monocytes, but so far there are no 
indications that cell surface carbohydrate-binding molecules are also used for infection of 
enterocytes. If the glycosylation of the virus has indeed been changed, a reasonable 
explanation for the lack of infectivity in enterocyte cultures would be the steric hindrance of 
the sugar coating to allow efficient spike-receptor interactions. Further experiments with 
glycosidases should reveal whether or not this is indeed the case. Figure 6.3 gives an 
overview of the hypothetical model for the initiation of intestinal infections and the sources of 
FECV shedding. 
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Figure 6.3. Alternative route for intestinal infections and possible sources of FCoV particles found in 
faeces. 1) After oral uptake, FECV can pass the stomach, to finally encounter its target cell, the enterocyte, in the 
intestine, resulting in subsequent shedding from the infected enterocytes. 2, 3) Possibly, FECV is also capable of 
reaching the intestine by the systemic route, resulting from uptake of the virus in cells of the monocytic lineage 
in the oral cavity and subsequent extravasation of these cells in the intestinal mucosa. Subsequent shedding 
resulting from this alternative route of intestinal infection can theoretically occur by basolateral (cell-free or cell-
associated?) infection of enterocytes (2), or by shedding from monocytic cells (3), the latter which can result in 
phenotypic changes of the virus by mutation or different post-translational modifications. 
6.1.4  Total faecal RNA copies, infectious titres and neutralizing antibodies during FECV 
infections 
The availability of FECV-susceptible cell cultures allowed for the first time to compare 
infectious titres with RT-qPCR titres, and to assess the presence of neutralizing serum 
antibodies. Two different RT-qPCR tests were used: 1) the generally used qPCR targeting the 
3’ part of the genome and all subgenomic mRNAs, and 2) a newly developed qPCR 
recognizing ORF1b (chapter 3) which is only present in genomic RNA. When comparing 
both RT-qPCRs, it was found that by using the 3’ qPCR for the assessment of viral genomes 
as is regularly done, a titre overestimation of 3 to 4.3 log10 occurs, explaining why only 
1/1,000,000 to 1/100,000,000 of these “particles” seemed to be infectious. When using the 5’ 
qPCR, the difference between total genomic RNA and infectious virus was more acceptable, 
although this difference varied in between the time points p.i. at which the shedding was 
monitored. Indeed, whereas total genome copies were 3-4 log10 higher than infectious titres 
during the first week, this ratio further increased to 4.5-8 log10 during the remainder of the 
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experiment. This decreased infectivity coincided with the onset of neutralizing antibodies 
(Figure 6.4).  
 
 
Figure 6.4. Quantification of virus and neutralizing antibodies in the two cats with the normal infection 
pattern. 
The presence of the neutralizing IgA antibodies in faecal suspensions should be further 
investigated, but it seems reasonable that these started to affect the infectivity estimation in 
our cell culture-based assay. This could also explain the variable infectivity of faecal field 
samples described in chapter 3. In addition, the highly neutralizing capacity of antibodies is 
potentially the reason why kittens can remain fully protected by maternal antibodies during 
the first weeks of life, and why superinfections only rarely occur during natural infections 
(Addie & Jarrett, 1992; Addie et al., 2003; Herrewegh et al., 1997). However, it remains a 
mystery how FECV manages to continue infection for many months or even years, whereas 
other enteric viruses would already have been cleared within 1-2 weeks p.i. Extensive 
research on FIPV has revealed that this virus has many immune-evasion strategies 
(Cornelissen et al., 2007, 2009; Dedeurwaerder et al., 2014; Dewerchin, 2008; Dewerchin et 
al., 2006; Vermeulen et al., 2013), and it seems reasonable to assume that this is not only a 
hallmark of FIPV, but also determines the strengths of the “harmless” parent virus, allowing it 
to reside within all cat populations by establishing long-lasting infections. 
6.2 Targeting FIP by managing the faecal-oral transmission of FECV (Chapter 5.2) 
It has been recommended before that: “Control of FIP must be directed first at control of its 
parent virus, and should that fail, at FIPV itself” (Addie et al., 2004). However, not only the 
development of curative tools to overcome FIPV, but also the prevention of FECV infections 
have shown to be more easily said than done, since FECV is still residing in virtually all 
multi-cat households worldwide. The major strength of this virus is its capability to establish 
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unnoticed, long-lasting infections, thereby seemingly ‘co-existing’ with cats. This is why 
most owners are not aware of the presence of this virus until one or more of their cats 
succumb(s) to FIP. And even then, they often do not realize that except for their FIP cat, most 
other cats are infected with an FCoV at that time and that the losses from FIP have their roots 
in these concealed infections. Shocked by the sudden death of their young and valuable cats, 
many owners often desperately search/ask for efficient control measures to prevent future FIP 
losses. Early weaning followed by complete isolation of kittens can be an effective way to 
prevent transmission from positive animals to kittens (Addie et al., 2009; Addie & Jarrett, 
1992). However, the fact that this method does not guarantee success, and notably the fact 
that reduction in FIP losses does not outweigh the impact on the socialisation explains why 
this is not regularly applied in practice. Therefore, many cat owners start to spend a lot of 
money on antibody testing and group their cats according to these results in order to reduce 
the infection pressure, but this strategy is also very often fruitless. FECV remains endemic in 
cat populations by continuous transmission from (long-lasting) shedders to negative animals. 
Consequently, it should theoretically be feasible to control infections by avoiding contact 
between negative animals and shedders by grouping of cats based on their shedding status. 
However, knowing that FECV can be easily transmitted via fomites and that most catteries 
are established in a normal one- or two-storey house with a lot of people movement, the 
practical feasibility of this strategy has been questioned. In addition, some reports mention 
intermittent shedding in cats (Addie & Jarrett, 2001; Pedersen et al., 2008), and that a 
negative status can only be stated with certainty after 5 consecutive negative monthly tests 
(Addie & Jarrett, 2001). The enormous demand for control measures, and the lack of concrete 
data if and how FECV transmission can indeed be managed in normal households prompted 
us to evaluate whether this method of grouping would be practically feasible. Two essential 
conditions should be fulfilled for this method to be successful: 1) a highly sensitive PCR is 
needed to avoid false negative testing, and 2) the amount and housing of cats should allow for 
grouping of animals in at least 2 separate rooms. In Belgium, catteries are typically small to 
medium sized and established in normal one or two story houses, making grouping in separate 
rooms practically feasible. Knowing that the 5’ qPCR was able to detect various field strains 
(chapter 3) and gave the best correlation with the infectivity (chapter 5.1), this PCR was used 
in 2 average-sized catteries (chapter 5.2). It was clearly shown that grouping of cats based on 
their shedding state is practically feasible and cost-effective if one wants to avoid FECV 
transmission to kittens. By monitoring both shedding and antibody titres at regular time 
points, present thesis confirmed that antibody titres are not good parameters to assess a cat’s 
General discussion 191 
 
 
infectivity, and hence that it is certainly more worthwhile to invest in tests that monitor faecal 
shedding. In contrast to previous reports, no extremely variable intermittent shedding that 
could have interfered with the grouping was noticed with the RT-qPCR test used in the 
present thesis. However, two features that were noticed were 1) that shedding in positive cats 
could vary between low and high in between the samplings, and 2) that cats that were 
recovering from infection and were negative at one sampling, could be very low positive the 
next sampling, but these cats were no longer infectious for other cats, and hence this kind of 
‘intermittent shedding’ did not interfere with the grouping. 
Despite the lack on restrictions for clothing, handling of cats, and people movement, the 
persistent shedder could be very effectively identified in household 1 (1 year after the start of 
the monitoring), and this cattery was even totally cleared from FECV shedders after the 
persistent shedder had been removed. In household 2, 7/14 cats were still shedding 1 year 
after the start of the monitoring, but by grouping of cats, reinfection of the negative cats was 
efficiently prevented. These observations show that direct contact between cats and presence 
of persistent shedders are the major reasons for endemic FECV infections within a household. 
Consequently, if one wants to prevent FECV transmission to kittens without the need for 
early weaning, it should be assured that the queen and all future in contact animals are 
negative (= generate a negative breeding population), or that the complete cattery is free of 
shedders (= eradication of FCoVs) (Figure 6.5). Theoretically, the latter strategy is the most 
effective in assuring that no kittens will become infected. However, eradication of FCoVs 
takes at least 1-2 years, and is currently, due to the widespread distribution of FCoVs, only 
feasible in catteries that do not import new breeding animals. Therefore, the most practically 
feasible approach is to make a negative breeding population, as was done in the present thesis 
by regular monitoring of shedding and grouping of cats. It was shown that with this strategy, 
a sufficient amount of negative cats could be obtained within 9-12 months. The major 
drawback of this approach is that there is a continuous risk for inadvertent transmission of the 
virus to the negative kittens, especially when positive kittens/young cats (which shed 
enormous amounts of virus) are imported. Indeed, an inadvertent transmission of the virus 
was observed in the present thesis from a newly imported kitten to the negative kittens in the 
adjacent room. Therefore, it is certainly recommended to consider separation of young 
positive cats from negative cats by grouping in non-adjacent rooms and/or to prevent import 
of young cats as long as the negative kittens are present. Knowing that this separation strategy 
is effective in reducing FECV infections, sensitizing veterinarians/cat owners and applying 
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this strategy in more catteries could already be an enormous step in the right direction to deal 
with FIP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Recommendations for the prevention of feline enteric coronavirus transmission to kittens. 
Notwithstanding the feasibility, the long-lasting or even persistent shedding of the virus 
remains the major restriction and the reason why control of FECV transmission will always 
remain a time- and money-consuming activity. In addition, as long as FECV remains endemic 
in cat populations, control of FECV infections will be unfeasible in very large catteries or in 
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other multi-cat households (shelters/shops) where new cats are regularly imported or grouping 
cannot be appropriately performed. In depth analysis of serotype I FCoV-host interactions 
will be of key importance if one wants to combat future FIP cases, as only these insights will 
allow the development of adequate preventive or curative tools. Further investments in 
development of cell lines for the propagation and study of serotype I FIPVs should therefore 
be the next crucial step to be taken. 
6.3 Targeting FIP: future perspectives on FCoV curative and preventive measures 
When making statements on the development of new anti-FCoV measures, the question arises 
which measures (preventive or curative) are most opportune to invest in, and if these should 
target FECV, FIPV, or both.  
For many viral infections, vaccination has undoubtedly been very effective to reduce 
morbidity/mortality or even completely eradicate a virus within/from a certain population. In 
contrast to those successful vaccines, the efficacy of the only commercial available FIP 
vaccine (Primucell® FIP) is rather insufficient. In addition, all other attempts to provide better 
vaccines have failed so far, and many vaccines even induced accelerated disease progression. 
Knowing that vaccination completely relies on the host immune system, this failure is 
actually not surprising, as FCoVs (or at least FIPV) are masters in evading the cat’s immune 
system on all levels (innate, humoral and cellular) (Cornelissen et al., 2007, 2009; 
Dedeurwaerder et al., 2014; Dewerchin, 2008; Dewerchin et al., 2006; Vermeulen et al., 
2013). So far, vaccination trials have only been based on the evaluation of protection against 
FIPV challenge, and one can wonder if vaccine development and efficacy testing against 
FECV would be a more reasonable approach, as this is the only virus that circulates between 
cats. However, given that 1) FECV escapes from protective local immunity (as evidenced by 
its long-lasting shedding), 2) memory immune responses are lacking (as evidenced by the 
continuous reinfections), and that 3) theoretically one replication cycle is sufficient to 
generate FIPV mutants, this approach will probably not be the most effective way to combat 
FIP.  
The development of adequate curative measures will most probably be the key to tackle FIP. 
Antiviral drug development can be directed against viral proteins or against host proteins that 
are used by the virus to complete its replication. The advantage to target viral proteins is that 
those antivirals have fewer side effects than if one would target host proteins involved in 
normal physiological processes. The counterpart of targeting viral, and especially coronaviral, 
proteins is that these viruses can become rapidly resistant resulting from their high mutation 
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rate. Hence, combatting FCoVs, as all other coronaviruses, with antivirals will possibly need 
a multi-drug/target approach to be successful. In addition, the development of new FCoV 
treatments should ideally be directed against both pathotypes, because this cannot only help in 
curing cats from FIP, but can maybe also help in making the restriction of FECV transmission 
in multi-cat households more efficient by clearing the long-lasting FECV infections in 
positive cats. Combining the above described management strategy with “healing” the 
positive cats from long-lasting/persistent infections will be a very effective approach to tackle 
FIP. In that way, every household would be able to rapidly clear FECV infections and avoid 
re-entrance of the virus by testing and/or treating incoming cats. In light of this strategy, 
present thesis aimed at providing insights in host and viral proteases involved in the 
replication of serotype I FECV. In addition, this thesis also provided additional information 
on proteases involved in serotype II FCoV 79-1683 and TGEV replication (Chapter 4.2). In 
contrast to FCoV 79-1683 and TGEV, serotype I FECV did not depend on low pH, furin 
cleavage and/or cathepsin B cleavage for its entry in enterocytes, but the exact fusion trigger 
could not be revealed. However, a yet to be identified serine protease was recognized as 
involved in the replication. Interestingly, this serine protease was found to be virion-
associated, and not only involved in serotype I FECV, but also in FCoV 79-1683 and TGEV 
infections. In addition, it was shown that this viral protease fulfilled its job between 60 and 
120 min p.i. Based on the kinetic study performed with E64d, which showed that the viral 
cysteine proteases fulfilled their function from 30 to 120 min p.i., this indicates a role of the 
serine protease in a post-entry step, but the identity and function of this protease remain 
elusive. Figure 6.6 overviews a model for serotype I FECV and serotype II FCoV 79-1683 
entry and replication in enterocytes based on data obtained in the present thesis. As stated 
above, these data confirm that serotype I viruses follow different entry pathways compared to 
serotype II viruses in epithelial cells, and hence that the future search for effective antivirals 
in cell-based assays should be performed with the clinically relevant serotype I viruses.  
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In the present thesis, considerable attention was given to FECV, and it was shown that this 
parent virus can certainly be a future target if one wants to reduce the FIP incidence. 
However, FIP cases will remain to originate from insurmountable FECV infections, 
especially in places where large amounts of cats reside and are regularly imported. To deal 
with these FIP cases, investments should be made to identify as much druggable targets as 
possible in the FIPV-monocyte/host interaction. In contrast to FECV, it will be ethically more 
accepted to use drugs that have somewhat more side effects, as FIPV causes a life-threatening 
disease. The major problems in case of FIP, however, are that by the time a cat is diagnosed 
with FIP, 1) the virus has already caused extensive tissue damage for which we can wonder 
whether this is still reversible, and 2) that the disease is progressing in pyogranulomas, and it 
is unknown if optimal drug concentration/penetration occurs in these environments. 
Consequently, if one wants to cure FIP with any future drugs, decent 
discriminatory/confirmatory tests will be needed not only to enhance the survival rate by an 
early diagnosis of the disease, but also to avoid unnecessary treatment (or euthanasia as long 
as there are no treatments) of non-FIP cats. In order to establish a discriminatory test, full 
genome comparison has been performed on multiple enteric strains of healthy cats and tissue 
strains of FIP cats, although it recently became clear that one should be careful when making 
conclusion on these comparisons, as systemic ‘FECVs’ also differ from enteric ‘FECVs’. 
Indeed, whereas one study reported to find specific ‘FIPV mutations’ in the spike by 
comparing faecal strains of healthy cats with tissue strains of FIP cats (Chang et al., 2012), a 
following study reported that these mutations were also found in tissues of non-FIP cats and 
hence were not a hallmark of FIPV (Porter et al., 2014). Recently, a new test was launched 
based on these 2 mutations to aid veterinarians in the definite diagnosis of FIP. So far, no data 
are available on the sensitivity, specificity and predictive values of this test based on analysis 
of effusions/biopsies of a large number of both FIP and non-FIP cats. However, it was stated 
that blood samples are not recommended for the test, since the viral load in blood is often too 
low to be detected. This implies that even with such tests, it will remain challenging to obtain 
an early diagnosis. In addition, although these 2 mutations have been found in 96% of all FIP 
cases, it remains unknown if and how these mutations contribute to the onset of FIP. The fact 
that they are also found in tissues of non-FIP cats indicates that FIP is most probably the 
consequence of several (consecutive) mutational events in the genome. As stated above, the 
search for the FIPV-determining mutations has been seriously hampered by huge inter-FECV 
variations and by the lack of tools to study the effect of a certain mutation on the phenotype 
of the virus. Consequently, 3 tools will be absolutely required to solve the crucial question on 
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the pathotype-switching mutations: 1) genome sequences of multiple FECV/FIPV tandem 
strains will be needed to search for the exact FIP-related genetic changes, and hence to 
decrease the amount of non-FIP related inter-FECV variations when making comparisons, 2) 
manipulable FCoV genomes should be available to confirm a certain mutation to be the cause 
of the cell tropism- and pathotype switch, and 3) FCoV-sensitive cell cultures (enterocytes 
and monocytes) should be available to grow these viruses and rapidly screen the effect of a 
certain mutation on the phenotypical behaviour of the virus. By establishing feline enterocytes 
cultures (chapter 3) and collecting field material, from which until now 1 FECV/FIPV tandem 
has been generated (chapter 5.2), this thesis has provided at least some indispensable tools to 
find the “Holy Grail” in feline coronavirus research. 
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Feline infectious peritonitis (FIP) is caused by a feline coronavirus (FCoV) and has remained 
one of the few insurmountable and highly feared infectious causes of death in cats to date. In 
Chapter 1, an introduction is given on the classification of FCoVs in two pathotypes (feline 
enteric coronavirus (FECV) and feline infectious peritonitis virus (FIPV)) and two serotypes 
(serotype I and II), on the general viral structure and proteins, the replication cycle, and the 
current understanding of the pathogenesis. It is also described that an early and certain 
diagnosis of FIP remains challenging and that adequate preventive and/or curative tools 
against FIP are still lacking. Given the fact that FECV infections precede the onset of FIP, 
they can be important targets in the fight against this fatal disease. Since the main part of the 
FECV-enterocyte interactions studied in present thesis involved the early beginning of the 
infection, the second part of chapter 1 overviews the current knowledge on this entry pathway 
for coronaviruses in general. 
Due to its low-pathogenic character, FECV has not received much attention, and hence very 
little information is available on the FECV-enterocyte/cat interactions and the 
possibility/feasibility to control this virus in the fight against FIP. Therefore, this thesis 
focussed on this root of all troubles to add upon the knowledge on the FECV pathogenesis 
and to provide insights in how its transmission can be restricted. These aims are formulated in 
Chapter 2. 
At the start of this project, no representative in vitro model nor FECV strain were available 
for the study of FECV-enterocyte interactions. Chapter 3 describes the research that was 
performed to address this lack. Therefore, long-term feline intestinal epithelial cell cultures 
were established from primary ileocytes and colonocytes by simian virus 40 T-antigen- and 
human telomerase reverse transcriptase-induced immortalization. Next, the reliability of these 
cultures as in vitro model for enteric FCoV infections was investigated. This was done by 
comparing the replication capacity of the enteritis-inducing serotype II FCoV WSU 79-1683 
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and the FIP-inducing FCoV WSU 79-1146 with the replication capacity in primary cultures. 
These experiments demonstrated that the avirulent, enterotropic FCoV strain 79-1683 infected 
enterocytes much more efficient compared to the FIP-inducing strain 79-1146, and that both 
viruses infected the immortalized enterocyte cultures similarly to what was observed for the 
primary cells. Consequently, it was concluded that the continuous cell cultures were reliable 
as in vitro model to study enteric FCoV infections. After having established this in vitro 
model, it was investigated whether these cultures would allow the propagation and study of 
field strains in order to make future research more reliable. Therefore, the enterocyte cultures 
were inoculated with faecal suspensions from healthy cats and with faecal or tissue 
suspensions from FIP cats. The cultures were susceptible to infection with different serotype I 
enteric strains and two of these strains (FECV UCD and UG-FH8) were further propagated. 
No infection was seen in cultures inoculated with FIPV tissue homogenates. Based on the 
data obtained in chapter 3, it was concluded that a new reliable model for FCoV investigation 
and growth of enteric field strains was established. In contrast to FIPV strains, FECVs 
showed a clear tropism for intestinal epithelial cells, giving an explanation for the observation 
that FECV is the main pathotype circulating among cats. 
The establishment of these enterocyte cultures and high titre serotype I FECV strains allowed 
the further unravelling of the FECV-enterocyte interactions. As nothing was known for these 
interactions, Chapter 4 bundles the research that was performed to address some of the 
players involved in the early beginning of FECV infections. Given that sialic acids act as 
attachment factors/receptors in many coronavirus infections, the role of these carbohydrates in 
FECV infections was investigated. In addition, knowing that coronavirus spike proteins 
require activation by low pH and/or proteases, the effect of various pH drop- and protease 
inhibitors was also examined. 
Chapter 4.1 describes how the FECV infectivity was affected by 1) neuraminidase (NA) 
treatment of enterocyte cultures, 2) NA treatment of the virus, and 3) the addition of sialylated 
compounds to the inoculum. NA treatment of cells greatly enhanced (up to 72 times) infection 
efficiency, showing that terminal sialic acid residues on the cell surface are not receptor 
determinants and even hamper efficient virus-receptor engagement. When studying the effect 
of NA treatment of the virus, it was shown that desialylated virus infected the cells up to 7 
times better compared to untreated virus, but that this increased infectivity was lost by the 
addition of sialyllactoses (α2,6- over α2,3-linked). These results gave an indication that FECV 
has a sialic acid binding capacity that becomes more pronounced by NA treatment of the virus 
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and that, although they are not receptor determinants, attachment to sialic acids can give the 
virus some advantages in its interaction with the enterocyte surface. Seemingly conflicting 
data were obtained when the infectivity of desialylated viruses were investigated in 
desialylated cells, since, in contrast to untreated cells, NA treatment of the virus was 
detrimental in NA-treated cells. However, the fact that sialic acids could serve as attachment 
factors, but are not a prerequisite for the initiation of enterocyte infections, could explain this 
feature, as receptor engagement becomes most efficient when the virus is not 
delayed/distracted by non-receptor sialylated molecules. These data strongly suggested that 
FECV resembles transmissible gastroenteritis virus (TGEV) in its sialic acid requirement, and 
hence that sialic acids are not receptor determinants, but that binding to sialic acids can be a 
strategy for this virus to attach to highly sialylated mucins covering the enterocytes. The 
FECV-mucin interaction was studied by performing competitive inhibition experiments with 
2 different, commercially available mucins, porcine gastric mucin (PGM) and bovine 
submaxillary mucin (BSM). Whereas PGM did not at all affect FECV infectivity in 
concentrations up to 50 mg ml-1, BSM potently inhibited FECV infections from 0.5 mg ml-1 
onwards. This effect was much less evident in desialylated cells, confirming that FECV-sialic 
acid/mucin interactions occur in untreated cell cultures, but that these interactions are not a 
prerequisite for the initiation of enterocyte infections in vitro. These data demonstrated that 
FECV is capable of interacting with mucins (rich in α2,6-linked sialic acids such as BSM), 
and a hypothesis was raised that this mucin binding capacity potentially not only allows 
FECV to escape from the intestinal flow by binding to the mucus layer, but that covering 
itself with mucins is probably also a strategy to survive the low pH and/or proteolysis in the 
upper gastro-intestinal tract.  
In Chapter 4.2, the effect of various lysosomotropic agents and protease inhibitors on the 
replication of serotype I FECV strains UCD and UG-FH8, serotype II FCoV strain WSU 79-
1683, and TGEV, in enterocytes was assessed. It was shown that, in contrast to FCoV 79-
1683 and TGEV, serotype I FECV entry occurred independently of acidic pH or cathepsin B. 
In addition, the furin inhibitor decanoyl-RVKR-CMK did not affect serotype I FECV entry or 
infectivity of progeny virus, but did inhibit FCoV 79-1683 and TGEV entry. The serine 
protease inhibitor AEBSF strongly reduced replication of all FCoVs and TGEV, when it was 
continuously present before and during replication or added after inoculation. Interestingly, 
this reduction resulted from the inhibition of a virion-associated serine protease, since a 
similar inhibition was observed when only the virus was treated with AEBSF. By performing 
a kinetic study, during which AEBSF was added at different time points p.i., it was shown 
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that this protease fulfilled its function between 60 and 120 min p.i. As expected, since 
coronavirus’ polyprotein processing occurs by viral cysteine proteases, the cysteine protease 
inhibitor E64d also inhibited replication, when it was continuously present before and during 
replication or added after inoculation. Neither AEBSF nor E64d inhibited replication when 
only the cells were pre-treated. Based on all these data, it was concluded that in contrast to 
serotype II FCoVs, serotype I FECVs do not rely on low pH, cathepsin B and/or furin 
cleavage for entry, but the exact fusion trigger could not be revealed. These observations 
strengthen the worries that care should be taken when generalizing data obtained with 
serotype II FCoVs to serotype I viruses, especially when it concerns viral entry. In addition, it 
was shown that serotype I FECVs (and some other alphacoronaviruses) carry a virion-
associated serine protease that is potentially involved in the initiation of the replication, 
thereby identifying a new target for future drug development. 
In Chapter 5, the in vivo FECV-host interactions were studied by either performing 
experimental infections (chapter 5.1) or by follow-up studies in catteries (chapter 5.2). 
Chapter 5.1 describes the research results that were obtained by monitoring oral and faecal 
shedding, neutralizing antibodies, viraemia, and leukocyte subsets for 3 months after oral 
inoculation of 3 FIV-, FeLV-, and FCoV-negative cats with serotype I FECV UCD. Virus 
shedding was quantified by 2 different RT-qPCRs (one recognising the 3’ of all genomic and 
subgenomic (m)RNAs (3’ qPCR), and the other recognising the ORF1b of the genomic RNA 
(5’ qPCR)), and by virus titration in enterocyte cultures. In two of the three cats, faecal 
shedding started within 2-4 days p.i., and viral RNA remained detectable in faeces for 2 
months. Infectious virus was found from day 4 until day 28 p.i., and neutralizing antibodies 
were found from 9 days p.i. onwards. A cell-associated viraemia was detected in both cats at 
infrequent time points after the onset of faecal shedding. No abnormal leukocyte numbers 
were noticed, except for a granulocytopenia in cat 1. It was found that by using the 3’ qPCR 
for the assessment of viral genomes as is regularly done, a titre overestimation of 3 to 4.3 
log10 occurs, making it not surprising than that only 1/1,000,000 to 1/100,000,000 of these 
“particles” seemed to be infectious. When using the 5’ qPCR, the difference between total 
genomic RNA and infectious virus was more reasonable, although this difference varied in 
between the time points p.i. at which the shedding was monitored. Indeed, whereas total 
genome copies were 3-4 log10 higher than infectious titres during the first week, this ratio 
further increased to 4.5-8 log10 during the remainder of the experiment. This decreased 
infectivity coincided with the onset of neutralizing antibodies, and it was suggested that 
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neutralizing antibodies in faeces could have led to an underestimation of infectivity in vitro, 
but this needs to be further investigated. Surprisingly however, one of the three cats showed 
an aberrant infection pattern, characterized by a delayed faecal shedding (from day 14 instead 
of day 2-4 p.i.), absence of infectivity in enterocytes cultures of the excreted virus, a delayed 
rise in antibody titres, and viraemia that was detected far before any intestinal replication. To 
link the early viraemia with the delayed faecal shedding, an alternative route of intestinal 
infection was hypothesized, speculating that the virus could have been taken up by permissive 
(monocytic) cells in the tonsils, from where subsequent viraemia occurred, finally resulting in 
the extravasation of these infected cells in the intestinal mucosa. The lack of in vitro 
infectivity of the excreted virus from this cat was explained by the fact that excretion occurred 
from monocytic cells and that adaptation to/replication in these cells could have changed the 
virus, but this needs to be further confirmed. No abnormalities or differences could be seen in 
leukocyte numbers compared to the other two cats, with the exception of CD8+ regulatory T 
cells, but if and how these cells played a role remains elusive. 
The huge demand for control measures and the lack of data on the feasibility to control FECV 
transmission in the prevention of FIP prompted us to monitor FECV shedding in cattery cats 
and control its transmission by avoiding contact between shedders and negative animals. In 
Chapter 5.2, FCoV genomes were semi-quantitatively assessed in regularly taken faecal 
samples with the 5’ qPCR, and cats were grouped in the house based on their shedding state, 
generating at least one positive and one negative group. One year after the start of the 
monitoring, the persistent shedder could be identified in household 1, and this cattery was 
even totally cleared from FCoV after the removal of the persistent shedder. In addition, 2 
FCoV-negative litters were raised. However, this cattery could not be kept negative due the 
import of FECV shedders, but separating these cats from the negative cats could prevent the 
virus to spread again throughout the complete cat population. Due to the success of this 
strategy in this household, the same method was applied in another household, where 
separating shedders from non-shedders was also successful to avoid reinfections. In contrast 
to household 1, 7 out of 14 cats remained shedding for more than 1 year, and future follow up 
is needed to identify the real persistent shedder(s). Grouping based on antibody titres is a 
strategy that is still regularly applied in practice, but by comparing faecal shedding with 
antibody titres, it was clearly demonstrated that antibody titres are not good parameters to 
reliably estimate the infectivity of the cat. From all data obtained in both households, it was 
concluded that FECV transmission can be successfully controlled in small to medium-sized 
catteries (<15 animals) by regularly monitoring of shedding and grouping of cats, without the 
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need for strict measures concerning people movement, clothing, or handling of cats. Cost-
effectiveness of this strategy depended on the household, showing that especially in multi-cat 
environments with major FIP problems it is worthwhile to thoroughly monitor FECV 
transmission, as this will prevent enormous financial losses by kitten mortality. Although 
effective, monitoring is (and will always be) a time- and money-consuming approach, due to 
the worldwide distribution, the long-lasting shedding and the highly contagious character of 
FECV. This further supports the need to invest in the development of efficient tools for the 
prevention and/or treatment of FCoV infections. 
In Chapter 6, all data obtained in the present thesis are reviewed and discussed. A 
hypothetical model is depicted for the role of sialic acids in the initiation of intestinal FECV 
infections, and it is discussed that both passage through the stomach and intestinal infection 
by the systemic route can potentially result in faecal shedding of the virus. In addition, 
guidelines are given to reduce the FIP incidence in small to medium-sized catteries by 
monitoring of the FECV transmission. Given that this management strategy is time- and 
money-consuming due to the long-lasting shedding of FECV and that this will be hardly 
feasible in very large catteries or other multi-cat households where many cats from different 
origin are regularly imported (shelters, shops), the final part discusses some future 
perspectives to tackle FIP and describes some potential targets in serotype I FECV infections 
in enterocytes identified in the present thesis. 
In summary, the main achievements and conclusions obtained in the present thesis include: 
• Two novel feline intestinal epithelial cell lines were established by immortalization of 
primary ileocytes and colonocytes. 
• The established enterocyte cultures allowed for the first time to propagate FECVs and 
to study FECV-enterocyte interactions. In addition, this will be one of the necessary 
tools to study underlying viral factors involved in the pathotype switch.  
• FECV has a sialic acid binding capacity (α2,6- over α2,3-linked) that is partially 
masked by virion-associated sialic acids. 
• Attachment to sialic acids is not a prerequisite for the initiation of in vitro enterocyte 
infections, and even delays/distracts the virus from efficient receptor engagement. 
However, this feature potentially gives FECV advantages in its confrontation with the 
harsh digestive conditions and mucus barrier in vivo. 
• In contrast to serotype II viruses, serotype I FECVs do not depend on acidic pH, 
cathepsin B and/or furin for entry in enterocytes, but the exact fusion trigger remains 
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to be elucidated. 
• AEBSF is a potent inhibitor of FCoV and TGEV replication, and targets a yet to be 
identified virion-associated serine protease that fulfils its job between 60 and 120 min 
p.i. 
• Experimental FECV infections in three cats revealed an aberrant infection pattern in 
one cat, characterized by a delayed faecal shedding (from day 14 instead of day 2-4 
p.i.), absence of infectivity in enterocytes cultures of the excreted virus, a delayed rise 
in antibody titres, and a viraemia that was detected far before any intestinal 
replication. Based on these data, it was hypothesized that intestinal FECV infections 
can potentially not only be initiated by passage through the stomach, but also by the 
systemic route.  
• The generally used 3’ RT-qPCR gives an overestimation of viral genome copies of 
about 3-4.3 log10.    
• Restriction of FECV infections by management of the faecal-oral transmission, and 
not by antibody titre determination, is a feasible strategy to reduce the number of FIP 
cases in small to medium-sized catteries. 
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Feliene infectieuze peritonitis (FIP) wordt veroorzaakt door een felien coronavirus (FCoV) en 
blijft tot op heden één van de weinige onoverkomelijke en erg gevreesde virale infecties bij 
katten. Hoofdstuk 1 geeft een literatuuroverzicht over de classificatie van feliene 
coronavirussen in 2 pathotypes (felien enterisch coronavirus (FECV) en feliene infectieuze 
peritonitis virus (FIPV)) en 2 serotypes (serotype I en II), over de algemene virusstructuur en 
virale eiwitten, de replicatiecyclus en de huidige kennis over de pathogenese. Hoofdstuk 1 
beschrijft ook dat het stellen van een vroege en zekere FIP diagnose moeilijk is en dat 
adequate preventieve en curatieve middelen nog steeds ontbreken. FIPV ontstaat door mutatie 
tijdens een FECV infectie, en dus kan FECV een belangrijk doelwit zijn in de strijd tegen 
FIP. In de huidige thesis werd vooral de nadruk gelegd op de initiële FECV-enterocyt 
interacties, en het tweede deel van hoofdstuk 1 geeft dan ook een literatuuroverzicht van de 
huidige kennis omtrent opname van coronavirussen in het algemeen. 
Omdat FECV op zich onschadelijk is, is er in het verleden relatief weinig aandacht besteed 
aan dit virus. Bijgevolg is er heel weinig geweten over de FECV-enterocyt/kat interactie en de 
mogelijkheid om dit virus aan te pakken in de strijd tegen FIP. Omdat FECV aan de basis ligt 
van elke FIPV infectie, was het doel van de huidige thesis om de kennis omtrent de FECV-
cel/kat interacties te verruimen en betere inzichten te krijgen in hoe de transmissie van dit 
virus kan beperkt worden. Deze doestellingen worden beschreven in hoofdstuk 2. 
Aan het begin van het huidige project was er geen enkel representatief in vitro model of 
cultiveerbare FECV stam beschikbaar om de FECV-enterocyt interactie te kunnen bestuderen. 
Hoofdstuk 3 beschrijft het onderzoek dat werd uitgevoerd om aan dit tekort tegemoet te 
komen. Hiervoor werden, via expressie van simian virus 40 T-antigen en humaan telomerase 
reverse transcriptase, geïmmortaliseerde, continue cellijnen gemaakt van primaire feliene 
intestinale epitheelcellen afkomstig uit het ileum (ileocyten) en het colon (colonocyten). Om 
na te gaan of deze cellen geschikt waren als in vitro model voor enterocyt infecties werd de 
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replicatie-capaciteit van het enteritis-inducerende serotype II FCoV WSU 79-1683 en het FIP-
inducerende FCoV WSU 79-1146 bestudeerd en vergeleken met hun replicatie-capaciteit in 
primaire cellen. Deze experimenten toonden aan dat de avirulente, enterotrope 79-1683 stam 
de enterocytenculturen veel efficiënter infecteerde in vergelijking met de FIP-veroorzakende 
79-1146 stam. Bovendien was de replicatie-capaciteit van beide virussen vergelijkbaar met 
wat werd gezien in primaire cellen, en werd besloten dat de geïmmortaliseerde cellijnen dus 
betrouwbare modellen zijn voor het bestuderen van enterische FCoV infecties. Nadien werd 
onderzocht of deze cellijnen ook zouden toelaten om serotype I veldvirussen te groeien en te 
bestuderen om zo het toekomstig FCoV onderzoek meer relevant te kunnen maken. Daarvoor 
werden de cellen geïnoculeerd met mestsuspensies van gezonde katten en mest- of 
weefselsuspensies van FIP katten. Het werd aangetoond dat de enterocyten-cellijnen gevoelig 
waren voor verschillende serotype I enterische stammen en 2 stammen (FECV UCD en UG-
FH8) werden verder opgegroeid om te kunnen gebruiken voor latere in vitro studies. Na 
inoculatie met FIP weefselsuspensies werd geen infectie gezien. Gebaseerd op de gegevens 
verkregen in hoofdstuk 3 werd geconcludeerd dat een nieuw betrouwbaar in vitro model werd 
gemaakt voor FCoV onderzoek en groei van enterische stammen. In tegenstelling tot FIPV 
stammen hadden FECV stammen een duidelijk tropisme voor enterocyten, wat een verklaring 
kan bieden voor het feit dat FECV het belangrijkste pathotype is dat tussen katten wordt 
overgedragen.   
Het ontwikkelen van de feliene enterocyten-cellijnen en het groeien van enterische stammen 
tot voldoende hoge titers liet toe om de FECV-enterocyt interacties verder te ontrafelen. 
Aangezien niets geweten was over deze interacties werd in de huidige thesis de focus gelegd 
op het begin van de infectie, en de resultaten bekomen uit deze experimenten werden 
gebundeld in hoofdstuk 4. Aangezien siaalzuren vaak betrokken zijn in coronavirus infecties 
werd eerst onderzocht of deze suikers ook betrokken zijn in FECV infecties. Wetende dat de 
coronavirus spike proteïnen geactiveerd moeten worden door zure pH en/of proteasen 
vooraleer het genoom kan worden vrijgesteld, werd nadien ook onderzocht wat het effect was 
van verscheidene pH drop- of protease-inhibitoren op de FECV infectie.   
Hoofdstuk 4.1 beschrijft hoe de infectiviteit van FECV beïnvloed werd door 1) 
neuraminidase (NA) behandeling van de enterocyten culturen, 2) NA behandeling van het 
virus en 3) het toevoegen van siaalzuurhoudende componenten aan het inoculum. NA 
behandeling van de enterocyten zorgde voor een sterke toename in het aantal geïnfecteerde 
cellen (tot 72 keer meer), waaruit kon opgemaakt worden dan siaalzuren geen receptor 
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determinanten zijn en zelfs een efficiënte FECV infectie verhinderen in vitro. Bij het 
bestuderen van het effect van de NA behandeling van het virus werd aangetoond dat NA-
behandeld virus de cellen tot 7 keer beter infecteerde, maar dat deze toename in infectiviteit 
teniet werd gedaan door het toevoegen van sialyllactoses (α2,6- meer dan α2,3-sialyllactose). 
Deze resultaten gaven een indicatie dat FECV een siaalzuur-bindende capaciteit heeft die 
meer uitgesproken wordt door NA behandeling van het virus en dat, ondanks het feit dat het 
geen receptordeterminanten zijn, binding aan siaalzuren op het enterocyt oppervlak het virus 
voordeel kan geven in het infecteren van enterocyten. Op het eerste zicht tegenstrijdige 
gegevens werden verkregen bij het beoordelen van de infectiviteit van NA-behandelde 
virussen in NA-behandelde cellen, omdat in tegenstelling tot in onbehandelde cellen, NA 
behandeling van virus een negatief effect had in NA-behandelde cellen. Het feit dat siaalzuren 
kunnen dienst doen als bindingsfactoren maar dat binding niet nodig is om enterocyten te 
kunnen infecteren kon hiervoor echter een verklaring geven, aangezien receptorbinding het 
meest efficiënt is wanneer het virus niet langer wordt ‘afgeleid’ door niet receptor-
geassocieerde siaalzuren. Dit suggereerde dat FECV waarschijnlijk lijkt op het transmissiebel 
gastro-enteritis virus (TGEV) in de afhankelijkheid van siaalzuren tijdens infectie, en dus dat 
siaalzuren geen receptoren zijn, maar dat binding aan siaalzuren waarschijnlijk een strategie is 
van het virus om te kunnen binden aan de mucines die het enterocyt oppervlak bedekken. De 
FECV-mucine interactie werd onderzocht door competitieve inhibitie experimenten uit te 
voeren met 2 verschillende, commercieel beschikbare mucines, namelijk porciene gastrische 
mucine (PGM) en boviene submaxillaire mucine (BSM). In tegenstelling tot PGM dat geen 
effect had op FECV infecties tot 50 mg ml-1, kon BSM FECV infecties inhiberen vanaf 0,5 
mg ml-1. Dit inhiberende effect was veel minder uitgesproken in NA-behandelde cellen, wat 
opnieuw bevestigde dat FECV-siaalzuur/mucine interacties optreden in de celculturen maar 
geen voorwaarde zijn om enterocyten te infecteren in vitro. Deze bevindingen toonden aan dat 
FECV in staat is om met mucines (rijk in α2,6-gelinkte siaalzuren zoals BSM) te interageren, 
en een hypothese werd opgesteld dat deze interactie waarschijnlijk niet enkel een strategie is 
van het virus om te kunnen ontsnappen aan de intestinale flow, maar waarschijnlijk ook 
gebruikt wordt om zichzelf te beschermen tegen lage pH en proteasen in het begin van het 
gastro-intestinaal stelsel.  
In hoofdstuk 4.2 werd het effect van verscheidene lysosomotrope agentia en protease 
inhibitoren op de replicatie van serotype I FECV stammen UCD en UG-FH8, serotype II 
FCoV WU 79-1683 en TGEV in enterocyten onderzocht. In tegenstelling tot FCoV WSU 79-
1683 en TGEV was de serotype I FECV replicatie onafhankelijk van zure pH of cathepsine B. 
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De furine inhibitor decanoyl-RVKR-CMK had geen effect op de serotype I FECV opname of 
infectiviteit van geproduceerde virussen, maar wel op de start van de replicatie van FCoV 79-
1683 en TGEV. De serine protease inhibitor AEBSF had een sterk reducerend effect op de 
replicatie van alle FCoVs en TGEV wanneer het continu werd toegevoegd voor en tijdens de 
replicatie of wanneer het werd toegevoegd na inoculatie. Dit was het resultaat van de inhibitie 
van een virion-geassocieerd protease, aangezien dezelfde reductie in replicatie werd gezien 
wanneer enkel het virus werd behandeld met AEBSF. Aan de hand van een kinetische studie 
waarbij AEBSF op verschillende tijdstippen na inoculatie werd toegevoegd, werd aangetoond 
dat dit serine protease zijn functie vervulde tussen 60 en 120 min p.i. Zoals verwacht, 
gegeven dat het coronavirus’ polyproteïne geknipt wordt door virale cysteïne proteasen, 
inhibeerde de cysteïne protease inhibitor E64d de replicatie wanneer het continu werd 
toegevoegd voor en tijdens de replicatie of wanneer het werd toegevoegd na inoculatie. Noch 
AEBSF of E64d inhibeerde de replicatie wanneer enkel de cellen werden voorbehandeld. 
Gebaseerd op de gegevens uit hoofdstuk 4.2 kon besloten worden dat in tegenstelling tot 
serotype II FCoVs, serotype I FECVs niet afhankelijk zijn van lage pH, cathepsine B en/of 
furin voor hun entry, maar de exacte fusie trigger kon nog niet achterhaald worden. Deze 
observatie bevestigt dat het extrapoleren van data gebaseerd op serotype II virussen naar 
infecties met serotype I virussen met de nodige voorzichtigheid moet gebeuren, zeker wat de 
opname van het virus betreft. Bovendien kon geconcludeerd worden dat serotype I FECVs 
(en sommige andere alfa-coronavirussen) een virion-geassocieerd serine protease bevatten dat 
waarschijnlijk betrokken is in de start van de replicatie en dus een belangrijk doelwit kan zijn 
in toekomstige therapieën.  
In hoofdstuk 5 werden de in vivo FECV-kat interacties bestudeerd door enerzijds katten 
experimenteel te infecteren (hoofdstuk 5.1) en anderzijds door kattenkwekerijen op te volgen 
(hoofdstuk 5.2). 
Hoofdstuk 5.1 beschrijft de onderzoeksresultaten die verkregen werden door, na 
experimentele inoculatie van drie FIV-, FeLV- en FCoV-vrije katten met serotype I FECV 
UCD, de orale en fecale uitscheiding, de neutraliserende antistoftiters, viremie en leukocyten 
subsets op te volgen gedurende 3 maanden na inoculatie. Virus uitscheiding werd 
gekwantificeerd met behulp van 2 verschillende RT-qPCRs (één die het 3’ uiteinde van alle 
genomische en subgenomische (m)RNAs (3’qPCR) en één die ORF1b van het genomische 
RNA herkent (5’qPCR)), en met behulp van virustitratie in de enterocytenculturen. Bij twee 
van de drie katten startte de uitscheiding vanaf 2-4 dagen p.i. en bleef viraal RNA 
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detecteerbaar in de feces gedurende 2 maanden. Infectieus virus werd gevonden van dag 4 tot 
dag 28 p.i. en neutraliserende antistoffen werden merkbaar vanaf dag 9. Een cel-
geassocieerde viremie werd gezien op inconsistente tijdstippen na het beginnen van de fecale 
uitscheiding. Er werden geen abnormale leukocyten aantallen waargenomen, met 
uitzondering van een granulocytopenie bij kat 1. Er werd aangetoond dat een titer 
overschatting van 3-4.3 log10 werd gemaakt indien de 3’ qPCR gebruikt werd om het aantal 
virale genoom kopieën in te schatten zoals vaak wordt gedaan. Het is dan ook logisch dat 
enkel 1/1.000.000 tot 1/100.000.000 van die ‘partikels’ infectieus waren. Het verschil tussen 
totale virale RNA kopieën en infectieuze titers was meer plausibel met het gebruik van de 5’ 
qPCR, alhoewel dit verschil afhankelijk was van het tijdstip p.i. waarop het werd beoordeeld. 
De hoeveelheid totaal viraal RNA was namelijk 3-4 log10 hoger dan de infectieuze titer tijdens 
de eerste week na inoculatie, maar deze ratio steeg naar 4.5-8 log10 tijdens de rest van het 
experiment. Deze verlaagde in vitro infectiviteit viel samen met het opkomen van 
neutraliserende antistoffen in het bloed en er werd gespeculeerd dat neutraliserende 
antistoffen in de mest een onderschatting van de infectieuze titer konden hebben veroorzaakt, 
maar dit moet nog verder bevestigd worden. Verrassend genoeg was er één van de drie katten 
die een afwijkend infectiepatroon vertoonde. Dit was gekenmerkt door een sterk verlate fecale 
uitscheiding (vanaf dag 14 in plaats van dag 2-4 p.i.), gebrek aan infectiviteit van het 
uitgescheiden virus in the enterocyten culturen, een vertraagde opkomst van antistoffen en 
een viremia die reeds detecteerbaar was lang voordat enige intestinale replicatie optrad. Om 
deze vroege viremie te kunnen linken met de vertraagde intestinale replicatie werd een 
hypothese opgesteld die een alternatieve route voor intestinale infectie voorstelt. Hierbij 
wordt vooropgesteld dat FECV mogelijks door gevoelige (monocytaire) cellen in de tonsillen 
kan worden opgenomen, van waaruit viremie optreedt en waarna deze cellen finaal in de 
intestinale mucosa zullen uittreden. Het gebrek aan in vitro infectiviteit werd verklaard het 
gevolg te kunnen zijn van de excretie vanuit monocytaire cellen, waarbij het virus 
fenotypische veranderingen had ondergaan door adaptatie aan/replicatie in deze cellen, maar 
dit moet nog verder onderzocht worden. Er werden geen abnormaliteiten of verschillen in 
leukocyten aantallen waargenomen in vergelijking met de andere 2 katten, met uitzondering 
van de CD8+ regulatorische T cellen, maar of en hoe deze cellen betrokken zijn blijft 
ongekend. 
De enorme vraag naar controle maatregelen en het gebrek aan gegevens over de haalbaarheid 
om de FECV transmissie te beperken in de preventie van FIP stimuleerde ons om in 
kattenkwekerijen de FECV uitscheiding te monitoren en te onderzoeken of de transmissie kon 
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beperkt worden door contact tussen uitscheiders en negatieve dieren te vermijden. In 
hoofdstuk 5.2 werden FCoV genomen semi-kwantitatief beoordeeld met de 5’ qPCR in 
meststalen die op regelmatige tijdstippen werden genomen. Op basis van deze resultaten 
werden katten gegroepeerd in het huis in op z’n minst één positieve en één negatieve groep. 
Eén jaar na de start van de monitoring kon de persisterende uitscheider geïdentificeerd 
worden in huishouden 1. Deze kwekerij was zelfs volledig vrij van uitscheiders na het 
verwijderen van de persisterende uitscheider en twee FCoV-negatieve nesten konden worden 
opgegroeid. De kwekerij kon echter niet volledig negatief worden gehouden door de 
regelmatige import van nieuwe FECV uitscheiders, maar door deze katten gescheiden te 
houden van de rest kon wel voorkomen worden dat het virus zich weer over de volledige 
kwekerij ging spreiden. Door het succes van deze strategie werd deze ook in een tweede 
kwekerij toegepast, waar het scheiden van uitscheiders en negatieve dieren ook succesvol 
was. In tegenstelling tot huishouden 1 bleven echter 7 van de 14 katten positief na 1 jaar 
monitoren, en verdere opvolging is nodig om de echte persisterende uitscheider(s) te 
identificeren. Groepering van katten op basis van antistoftiters wordt nog steeds regelmatig 
toegepast in de praktijk, maar door de uitscheiding te vergelijken met antistoftiters werd 
duidelijk aangetoond dat antistoffen geen goede parameter zijn om de infectiviteit van een kat 
in te schatten. Uit hoofdstuk 5.2 werd besloten dat FECV transmissie succesvol kan beperkt 
worden in kleine tot matig grote kattenkwekerijen door het regelmatig monitoren van de 
uitscheiding en het groeperen van katten, zonder dat strikte maatregelen nodig zijn met 
betrekking tot het verkeer van mensen, kledij of het aanraken van katten. In kwekerijen waar 
regelmatig FIP gevallen optreden, is het zeker de kosten waard om de FECV transmissie 
regelmatig te monitoren omdat dit de enorme economische verliezen door kittensterfte ten 
gevolge van FIP kan voorkomen. Hoewel deze strategie efficiënt is, zal het altijd een tijd- en 
geld-rovende methode blijven omdat FECV zo wijdverspreid voorkomt, langdurig wordt 
uitgescheiden en erg besmettelijk is. Verdere investeringen in het ontwikkelen van adequate 
preventieve en/of curatieve middelen zullen dan ook nodig zijn in de strijd tegen FIP. 
In Hoofdstuk 6 werd een overzicht en discussie gegeven van alle resultaten die verkregen 
werden in de huidige thesis. Een hypothetisch model voor de rol van siaalzuren in de start van 
intestinale FECV infecties werd besproken. Bovendien werd bediscussieerd dat FECV 
waarschijnlijk zowel via passage door de maag als via het bloed een intestinale infectie kan 
initiëren, wat kan leiden tot uitscheiding van het virus in de mest. Bovendien werden ook 
richtlijnen gegeven om in kleine tot matig grote kattenkwekerijen de incidentie van FIP te 
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reduceren via het controleren van de FECV transmissie. Gegeven dat deze 
managementstrategie tijd- en geld-rovend is omwille van de langdurig uitscheiding van 
FECV, en dat deze strategie moeilijker haalbaar zal zijn in erg grote kwekerijen of andere 
multi-kat omgevingen (asielen/verkoopscentra) waar zeer regelmatig nieuwe dieren worden 
binnengebracht, werden in het laatste deel van hoofdstuk 6 enkele mogelijke toekomstige 
benaderingen om FIP aan te pakken bediscussieerd en werden mogelijke doelwitten in de 
serotype I FECV replicatie, die in deze thesis werden geïdentificeerd, beschreven. 
Samengevat zijn de belangrijkste verwezenlijkingen en conclusies uit de huidige thesis als 
volgt: 
• Twee nieuwe feliene intestinale epitheelcellijnen werden ontwikkeld door 
immortalisatie van primaire ileocyten en colonocyten. 
• Deze enterocyten-cellijnen lieten voor de eerste maal toe om FECV stammen op te 
groeien en FECV-enterocyten interacties te bestuderen. Bovendien zal dit één van de 
onmisbare tools zijn om onderliggende virale factoren betrokken in de pathotype 
switch te bestuderen. 
• FECV heeft een siaalzuurbindend vermogen (α2,6-gelinkte- meer dan α2,3-gelinkte 
siaalzuren) dat gedeeltelijk gemaskeerd is door virion-geassocieerde siaalzuren. 
• Binding aan siaalzuren is geen noodzaak om in vitro enterocyt-infecties te kunnen 
induceren en zorgt er zelfs voor dat het virus minder efficiënt kan interageren met de 
receptor. Niettegenstaande het in vitro nadeel van siaalzuurbinding, geeft dit FECV 
waarschijnlijk een voordeel in vivo om te kunnen omgaan met de ongunstige 
verteringscondities en mucus barrière in het gastro-intestinaal stelsel.  
• In tegenstelling tot serotype II virussen zijn serotype I FECV stammen niet 
afhankelijk van zure pH, cathepsine B en/of furin voor hun replicatie in enterocyten, 
maar de exacte fusie trigger kon nog niet achterhaald worden. 
• AEBSF is een sterke inhibitor van de FCoV en TGEV replicatie dat een nog te 
identificeren virion-geassocieerd serine protease inhibeert. Dit protease werkt tussen 
60 en 120 min p.i. 
• Experimentele FECV infectie van 3 katten toonde een afwijkend infectie-patroon in 
één van de katten, gekenmerkt door een sterk verlate fecale uitscheiding (vanaf dag 14 
in plaats van dag 2-4 p.i.), gebrek aan infectiviteit van het uitgescheiden virus in de 
enterocyten-culturen, een vertraagde opkomst van antistoffen en een viremia die reeds 
optrad lang voordat enige intestinale replicatie te zien was. Gebaseerd op deze 
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gegevens werd een hypothese opgesteld dat intestinale FECV infecties waarschijnlijk 
niet enkel via passage door de maag, maar ook via het bloed kunnen worden 
geïnitieerd. 
• De algemeen gebruikte 3’ qPCR geeft een overschatting van het aantal virale genomen 
met ongeveer 3-4.3 log10. 
• Het beperken van FECV infecties door het controleren van de feco-orale transmissie, 
en niet via antistoftiter bepaling, is een haalbare strategie om het aantal FIP gevallen 
in kleine tot matig grote kattenkwekerijen te reduceren. 
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Dit is het dan, het laatste hoofdstuk van dit vier jaren durende avontuur. En dat was het zeker! 
Net zoals het een goed avontuur beoogt, vond ook dit doctoraat zijn weg over talrijke bergen, 
dalen, woelige wateren of eindeloos lijkende vlaktes, om uiteindelijke moe maar voldaan te 
stranden op het eindpunt, dat door de (onvoorziene?) omstandigheden misschien wel wat 
afwijkt van het initiële doel. Logisch ook, want onderzoek zou namelijk niet zijn wat het is als 
we op voorhand zouden weten waar we moeten uitkomen. Wat mij persoonlijk het meest zal 
bijblijven, is dat een doctoraat niet alleen over onderzoek gaat, maar een ontdekkingsreis is op 
alle mogelijk vlakken. Iedere PhD lijkt van start te gaan met het streven naar dat ene 
wereldschokkende of baanbrekende resultaat. Maar onder het motto “De ware 
ontdekkingsreis is geen zoektocht naar nieuwe landschappen, maar het waarnemen met 
nieuwe ogen” (Marcel Proust), maakt dit streven ook snel plaats voor de fascinatie en 
bewondering voor de vele mysteries waarmee we als PhD student geconfronteerd worden, 
maar ook voor dankbaarheid tegenover alle mensen die elke dag opnieuw klaarstaan om dit 
avontuur tot een goed einde te brengen. In dit laatste hoofdstuk maak ik dan ook graag tijd om 
alle hoofdrolspelers, figuranten en (toevallige?) passanten, die mijn weg doorheen dit 
doctoraat mee hebben bepaald, uitvoerig te bedanken. 
In tegenstelling tot de alom bekende avonturier die schreef “For the execution of the voyage 
to Indies, I did not make use of intelligence, mathematics or maps”, (niet zo verwonderlijk 
dan dat onze Christoffel aan de andere kant van de wereld uitkwam, toch?) kon dit doctoraat 
niet tot stand komen zonder de nodige intelligentie en wetenschappelijke input van de 
promotor. Hans, ik herinner me nog de dag waarop je op de proppen kwam met het FWO-
project dat dit doctoraat moest ondersteunen. Je vroeg me wat ik er zelf van dacht en vooral of 
ik het (met mijn ervaring die ik reeds mocht opdoen in het labo tijdens de masterproefjaren) 
haalbaar zag, waarop ik toen nog vol overtuiging “ja, zeker!” antwoordde. Van het originele 
project over darm-explanten, receptoren en discriminerende testen is echter niet meer veel 
terug te vinden in dit doctoraat, maar net zoals de input hebben jouw onuitputtelijke 
enthousiasme, (out of the box) ideeën en neiging om van iedere gelegenheid een 
brainstormsessie te maken ook de output van dit werk bepaald. Bedankt om jouw passie voor 
het onderzoek “viraal” te maken en ons te leren dat een gezonde kritische houding, een 
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vleugje gezond (en liefst ook wat abstract) verstand en vooral doorzettingsvermogen en 
zelfvertrouwen de belangrijkste sleutels zijn tot succes.  
Ook zonder de ex-FIP’ers zou dit doctoraat niet zijn wat het is. Hannah, Evelien en Els, jullie 
input heeft onmiskenbaar de fundamenten gelegd voor het huidige FIP-onderzoek, waar niet 
alleen ik, maar ook vele andere van hebben mogen en nog van zullen profiteren. Hannah, jij 
was diegene die me reeds als masterproefstudente wegwijs maakte in het labo en de knepen 
van het vak leerde. Ook aan de start van dit doctoraat stond je klaar om ieder probleem(pje) of 
teken van frustratie uit te weg te ruimen door me te laten inzien dat elke ‘tegenslag’ ook zijn 
positieve kant heeft. Ook jouw onuitputtelijke bron van kennis (inclusief de nodige 
referenties!) was indrukwekkend. Ik ben dan ook heel blij dat je er ook in de eindfase van dit 
doctoraat als deel van de begeleidingscommissie weer bij was om de puntjes op de i te zetten. 
Bedankt voor alles! Evelien, onze samenwerking begon ergens bij de darm-explanten en even 
zag het naar uit dat dit ook zou verder gezet worden in de enterocyten cellijnen, maar jouw 
passie voor microscopie besliste daar anders over. Maar ook al was onze tijd samen kort, ook 
jij hebt enorm veel voor mij betekend bij zowel de eerste stapjes als bij de laatste loodjes. 
Bedankt voor alle kennis, protocols en levenswijsheden die je met mij hebt gedeeld en om de 
tijd te nemen om deze thesis in drukke tijden toch grondig na te lezen! Dominique, ook jij 
vervoegde (wat onverwacht?) de begeleidingscommissie, maar na jarenlange nauwe 
samenwerking leek dit voor mij niet meer dan normaal. Ik heb altijd enorm veel ontzag gehad 
voor het geduld en de nauwkeurigheid waarmee je bepaalde zaken te lijf ging, en hoe je 
eigenlijk zonder al te veel moeite (persoonlijke) problemen in de groep durfde te gooien. Je 
leek het zelf niet altijd goed te beseffen maar je bent een straffe madam, die niet bang is om 
de handen uit de mouwen te steken of wat overuren te kloppen indien nodig. Je was dan ook 
vaak op onmenselijke tijdstippen in het labo te vinden. Vooral in het begin, waar van continue 
cellijnen nog geen sprake was, en katten in de praktijk nu eenmaal niet binnen de 
‘kantooruren’ moesten worden geëuthanaseerd, behoorden we samen ogenschijnlijk meer tot 
het meubilair dan tot het personeel van het labo. Ook al misten we daardoor wel meerdere 
‘social events’, het was toch fijn om op die momenten bij jou een partner in crime te vinden. 
Maar geef toe, ik denk dat we er meer memorabele momenten aan hebben overgehouden dan 
we gemist hebben J. Bedankt voor het trainen van mijn lachspieren tijdens alle leuke, of 
minder leuke (‘ik krijg precies kramp in mijn vingers’…. J) momenten en voor alle serieuze 
of minder serieuze babbels. Annelike, jouw luisterend oor heeft menig van ons kunnen 
bekoren. Het is bewonderenswaardig hoe jij op elk moment klaarstond om iedereen uit de 
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nood te helpen, ook op momenten waar je het zelf even niet meer zag zitten. In zal ook nooit 
vergeten hoe jij als een geroutineerde jager die wilde katten met je blote handen te lijf ging, 
terwijl Dominique en ik tot de tanden gewapend met overalls, handschoenen en borstels 
compleet verbouwereerd aan de grond genageld bleven toekijken J. Bedankt voor alles wat 
je voor mij hebt gedaan. Ben, ook wij hebben heel wat katjes moeten geselen de voorbije 
jaren, maar de resultaten mochten er zeker zijn. Bedankt voor jouw praktische, 
wetenschappelijke en software-gerelateerde bijdrage aan dit doctoraat. Leslie, ook jij hebt als 
ex-collega zeker je steentje bijgedragen aan het huidige FIP onderzoek, hoe kort jouw 
avontuur bij ons ook was. Ik wil je ook graag bedanken om als lid van de examencommissie 
de tijd te nemen om deze thesis te beoordelen.  
Uiteraard zou ik ook alle andere leden van de lees- en examencommissie, Prof. Eric Cox, 
Prof. Berend Jan Bosch, Prof. Sylvie Daminet en Prof. Etienne Thiry, willen bedanken voor 
alle inspanningen om dit werk te beoordelen. Berend Jan, jou wil ik graag in het bijzonder 
nog extra bedanken voor de korte maar krachtige samenwerking en de gastvrijheid van het 
voorbije jaar. Als alom gekende expert op het gebied van coronavirussen en entry was het 
voor mij een enorme eer om met jou te kunnen samenwerken en van jou te kunnen leren. Ook 
Prof. Rottier wil ik graag langs deze weg bedanken. Uw niet aflatende kennis, enthousiasme 
en passie voor het FCoV onderzoek maakten van elke brainstormsessie een eyeopener voor 
mij. Bedankt om mij te willen ontvangen in het labo, elke dag was er één om te koesteren. 
Huihui, thanks for being my guide and partner in crime at the Utrecht University. I wish you 
all the best with your upcoming PhD defence and with the rest of your undoubtedly beautiful 
career! 
Vervolgens is er het kloppende hart van de virologie, alle administratieve en technische 
medewerkers die dag na dag klaarstaan om het labo draaiende houden. Gert’je’ (of Hert’je’ 
voor de West-Vlamingen J), Mieke, Marijke, Dirk en Ann M., bedankt om vaak in drukke 
tijden klaar te staan om allerlei kleinere en grotere administratieve, en in geval van Dirk ook 
computer-gerelateerde, problemen op te lossen en ons op die manier heel wat werk uit handen 
te nemen. Ook Zeger en Loes (en in wat langer vervlogen tijden ook Geert, Fernand en Bart) 
wil ik graag bedanken voor het dag na dag voorzien van proper/steriel materiaal, voor hun 
bijdrage aan de experimentele infectiestudies, om ervoor de zorgen dat onze dieren alles 
krijgen wat ze nodig hebben en natuurlijk ook voor de fijne babbels tussendoor. Verder wil ik 
natuurlijk ook alle laboranten (Lieve, Nele, Melanie, Chantal, Carine, Tim en Ytse) bedanken 
voor hun onschatbare bijdrage aan alle experimenten en diagnoses. Ytse, bedankt voor het 
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uitvoeren van de vele extracties, PCR’s, kleuringen en suspensies de voorbije 4 jaren, en om 
ons mini-labo’tje keer op keer van alle benodigdheden te bevoorraden. Je bent echt een 
toplaborante, of eigenlijk meer een pseudo-PhD student, die altijd klaarstaat om ons te helpen, 
niet alleen voor het uitvoeren van experimenten maar ook voor het vinden van oplossingen of 
om de fouten uit onze protocols te halen! Bedankt om heel wat last van onze schouders te 
halen en geniet met volle teugen van het prille moederschap! 
Dit brengt mij vervolgens bij alle “lot”genoten, collega (of ex-collega) PhD studenten 
zonder wie dit doctoraat (en bijhorende publicaties) niet zou zijn wat het is. Zoals de meeste 
mensen weten, bevond de thuishaven van dit doctoraat zich op de eerste verdieping, waar 
tussen alle parasitologen een kleine groep virologen gedijt in het FIP/FIV/Rota-labo en 
bijhorende “eerste bureau”. Bas, jij verscheen reeds gedurende de masterjaren op het toneel, 
waar ons professioneel gepruts met de darm-explanten de basis heeft gelegd voor een 
ongetwijfeld mooie samenwerking en vriendschap. Als vat vol kennis over de meest 
uiteenlopende zaken (dit moet het zijn wat jou zo aantrekt in het IWT? J) en fascinatie voor 
de meer moleculaire kant van het onderzoek ben je echt van onschatbare waarde geweest, niet 
alleen voor mij, maar (aan de neiging tot rij-vorming achter jouw bureau te beoordelen J) 
ook voor vele anderen. Maar daarnaast zorgden jouw goedlachse ingesteldheid (en wat 
onhandige vrienden J) voor een opperbeste sfeer en boeiende verhalen. Als rasechte 
Antwerpenaar was je om één of andere reden ook al snel gefascineerd door het West-Vlaamse 
taaltje, en ergens onderweg werd dan ook het (reeds volledig ingeburgerde) woord 
“Tsjoolder” geboren. En ook de vele, al dan niet door copyright beschermde, oneliners 
toverden telkens weer die glimlach op mijn gezicht. Dus, Tsjoolder, ik ben blij dat ik in jouw 
team zat, waar er vol discipline, dedication and friendship keer op keer ruimte was voor een 
“met mij kunde lachen hé” moment! Bedankt voor alles! Inge, ook jij kruiste niet zo snel na 
mijn start mijn pad, al leek jouw doorstart wat moeilijker dan verwacht. Maar jouw vechtlust 
(letterlijk én figuurlijk), enorm probleemoplossend vermogen en veelzijdigheid hebben niet 
alleen van het huidige FIV onderzoek een pareltje gemaakt, maar hebben ook velen van ons 
vaak terug op weg geholpen. Jouw zin voor humor en enorm aanstekelijke lach zorgden 
bovendien voor de nodige sfeer, terwijl jouw uit het niets opduikende drang naar opruimen en 
organisatorisch talent dan weer voor de nodige dedication en position-switches zorgden om 
het labo en bureau voor iedereen zo aangenaam mogelijk te houden. Isaura, jij kwam ons wat 
later vervoegen in het bureau op de eerste verdieping, maar al snel werd duidelijk dat deze 
nauwere samenwerking voor ons allen een enorme boost was, zowel op wetenschappelijk 
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niveau als qua amusementsgehalte. Jouw talenten en kennis zijn voor menig van ons al van 
onschatbare waarde geweest, en het was (en blijft) verbazingwekkend hoe jij vaak razendsnel 
een oplossing vond voor wat voor mij (en andere dierenartsen onder ons) vaak moeilijk 
oplosbare problemen leken. Bedankt voor je enorme bijdrage aan het FIP onderzoek! 
Delphine, al vanaf de eerste dag, waarop jij als volleerd FIP-onderzoeker vol overgave met 
ons mee discussieerde, merkten we dat jij een aanwinst zou zijn voor de FIP-groep (en onze 
lachspieren…). En ook de studenten mogen zich gelukkig prijzen met zo’n fantastische 
assistente. Ik wens je veel succes met wat nog komen zal, maar ik weet nu al zeker dat je met 
jouw capaciteiten (en de nodige inspanningen uiteraard J) het FIP-onderzoek naar een 
volgend niveau zal kunnen brengen. Elke, wij leerden elkaar nog niet zo lang geleden kennen, 
maar ik stond meteen versteld van alle werklust die je in je hebt. Ik ben er zeker van dat met 
deze ingesteldheid de toekomst je toelacht! En dan zijn er nog alle andere (ex-)collega’s die 
één voor één op hun eigen manier hun steentje hebben bijgedragen ergens in de loop van dit 
doctoraat. Wander, Caroline, Merijn, Lennert, Sarah G., Sarah C., Annelies, Marc, Sjouke, 
Miet, Karen O., Karen V., Bauke, Inge H., Hanne, Mieke V., Karl, en alle andere die ik 
misschien nog vergeet, ik wil jullie graag bedanken voor alle steun, tips en natuurlijk ook 
voor de onmisbare ontspannende momenten tussendoor. Weet dat elke input van jullie kant 
enorm geapprecieerd werd. Ook de mensen van de immuno (Thary, Jochen, Korneel, Maria 
en Céline) verdienen een woordje van dank om ons uit de nood te helpen met producten of 
andere benodigdheden (zoals de posterkoker) indien dit nodig was. Also thanks to all past and 
present non-Dutch speaking people (Sabine, Sabrina, João, Dipu, Uladzimir, Amy, Angela, 
Hoessein, Kathlyn, Kevin, Charlie, Vishi, Garba, Jing, Yu, Wengfeng, Ivan, Ilias, José, 
Yewei, Fang, Jason, Tingting, Mohammed,…) for their contribution to this work and/or for 
the pleasant talks in between all work. I wish you all the best with your upcoming careers. 
Ook alle andere medewerkers van dit doctoraat, dierenartsen en eigenaars, verdienen een 
woordje van dank voor hun bijdrage. In het bijzonder Frederik, Kathy, Kurt en Roosje zou ik 
willen bedanken om hun cattery voor ons onderzoek open te stellen!  
Tenslotte zou dit alles niet mogelijk zijn geweest zonder de nodige steun van familie en 
vrienden. Mijn ouders (inclusief stiefouders of hoe je dit ook mag definiëren) en 
schoonouders wil ik uit de grond van hart bedanken voor alles wat jullie voor mij betekend 
hebben in de afgelopen jaren. Niemand van jullie heeft waarschijnlijk ooit echt volledig 
begrepen wat ik “daar in Merelbeke” zat uit te spoken (“moet iets met virussen, katten en 
darmen geweest zijn?”) en vooral niet waarom het werk op vrijdag niet stopte zoals bij de 
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meeste jobs. Maar desalniettemin dit “communicatie probleem”, bleven jullie steeds vol 
interesse polsen naar de vorderingen en geboeid luisteren naar wat ik te vertellen had. En ook 
wist ik dat ik bij jullie altijd de nodige ontspanning kon vinden in drukke tijden. De mama’s 
wil ik graag nog extra bedanken om ons na lange werkdagen zeer regelmatig te voorzien van 
de nodige spijs en drank, zodat we ons geen zorgen hoefden te maken om vóór sluitingstijd de 
winkel nog te bereiken of het grootste deel van de meestal zeer korte avond nog te verliezen 
aan koken of afwassen. Bedankt voor alles! Ook Mathias en Delphine, Sofie en Arnaud en 
natuurlijk bijhorende schatten van kinderen wil ik graag bedanken voor alle momenten van 
ontspanning tussen het harde werk door. En die ontspanning was er natuurlijk ook altijd bij de 
vrienden! Joke, Laurent, Anne, Arne, Hannes en Kim, bedankt voor alle gezellige etentjes en 
uitstapjes. Joke, jij bent het organisatorisch talent van de bende, dus zonder jou zouden de 
voorbije jaren er misschien wel heel wat saaier hebben uitgezien. En ook van jouw neiging 
om regelmatig nieuwe recepten uit te proberen hebben we, als proefkonijn, altijd ten zeerste 
genoten! Bedankt voor al jouw inspanningen! Laurent, wij hebben voor het grootste deel 
hetzelfde traject afgelegd, tot in het laatste jaar diergeneeskunde, waar door mijn passie voor 
het onderzoek en jouw meer uitgesproken interesse in het klinische aspect van het vak onze 
professionele wegen gescheiden leken te worden. Maar niets was minder waar, want zonder 
jouw input zou dit doctoraat (en ook reeds voorbije doctoraten) maar een fractie zijn van wat 
het nu is. Jij was namelijk diegene die steeds onvoorwaardelijk moeite bleef doen om ons te 
voorzien van de nodige weefselstalen, waarmee we uiteindelijke heel wat in vitro tools 
hebben kunnen creëren. Maar naast deze professionele samenwerking, blijf je natuurlijk een 
vriend voor het leven en heb je altijd (bewust of eerder accidenteel J) voor het nodige 
entertainment gezorgd. Bedankt voor alles! Anne, wij leerden elkaar reeds in ver vervlogen 
tijden ergens in het verre Wevelgem kennen, waarna je voor ongeveer 10 jaren van de radar 
verdween, tot je plots opdook in het auditorium tussen alle eerstejaarsstudenten 
Diergeneeskunde. Sindsdien werd onze band steeds hechter. Uiteindelijk volgden we ook 
hetzelfde traject en konden we al onze (onderzoeks)avonturen met elkaar blijven delen tijdens 
de gezellige etentjes of uitstapjes. Bedankt voor alle mooie momenten en ik wens je veel 
succes met het finaliseren van jouw doctoraat. Hannes, ook jou wil ik graag nog bedanken 
voor alle mooie momenten die we samen hebben gedeeld, niet alleen tijdens onze studies 
maar ook erna. Ook alle mensen van de volleybal zou ik willen bedanken voor fantastische 
tijd die we samen hebben gehad. Mijn “carrière” heeft zich uiteindelijk noodgedwongen 
moeten stoppen maar ik blijf jullie overwinningen (en uitzonderlijke nederlagen J) op de 
voet volgen. Bedankt voor alle ontspannende momenten. Bie, wij leerden elkaar ook in ver 
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vervlogen tijden (moet nu ongeveer 19 jaren geleden zijn) kennen in het volleybalmilieu, 
maar sindsdien ben je altijd een belangrijk deel van mijn leven geweest. De laatste jaren was 
je er wat minder door je bewonderenswaardige keuze om de liefde van je leven te volgen over 
de hele wereld. Toch bedankt voor alle fijne babbels op momenten dat je toch even in het land 
was en ik hoop jullie snel hier in ons Belgenlandje te zien settelen, zodat er weer meer tijd is 
om bij te praten (en vooral te lachen J) zoals in de goede oude tijd.  
En dan, last but not least, de persoon die alles vanop de eerste rij heeft mogen/moeten 
meemaken. Schat, wij leerden elkaar ergens tijdens de middelbare studies kennen, toen nog 
jong en volledig onbezonnen en nog geen idee wat de toekomst ons zou brengen. Nu, 
ongeveer 12 jaren later, heb ik nog steeds geen moment spijt gehad van mijn keuze om mijn 
leven met jou te delen. En ik geef toe, het leven ging er misschien heel wat makkelijker 
uitgezien hebben moest ik, met mijn voorkeur om in de vroege uurtjes het bed uit te springen, 
postbode geworden zijn, zoals je wel eens lachend durft aanhalen, maar ik ben blij dat je 
ondanks de vaak eenzame momenten mij onvoorwaardelijk bent blijven steunen in mijn 
keuze. Bedankt om altijd je rustige zelf te blijven en ten alle tijden voor mij klaar te staan. Ik 
weet zeker dat we samen een mooie toekomst tegemoet gaan! 
 
Lowiese 
 
 
 
 
 
 
 
 
 
 
  
	  
